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All biomedical research is conducted in animal models first.  In addition, the Food 
and Drug Administration requires extrapolation from animal data to predict human 
responses.  There are ongoing scientific and regulatory challenges translating 
interspecies comparisons and predictions.  Metabolic pathways are a cornerstone to 
understanding drug metabolism and toxicities and the liver is a key organ in this process.  
Bile acids (BAs) play a central role in the hepatobiliary toxicities of chemicals, toxins, and 
biological reagents.  BAs have many physiological functions including regulation of 
genes involved in cholesterol and glucose metabolism and BA homeostasis.  However, 
BAs also have several pathological effects including carcinogenicity and liver toxicity.   
Maintenance of bile acid (BA) homeostasis is essential to achieve their physiologic 
functions and avoid their toxic effects.  Several metabolic pathways including sulfation by 
sulfotransferase (SULT), glucuronidation by UDP-glucuronosyltransferases (UGTs), and 
oxidation by Cytochrome-P450 (CYP450) enzymes participate in the direct 
detoxification, enhance the elimination of BAs, and help maintain their homeostasis.  In 
addition, influx and efflux transporters at both the sinusoidal and basolateral membranes 
play an important role in determining intracellular BA concentration, and therefore their 
hepatotoxicity.  There are known species differences in BA metabolism and transporter.  
There are known species differences in the composition of the BA pool, the toxicity of 
BAs, and drug-induced hepatotoxicity related to BAs.  These species differences can 
  
prevent extrapolation of toxicity profiles of xenobiotics between species causing a 
serious disconnect between preclinical safety findings in rodent and canine animal 
models and safety finding at clinical stages.  In this thesis, we compare the metabolic 
profile of representative BAs between several species including humans, chimpanzee, 
monkeys, minipigs, hamster, rabbits, dogs, rats, and mice.  The metabolic profile was 
characterized by the identification of BA metabolites and by quantifying the kinetics of 
their formation in hepatocyte S9 in-vitro system.  The relative contributions of individual 
metabolic pathways were determined.  LC-MS/MS was used for the qualitative and 
quantitative analysis of BAs and their metabolites.  A mixture of stable-isotope labeled 
(2H4) and unlabeled BAs were used to facilitate the identification of all minor and major 
metabolites.  Major species differences were found in the metabolism of BAs.  Amidation 
with taurine and glycine was the major pathway in all species.  Sulfation was 
predominant in humans, whereas oxidation and glucuronidation were predominant in 
rodents and dogs, respectively.  Glucuronidation and amidation of BAs are exclusive, 
where glucuronidation only takes place for unamidated BAs.  In vitro-In vivo 
extrapolation (IVIVE) is performed to establish the correlation of the in vitro results and 
the bile acid profile in vivo.  These results explain, at least in part, the dissociation 
between preclinical toxicity data in various in vitro and in vivo models and toxicities 
observed in humans.  Furthermore, more relevant species are suggested based on the 
similarity to the human BA metabolism.   In addition, we also screened different bile 
acids as a potential biomarker for transporter activity using cynomolgus monkey as 
preclinical model.  This resulted in identification of key bile acid sulfates as biomarker for 
transporter mediated drug-drug interactions.      
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CHAPTER 1 
Species Differences in Bile Acid Metabolism 
1.1 Introduction 
1.1.1 History of Bile Acids 
Bile acids (BAs), the end products of cholesterol metabolism, are synthesized in 
the liver and excreted into bile, which flows to the small intestine via the bile duct.  Most 
of BAs are reabsorbed from the intestine into the portal circulation and they undergo 
enterohepatic recirculation.  Bile was known as early as the Greek-Roman medicine as 
part of the humorism concept.   Bear bile and gallbladders were also used in traditional 
Chinese medicine to treat diseases in the 1st-2nd century BC [1], but It was only in 1827 
when L. Gamlin first succeeded in isolating the 1st BA, glycocholic acid (G-CA) [2].  The 
term “bile acid ” was first coined in 1838 by H. Demarcay [3].  Subsequent studies in 
1848-1911 identified additional BAs including lithocholic acid (LCA), chenodeoxycholic 
acid (CDCA), ursodeoxycholic acid (UDCA), and muricholic acid (MCA) from ox, goose, 
bear, and rodents, respectively [4].  BAs were first commercially synthesized in 1917 
when the pharmaceutical company Ingelheim (Germany) isolated cholic acid (CA) from 
ox bile [5].  Figure 1.1 shows chemical structures of major BAs in humans and various 
animal species.  
1.1.2 BA Synthesis 
 BA synthesis occurs in hepatocytes via cytochrome P450-mediated oxidation of 
cholesterol in a multi-step process [6].  The major pathway of BA synthesis is initiated 
via the hydroxylation of cholesterol at the 7α position by CYP7A1 [7].  This pathway of 
BA synthesis is called the "classic" or "neutral" pathway.  Next steps include the 
oxidation of the 3β-OH and isomerization of the C5-C6 double bond by the microsomal 
C27-3β-hydroxysteroid dehydrogenase (C27-3β-HSD).  The resulting intermediate is 
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either, hydroxylated at the 12α position by the microsomal CYP8B1 or passed on directly 
to the next step.  The 12α-OH intermediates and those that escaped 12α-hydroxylation 
are then subjected to reduction of the C4-C5 double bond by the enzyme oxosteroid 5β 
reductase.  This is followed by reduction of the C3-oxo group by the enzyme 3α-HSD to 
yield 3α-OH intermediates [7, 8].  The 12α-hydroxylated intermediates ultimately 
produce CA, whereas the intermediates that were not hydroxylated, ultimately produce 
CDCA.  CDCA and CA are the primary BAs in humans.  Next steps in BA synthesis 
introduce a hydroxyl group at C27, followed by its oxidation into a carboxylic acid by the 
mitochondrial CYP27A1. This is followed by ligation to coenzyme A by the bile acid 
coenzyme-A synthetase (BAS) [9].  The side chain of these C27 intermediates are then 
shortened to C24 BAs by series of β-oxidation reactions catalyzed by various enzymes 
in the peroxisomes including bile acid CoA ligase, CoA racemase, acyl-CoA oxidase, 
and peroxisomal thiolase.  The last step in BA synthesis is the amidation of the bile acid-
CoA with an amino acid (glycine (G) or taurine (T)), by the bile acid-CoA:amino acid N-
acyltransferase (BAT) [10].  
There are minor pathways for BA synthesis, which do not require the initiation by 
CYP7A1 [11]. These pathways are initiated via the hydroxylation of the cholesterol side 
chain at the different positions (C24, C25, or C27) by various enzymes including, 
CYP46A1, cholesterol 25-hydroxylase, and CYP27A1. The resulting oxysterols are then 
hydroxylated at the 7α position by CYP7B1 or CYP39A1.  These pathways of BA 
synthesis are called the "alternative" or "acidic" pathways.  In contrast to the classical 
pathway, these alternative pathways predominantly produce CDCA [12].  Alternative BA 
pathways are important in conditions associated with a deficiency in CYP7A1 activity 
[13]. 
1.1.3 Enterohepatic Recirculation of BAs 
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BAs synthesized in the liver are secreted into bile, which flows through the bile 
duct to the duodenum.  BAs are efficiently absorbed from the terminal ileum and 
returned to the liver where they are once again secreted into bile.  This cycle is called 
the enterohepatic recirculation of BAs [6].  Enterohepatic cycling of BAs is efficiently 
controlled by various transporters in the hepatocytes and enterocytes [6, 14, 15].  BAs 
are actively absorbed in the ileum by the Na+-dependent bile salt transporter (ASBT) 
located on the apical side of enterocytes.  Organic solute transporters (OST-α/β) and 
multidrug resistance-associated protein 3 (MRP3), located on the basolateral side of 
enterocytes, transport BAs from the intestinal lumen to blood [15, 16].   Absorbed BAs 
are carried in the portal vein and extracted by the liver via the Na+-taurocholate co-
transporting polypeptide (NTCP) and members of the organic anion transporting 
polypeptide (OATP) family (OATP1B1, 1B3, and 2B1) [6, 17].  BAs spill-over across the 
basolateral side of hepatocytes into systemic circulation takes place via MRP1, MRP3, 
MRP4, MRP6, and OST-α/β transporters [18, 19].   
At the canalicular membrane of hepatocytes, BAs are excreted into bile via the 
canalicular bile salt export pump (BSEP), MRP2, and multi-drug resistance protein 1 
(MDR1) [20].  In species that have gallbladders such as humans, chimpanzees, 
monkeys, dogs, and mice, secreted bile is stored in the gallbladder, which contracts to 
empty its content into the duodenum under the influence of cholycystokinin secretion 
after meal ingestion [14].  In species without a gallbladder such as rat, deer, elephant, 
and horse, and in patients who have undergone surgical removal of the gallbladder, bile 
acids also have an enterohepatic circulation, but presumably the bile acid pool is stored 
in the small intestine during overnight fasting [14].  In the small intestine, most 
conjugated BAs are actively absorbed in the ileum, while unconjugated BAs are 
passively absorbed throughout the intestinal tract [21, 22].  Partial deconjugation takes 
place by the bacteria in the distal parts of the small intestine, and the liberated 
4  
unconjugated BAs are passively absorbed [21, 23].  Unabsorbed BAs are passed along 
the intestinal tract. In the large intestine, BAs undergo bacterial transformations, 
including deamidation, desulfation, deglucuronidation, dehydroxylation, epimerization, 
and/or dehydrogenation to produce secondary BAs [6, 24].  DCA and LCA are 
secondary BAs produced from the dehydroxylation of CA and CDCA, respectively, in the 
intestine.  Unabsorbed BAs are excreted in feces.  Ninety-five percent of BAs excreted in 
bile are reabsorbed throughout the intestinal tract and less than 5% are excreted in 
feces [6].  Absorbed BAs are carried in the portal vein and extracted by the liver via 
active or passive diffusion.  In hepatocytes, most BAs undergoes amidation, but other 
metabolic pathways also take place including, hydroxylation and sulfate or glucuronide 
conjugation.  The reabsorbed and newly synthesized BAs are then excreted into bile to 
complete the enterohepatic cycle. 
1.1.4 Physiological Functions of BAs 
BAs are essential for the formation of mixed micelles in the small intestine,  
which facilitates the solubilization, digestion, and absorption of cholesterol, dietary lipids, 
and fat-soluble vitamins [25].  Hepatic conversion of cholesterol to BAs and subsequent 
excretion in feces represent the only significant mechanism for the elimination of excess 
cholesterol from the body [26].  Micelles present in the gallbladder solubilize cholesterol 
in bile and prevent cholesterol crystallization and gallstone formation.  BAs also induce 
the BA-dependent bile flow from hepatocytes through bile canaliculi to the gallbladder 
[27].  This eventually helps in the excretion of some substances like bilirubin and some 
drugs and toxins [27].  BAs also have bacteriostatic effects that maintain sterility in the 
biliary tract and control the normal flora composition in the intestine [28, 29].   
Over the last two decades, new insights have been introduced about the 
biological activities of BAs.  Recent findings have demonstrated that BAs are involved in 
their own homeostasis, regulation of energy expenditure, glucose and lipid metabolism, 
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thyroid hormone signaling, and cellular immunity.  Specific BAs differentially activate 
various nuclear and surface receptors, namely farnesoid X receptor (FXR), pregnane X 
receptor (PXR), vitamin D receptor (VDR), and G protein-coupled receptor (TGR5), 
which mediate their various hormonal functions [30-33].   
1.1.5 Pathological Effects of BAs 
Despite their physiological roles, BAs are also cytotoxic when present at high 
concentrations.  BAs exhibit pathological effects due to their direct detergent effects on 
biological membranes, apoptotic and necrotic effects via mitochondria and endoplasmic 
reticulum-mediated toxicities, and cancer promoting effects [25].   
Due to their detergent activity, BAs can bind to lipid bilayers and solubilize 
plasma membranes, causing cell lysis [34].  In addition, elevated intracellular levels of 
BAs can deteriorate mitochondrion integrity, causing permeabilization of mitochondrial 
membranes, which provokes depolarization of the organelle, uncoupling of oxidative 
phosphorylation, and mitochondrial swelling [35, 36].  Ultimately this leads to 
mitochondrial collapse, cytochrome c release, and activation of apoptosis [37, 38].  BAs 
can also induce apoptosis by causing endoplasmic reticulum (ER) stress [39].  BAs can 
also cause cell necrosis through various mechanisms including generation of 
hydroperoxides, ATP depletion, and sustained rise in cytosolic free Ca2+ [40].  
Furthermore, BAs act as cancer promoters by stimulating cell invasion and migration 
through activation of multiple oncogenic signaling pathways [41, 42]. 
Hepatotoxicity is a well-characterized toxicity of BAs.  Cholestatic diseases are 
hepatobiliary diseases associated with reduction in bile flow due to defects in bile 
production or impairment of bile flow through the canaliculi into bile duct [43].  Several 
studies in animal models including mice, rats, cats, and dogs clearly showed that various 
hepatobiliary diseases result in the accumulation of BAs in the liver, systemic blood, and 
extrahepatic tissues [44].  Accumulation of toxic BAs during cholestasis induces 
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hepatotoxicity, extrahepatic toxicity such as encephalopathy, and contributes to the 
unfavorable prognosis of these diseases such as liver failure [44-46].  Furthermore, 
several studies in animals indicate that the accumulation of toxic BAs in the liver is 
associated with the incidence and severity of complications after liver transplant [45, 47, 
48], where patients with lower secretion of biliary BAs are less likely to develop bile duct 
complications after liver transplant [49, 50].  The cholestatic activity of BAs is attributed 
to their water insolubility because BAs with low solubility may form insoluble BA salts, 
such as Ca+2salts, which precipitate in and damage the canaliculi [51-53].  Another 
mechanism of liver injury by BAs, is  increasing the biliary secretion of phospholipids 
causing their depletion and allowing BAs to solubilize membrane phospholipids, which 
disturbs the integrity of the canalicular membranes [6].   
1.1.6 Differences between Individual BAs  
Individual BAs vary widely in their physicochemical properties, physiological 
functions, and toxicities.  BA hydrophobicity is influenced by both the BA nucleus and the 
side chain structures [54].  There is an inverse relationship between the number of OH 
groups present on steroid nucleus and lipophilicity.  The Mono-hydroxy (mono-OH) BA 
(LCA) is more hydrophobic than di-hydroxy (di-OH) BAs (CDCA and DCA), which in turn 
are more hydrophobic than tri-hydroxy (tri-OH) BAs (CA, MCA, and HCA).  
Hydrophobicity is also determined by the position and stereochemistry of hydroxyl 
groups.  For example the 7β, 6α, and 6β- OH substitutions result in the formation of 
more hydrophilic BAs.  BAs possess two distinct hydrocarbon surfaces, the convex 
hydrophobic side and the concave hydrophilic side.  7β, 6α, and 6β- OH groups are 
located above the steroid nucleus and are equatorial to the plane of steroid nucleus, 
while 7α and 12α- OH groups are located below the steroid nucleus and are axial to the 
plane of the steroid nucleus.  The equatorial location of hydroxyl groups confers polarity 
to the hydrophobic concave side of the steroid nucleus and they are more resistant to 
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the loss of associated water [15, 55, 56].  Therefore, UDCA (7β- OH) is more hydrophilic 
than CDCA (7α- OH) and DCA (12α- OH).  Similarly, MCAs, containing both 6α and 7β-
orientated hydroxyl groups, is more hydrophilic than HCA (6α and 7α- OH), which in turn 
is more hydrophilic than CA (7α and 12α- OH).   
Amidation increases the acidity of unconjugated BAs, where pKa is reduced from 
about 5.5 for the unamidated BAs to 4.5 and 1.5 for those with G- and T-amidation, 
respectively [51].  This increase BA ionization and solubility at physiological pH.  
Conjugation of the BA backbone with sulfate or glucuronide groups also increases BA 
ionization and solubility.  This result in complete ionization of BAs at physiological pH, 
which markedly reduces their lipophilicity, increases their solubility, decreases 
membrane permeability, and increases their urinary and biliary excretion [51, 57].   
The term hydrophobicity index (HI) was introduced to describe the hydrophilic- 
hydrophobic balance of BAs based on their relative retention time and capacity factor in 
C18 reversed-phase HPLC.  HI of BAs ranges from +1.46 for the most hydrophobic BA 
(LCA) to -0.94 for the most hydrophilic BA (T-UDCA) [58, 59].  A composite HI index can 
be calculated for any BA pool based on the HI of individual BAs normalized with their 
concentrations, which describes the overall hydrophobicity of the BA pool [58, 59].   
As amphipathic molecules with hydrophobic and hydrophilic regions BAs 
form micelles.  The concentration at which BAs start forming micelles is called the critical 
micelle concentration (CMC).  The lower the CMC, the more stable is the micelle and the 
more efficient micelle former is the BA.  The CMC values of mono-OH BAs are lower 
than Di-OH BAs, which in turn are lower than tri-OH BAs. CMC values (in mM) for the 
various BAs are LCA (0.5) < DCA (3) < CDCA (4) < UDCA (7) < CA (11) < HDCA (16) < 
HCA (20) <α-MCA (32) < ωMCA (35) <β-MCA (50) [60-62].   In addition, amidation with 
G or T lowers the CMC [61, 62], while conjugation with sulfate or glucuronide increases 
the CMC of BAs [6, 63].  
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 Individual BAs also differ in their physiological effects.  As mentioned above, the 
more hydrophilic BAs have higher CMC values and are less efficient micellar formers; 
therefore, less efficient in cholesterol solubilization and absorption [64].  In addition, the 
effects of BAs on bile flow vary according to their hydrophilicity.  Hydrophilic BAs such as 
UDCA, MCA, HCA, and CA induce bile flow (cholaresis), whereas hydrophobic BAs 
such LCA, DCA, and CDCA decrease or block bile flow (cholestasis) [65-69].  Individual 
BAs also have marked differences in their affinities to their various receptors.  For 
example, the various BAs affinities for TGR5 are in the order of 
LCA>DCA>CDCA>CA>UDCA [32, 70]. In contrast, the various BAs affinities for FXR are 
in the order of CDCA>DCA>LCA>UDCA, CA [71, 72], while MCA acts as FXR 
antagonist [73].   
BA cytotoxicity has been extensively characterized in several cell lines including 
hepatocytes [74], HepG2 cell [75], erythrocytes [76], mast cells [77], and intestinal cells 
[78].  In general, BA cytotoxicity increases with hydrophobicity, where the tri-OH BAs are 
less toxic than the di-OH BAs, which in turn are less toxic than the mono-OH BAs.  In 
addition, G- and T- amidation, as well as glucuronide and sulfate conjugation decrease 
BA cytotoxicity [79-81].  Also, LCA and DCA are potent inducers of apoptosis compared 
with CA and UDCA [79, 82].   
1.1.7 Species Differences in BA Homoeostasis  
There are known species differences in BA metabolism and transport. BAs are 
metabolized via amidation (glycine or taurine), hydroxylation by CYP3A, or conjugation 
(sulfation by SULT2A1 and glucuronidation by UGTs).  Amidation with glycine is 
predominant in humans [43, 83], rabbits [84], and pigs [85], whereas taurine amidation is 
predominant in rats [86], mice [87, 88], dog [89], cats [90], and horses [91].  
Hydroxylation, on the 6-α, 6-β, and 7-β positions [92, 93] is a primary pathway that 
produces the most hydrophilic and least toxic HCA (pigs), MCA (rats and mice), and 
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UDCA (bears), respectively [94].  Equivalent to hydroxylation in rodents, sulfation is the 
major pathway of BA metabolism and detoxification in humans [6] and chimpanzees 
[95].   
Species differences in intestinal flora and anatomy of large intestine also affect 
the composition of bile acids [96].  For example, compared with other animals rabbit has 
unusually large cecum (10 times the capacity of stomach), where large quantity of 
anaerobic bacteria reside, which results into formation of higher secondary BAs (DCA) in 
rabbit compared with other species [84].  
In addition to BA metabolism, influx and efflux transporters at both the sinusoidal 
and basolateral membranes play an important role in determining intracellular BA 
concentration, and therefore their hepatotoxicity.  Similar to BA metabolism, major 
species differences were reported in BA transport [97-101].  The contribution of 
basolateral efflux via MRP transporters to ameliorate drug-induced toxicity was 5-fold 
higher in rats than humans [97].  Rodent Mrp3 transports BAs with high affinity, but 
human MRP3 with relatively low affinity [100, 101].  BAs uptake by NTCP and OATP 
transporters was 3-15 higher in rats compared to human hepatocyte [98].  Furthermore, 
OATP1B1 and OATP1B3 are poorly conserved in humans, rodents, and dogs [99].  
1.1.8 BAs and Drug Induced Liver Injury (DILI) 
DILI is the most common cause of acute liver failure in USA [102, 103].  An 
online database (http://www.livertox.nih.gov/) provides detailed information on more than 
600 drugs and herbal products associated with DILI.  DILI has an unpredictable and 
heterogeneous course, ranging from an asymptomatic rise in liver enzymes to acute liver 
failure.  DILI is one of the primary reasons for the failure of pharmaceutical agents during 
drug development as well as the withdrawal of approved drugs from the market [104].  
The mechanisms underlying DILI are not fully understood, but one of the established 
mechanisms is the alteration of BA homeostasis.  The relationship of altered BA 
10  
homeostasis and the pathogenesis of cholestatic liver diseases has been demonstrated 
in animal models of cholestasis, where the interruption of bile flow leads to BA retention 
in the liver and the biliary tree [105].  Because of their hepatotoxicity, intrahepatic 
accumulation of BAs itself can worsen and contribute to the pathogenesis of liver 
diseases [106, 107].  Similar to liver diseases, BA accumulation due to alterations of 
various aspects of their homeostasis caused by some drugs is proposed to be one of the 
major mechanisms underlying DILI [108, 109].  For example, total BAs concentrations 
were shown to correlate with the progression of liver and bile duct damage in bile-duct 
ligated and thioacitamide-induced cholestatic rats [105, 110].   
A variety of in vitro models including membrane vesicles expressing BA 
transporters, primary hepatocytes, micropatterned hepatocytes culture, and sandwich 
culture hepatocytes were developed and applied for high-throughput assessment of DILI 
risk [111].  However, such exercises have rendered mixed results with many false 
negative and positive predictions [112, 113].  For example, drugs that inhibit transporters 
involved in BA excretion from hepatocytes into bile such as BSEP and/or transporters 
involved in the basolateral efflux of BAs from hepatocytes into systemic blood such as  
members of the MRP family was shown to lead to intrahepatic accumulation of BAs and 
DILI [114, 115].  However, inhibition of BA transporters, by itself, is not always a 
predictor for DILI.  For example, telmisartan is a potent BSEP inhibitor, but is not 
associated with DILI in the clinic [116].  Similarly, rifabutin is known to cause DILI in 
humans, but it is a weak BSEP inhibitor [112].  Therefore, current DILI in-vitro models 
address one aspect of BA homeostasis, that is transport via one or a limited combination 
of transporters (BSEP and MRPs), but do not account for other transporters such as 
OATPs and NTCP.  Also, these in-vitro models do not account for other aspects of 
perturbation of BA homeostasis such as BA metabolism, synthesis, and excretion.   
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 In general, in vivo preclinical safety studies are conducted in two species, one 
rodent and one non-rodent [117, 118].  Preclinical safety studies in animals can capture 
various toxicities including carcinogenicity, teratogenicity, genotoxicity, and adverse 
effects of compounds on the cardiovascular, nervous, and respiratory systems, but they 
are not as predictive of DILI in humans [119].  Toxicology studies using rodent and non-
rodent species failed to detect DILI in approximately 45 % of cases [119].  For example, 
bosentan was not hepatotoxic in rats but it causes DILI in humans [104, 120].  In 
contrast, primidone was hepatotoxic in dogs, but was not in the clinic [121].  The marked 
differences in BA composition and homeostasis between preclinical safety models and 
humans may play a major role in the poor prediction of DILI using preclinical in vivo 
models.   Major species differences in the susceptibility to BA-induced hepatotoxicity 
were previously reported and were explained by species differences in BA metabolism.  
For example, CDCA  and LCA produced severe hepatic toxicity, in species that lack BA 
sulfation capabilities including rhesus monkeys [122, 123], rabbits [124], guinea pigs 
[125], and dogs [126].  However, in humans and chimpanzees, where sulfation is a 
primary metabolic pathway of BAs, CDCA and LCA are not associated with hepatic 
injury [122, 127-130].  In addition, mice [131] and rats [132] are more resistant to LCA 
and  CDCA hepatotoxicity because their BAs are more hydrophilic than humans due to 
efficient hydroxylation and taurine amidation [97, 133-135].  Collectively, strong evidence 
exists that species susceptibility to BA toxicity and therefore DILI, may be determined by 
their capability to efficiently metabolize BAs.    
Overall, DILI remains to be one of the most poorly predicted side effects in 
humans due to the shortcomings of the currently used preclinical in vivo and in vitro 
toxicity models.  
1.1.9 Objectives 
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There are major inter-species differences in BA homeostasis, which may play a 
major role in the poor predictability of DILI using the currently available preclinical in vitro 
and in vivo models.   In particular, there is a major gap in our knowledge regarding the 
differences in BA metabolism between preclinical species used in drug safety testing 
and humans.  Therefore, this work aims to i) quantify the in-vivo BA profile in plasma 
from various species, (ii) quantify the contribution of the various pathways involved in BA 
metabolism in-vitro using hepatocytes S9 fractions from various species, (iii) assess the 
in vitro-in vivo extrapolation of BA metabolism using our in vitro model in the various 
species, (iv) quantify the species differences in BA metabolism, composition, 
hydrophilicity, and toxicity (v) identify preclinical species that are most similar to humans 
in regards to BA metabolism.  Overall, this knowledge will facilitate the development of in 
vitro models more predictive of DILI as well as the identification of preclinical species 
that metabolize BAs in a similar fashion to humans and therefore are more relevant to in 
vivo testing of DILI.    
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1.2 Materials and Method 
1.2.1 Chemicals and Reagents  
Human, rhesus monkeys, cynomolgus monkeys, gottingen minipigs, begal dogs, 
new zealand rabbits, golden syrian hamsters, sprague dawley rats, and CD-1 mice 
hepatocyte S9 fractions were purchased from Sekisui XenoTech, LLC (Kansas City, 
KS).  Chimpanzees and C57BL/6 mice hepatocyte S9 fractions were purchased from 
BioreclamationIVT (Westbury, NY).  Plasma from Chimpanzees, Rhesus monkeys, 
Cynomolgus monkeys, Gottingen minipigs, Begal dogs, New Zealand rabbits, Sprague 
Dawley rats, CD-1 mice, C57BL/6 mice, and Golden Syrian hamsters were obtained 
from BioreclamationIVT (NY, USA).  Nicotinamide adenine dinucleotide phosphate 
(NADPH), uridine diphosphate glucuronic acid (UDPGA), D-Saccharic acid 1,4-lactone, 
3'-phosphoadenosine-5'-phosphosulfate (PAPS), glutathione (GSH), glycine, taurine, 
adenosine triphosphate (ATP), Coenzyme A (CoA) were purchased from Sigma-Aldrich 
(St. Louis, MO).  Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholicacid 
(DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), tauro-cholic acid (T-CA), 
tauro-chenodeoxycholic acid (T-CDCA), tauro-deoxycholic acid (T-DCA), tauro-
lithocholic acid (T-LCA),tauro-ursodeoxycholic acid (T-UDCA), glyco-cholic acid (G-
CA),glyco-chenodeoxycholic acid (G-CDCA), glyco-deoxycholic acid (G-DCA), glyco-
lithocholic acid (G-LCA), glyco-ursodeoxycholicacid (G-UDCA), LCA-sulfate and 
activated charcoal (DARCO®G-60, 100 mesh powder) were purchased from Sigma-
Aldrich (St Louis, MO).  β-muricholic acid (β-MCA), tauro-β-muricholicacid (T- β-MCA), 
hyocholic acid (HCA), glyco-hyocholic acid (G-HCA), tauro-hyocholic acid (T-HCA), 
hyodeoxycholic acid (HDCA), glyco-hyodeoxycholic acid (G-HDCA), tauro-
hyodeoxycholic acid (T-HDCA), murideoxycholic acid (MDCA), isolithocholic acid 
(isoLCA), isodeoxycholic acid (isoDCA), 7-oxoLCA, 12-oxoLCA,12-oxoCDCA, 3-
dehydroCA, and norDCA were purchased from Steraloids, Inc. (Newport, Rhode Island).  
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UDCA-sulfate, CDCA-sulfate, DCA-sulfate, CA-sulfate, their G- and T-amidates, as well 
as G-LCA-sulfate and T-LCA-sulfate were generously provided by Dr.Junichi Goto, 
Tohoku University, Aoba-ku, Japan. 2H4-G-CDCA, 2H4-T-CDCA, 2H4--CDCA, 2H4-G-
UDCA, 2H4-CA, and 2H4-LCA were purchased from C/D/N isotopes, Inc. (Pointe-Claire, 
Quebec,Canada).  HPLC-grade methanols, acetonitrile, water, ammonium acetate, 
ammonium hydroxide, formic acid, acetic acid, hydrochloric acid (HCl) were obtained 
from Fisher Scientific (Fair Lawn, NJ).   
1.2.2 Hepatocyte S9 Fractions Incubation Condition 
Hepatocyte S9 fractions from male humans, chimpanzees (23.3 mg/ml protein), 
rhesus monkeys (20 mg/ml protein), cynomolgus monkeys (20 mg/ml protein), beagle 
dogs (20 mg/ml protein), gottingen minipigs (20 mg/ml protein), new zealand rabbits (20 
mg/ml protein), sprague dawley rats (20 mg/ml protein), golden syrian hamster (20 
mg/ml protein), CD-1 mice (20 mg/ml protein), and C57BL/6 mice (21.3 mg/ml protein) 
were thawed carefully on ice and divided into aliquots for further experiments.  Prior to 
incubation, stock solutions of 200 mM GSH, 250 mM glycine, 250 mM taurine, 50mM 
ATP, 200 mM CoA, 500 mM D-saccharic acid 1,4-lactone, 10.1 mg/ml 3'-
Phosphoadenosine-5'-phosphosulfate (PAPS), 25 mM uridine 5’-diphospho-glucuronic 
acid (UDPGA), and 125 µg/ml alamethicin were prepared in potassium phosphate buffer 
(pH 7.4, 100 mM) containing 5 mM MgCl2.  BA substrate stock solutions of 20 mM 
unlabeled:labeled (1:1) substrate were prepared in MeOH.  Final MeOH concentration in 
the incubation mixture did not exceed 0.2%. Cofactors and hepatocyte S9 protein were 
10-x diluted with 100 mM potassium phosphate buffer (pH 7.4), and biotransformation 
reaction was initiated by adding a 50-µl mixture of cofactors and substrate to 50 µl of S9 
protein at a final concentration of 1 mg protein/ml and a final volume of 100 µl.  The 
reaction mixture was incubated for 60 min at 37°C and the reaction was terminated by 
adding a 100 µl of ice-cold methanol, followed by vortex-mixing and centrifugation at 
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16,000 g for 10 min.  Ten µl of supernatant was directly subjected to LC-MS/MS 
analysis.   For zero-min incubations, a 100 µl of ice-cold methanol was added to the 50 
µl mixture of cofactors before the addition of 50 µl of S9 protein.  Final concentration of 
reagents were 1 mM NADPH, 0.1 mM PAPS, 5 mM GSH, 5 mM glycine, 5 mM taurine, 1 
mM ATP, 0.4 mM CoA, 0.4 mM UDPGA, 25 µg/mL alamethicin, and 40 µM 
unlabeled:labeled substrate (1:1) in a final volume of a 100 µl.     
1.2.3 Identification of Metabolites Generated by Hepatocyte S9 fractions  
1.2.3.1 Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis 
A Waters ACQUITY ultra performance liquid chromatography (UPLC) system 
(Waters, Milford, MA) coupled to a 4000 Q TRAP® quadrupole linear ion trap hybrid 
mass spectrometer (MS) with an electrospray ionization (ESI) source (Applied 
Biosystems, MDS Sciex, Foster City, CA) was used.  Metabolite identification was 
performed by enhanced MS-information dependent acquisition-enhanced product ion 
scan (EMS-IDA-EPI) in negative ionization mode.  The EMS survey scan was conducted 
in the mass range from 160 to 750 Da, at a 1000 Da/s scan rate followed by an 
enhanced resolution (ER) scan at 250 Da/s.  The IDA threshold was set at 5000 counts 
per second (cps), above which enhanced product ion (EPI) spectrum collection is 
triggered from the precursor mass of that particular channel.  The EPI scan rate was 
4000 Da/s and the scan range was 70–750 Da.  The IDA method was also employed to 
trigger EPI scans by analyzing MRM signals.  The pMRM–IDA-EPI (predicted MRM-
enhanced production scan) method used pMRM (predicted MRM) as a survey scan.   
The pMRM channels were generated by an Analyst script from mass-to-charge ratio of 
the deprotonated molecules based on predicted biotransformation pathways.  A total of 
114 MRM channels for predicted metabolites were created for every compound, with 
dwell times of 5 msec/channel and pause times of 5 msec.  The same declustering 
potential (DP), collision energy (CE), and cell exit potential (CXP) values for every parent 
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compound were used for the MRM transitions of their predicted metabolites. The IDA 
threshold was set at a 1000 counts per second (cps), above which EPI spectra were 
collected from the parent mass of that particular channel.  The EPI scan was operated 
from m/z 100 to 700 at a scan rate of 4000 amu/s with dynamic fill and CE spread of 15 
eV.  The total cycle time for the MRM-IDA-EPI was 2.2 sec/cycle.  Metabolite 
identification was performed using LightSight 2.2 software by comparing MS spectrums 
obtained from samples after 60 min incubation with those obtained at zero-min 
incubations.  Mixtures of 1:1 unlabeled: stable-isotopically labeled parent BA substrates 
were used in all incubations.  Therefore, total ion chromatograms (TIC), obtained from 
the screening scans mentioned above, were filtered for the isotopic pattern of 1:1 
abundance of ion pairs with a mass difference of 4 Da, using the elemental targeting 
feature in Analyst software (AB Sciex, Framingham, MA). 
1.2.3.2 High resolution mass spectrometry (HRMS) analysis 
HRMS analyses were performed using a LTQ-Orbitrap Elite (ThermoFisher 
Scientific) fitted with an electrospray ionization (ESI) source in a continuous infusion 
mode.  Both sheath and auxiliary gases were high purity nitrogen, and the collision gas 
was ultra-high purity helium.  Parent mass range was set at m/z 100–1000; sheath gas, 
30 arbitrary units; auxiliary gas, 5 units; spray voltage, 4.5 kV; capillary temperature, 300 
°C; capillary voltage, 18 V; and energy for collision-induced dissociation (CID) was set at 
35 eV.  MS resolution was set at 60,000 FWHM for full MS scans.   Authentic parent BA 
standards and biosynthesized metabolites (1 µg/ml in MeOH: H2O) were injected into the 
instrument via a syringe pump at 10 µl/min. The instrument was controlled by Xcalibur 
1.4™ software (Thermo Fisher Scientific, CA, USA). 
1.2.4 Biosynthesis and NMR-based Quantification of UDCA Metabolites  
UDCA (100 µM) was incubated with the hepatocyte S9 fractions as describe 
above.  For the biosynthesis of oxidation and sulfation metabolites, cynomolgus and 
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rabbit hepatocyte S9s were used, respectively.  For the biosynthesis of glucuronidation 
and glutathione conjugates, dog hepatocyte S9 fractions were used.  Reactions were 
performed in final volumes of 500 µl and were allowed to proceed for 60 min at 37°C.  At 
the end of each incubation, reactions were terminated by adding 500 µl MeOH, followed 
by vortex-mixing and centrifugation at 16,000 g for 10 min.  Supernatants were aspirated 
and dried down by vacuum centrifugation.  Residues were dissolved in a 100 µl of 
MeOH:H2O.  Metabolites were separated using chromatographic conditions similar to the 
analytical-scale conditions described above, but the separation was carried out on HPLC 
column (XBridge BEH C18 5 μm, 150 × 4.6 mm) at a flow rate of one ml/min.  
Metabolites were fraction-collected from the HPLC column effluent, in a time-slice mode, 
into 12-mm test tubes.  Fractions containing metabolite of interest were pooled from 
multiple injections, vacuum centrifuged to remove the mobile phase solvents, 
reconstituted in 0.4 mL of 2H6-DMSO, and subsequently transferred to 5-mm NMR 
tubes. 
Proton spectra of biosynthesized metabolites were acquired using a Burker-600 
spectrometer (Billerica, MA) equipped with 5-mm CyroProbe operating at 600 MHz.  
Three hundred forty scans with an acquisition time of 4.5 S were collected for each 
spectrum.  A pre-acquisition delay of 60 S was used during the data acquisition.  1H 
NMR spectra were acquired at 30°C.  The signal of the protonated portion of the 
deuterated solvent was arbitrarily set to 100 and used as an internal reference to 
normalize the integral values within each spectrum.  NMR integral of a common proton, 
which was neither affected metabolically nor coincided with any endogenous signals, 
was obtained.  NMR spectra of UDCA were obtained at five different concentrations (5-
200 µM) and a calibration curve was constructed by plotting proton integral values 
against nominal concentrations.  Concentrations of metabolites in collected fractions 
were determined using the UDCA calibration curve.   
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1.2.5 BAs Quantification by LC-MS/MS 
BAs concentrations were measured by LC-MS/MS, as we described previously 
with some modifications [83, 87].  Briefly, a Waters ACQUITY ultra performance liquid 
chromatography (UPLC) system (Waters, Milford, MA) coupled to a 4000 Q TRAP® 
quadrupole linear ion trap hybrid mass spectrometer (MS) with an electrospray ionization 
(ESI) source (Applied Biosystems, MDS Sciex, Foster City, CA) was used.  The 
following MS source settings were used: ion spray voltage, -4000V; temperature, 500 
°C; curtain gas, 20; gas-1, 35; gas-2 35 (arbitrary units); collision gas pressure, high; 
Q1/Q3 resolution, unit; and interface heater, on.  Mobile phase consisted of 7.5 mM 
ammonium bicarbonate, adjusted to pH 9.0 using ammonium hydroxide (mobile phase 
A), and 30% acetonitrile in methanol (mobile phase B), at a total flow rate of 0.2 ml/min.  
The gradient profile was held at 52.5% mobile phase B for 12.75 min, increased linearly 
to 68% in 0.25 min, held at 68% for 8.75 min, increased linearly to 90% in 0.25 min, held 
at 90% 12 for 1 min, and finally brought back to 52.5% in 0.25 min followed by 4.75 min 
re-equilibration (total run time of 28 min per sample).  For the preparation of calibration 
curves, blank matrices were obtained by charcoal stripping as described previously [83, 
87]. Eleven -point calibration curves were prepared by spiking 10 µl of appropriate 
standard solution into 100 µl stripped matrices at final concentrations ranging from 1 to 
1000 ng/ml.   
For preparation of plasma samples, 100 µl of plasma samples were spiked with 
10 µl of IS, 1 mL of ice-cold alkaline ACN (5% NH4OH) was added, and samples were 
vortexed.  Samples were then centrifuged at 16,000 x g for 10 min and the supernatants 
were aspirated, evaporated under vacuum and reconstituted in 100 µl of 50% MeOH 
solution.  For urine, 100 µl of samples were spiked with 10 µl of IS, vortexed, and loaded 
onto SPE cartridges pre-conditioned with 4 ml MeOH and 4 ml H2O and eluted with 4 ml 
MeOH.  Eluates were then evaporated under vacuum at room temperature and 
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reconstituted in 100 µl of 50% MeOH solution.  Ten µl of reconstituted samples were 
injected for analysis.  
1.2.6 Calculation of BA Indices 
BA profiles in plasma and urine were characterized using BA “indices” that describe the 
composition, hydrophobicity, metabolism of total and individual BAs as we described 
previously [43, 44, 136].  Briefly, the composition of individual BAs was calculated as the 
ratio of the concentration of individual BAs in all of their forms (amidated, unamidated, 
sulfated, and unsulfated) to the total concentration of BAs.  The percentage of sulfation 
of individual BAs was calculated as the ratio of the concentration of sulfated BAs, in both 
the amidated and unamidated forms, to the total concentration of individual BAs in all of 
their forms (sulfated, unsulfated, amidated, and unamidated).  The percentage of 
amidation of individual BAs was calculated as the ratio of the concentration of amidated 
BAs, in both the sulfated and unsulfated forms, to the total concentration of individual 
BAs in all of their forms (sulfated, unsulfated, amidated, and unamidated).  In addition, 
percentages of amidation were divided into the percentages of BAs existing as glycine 
(G) vs. taurine-(T) amidates.  The percentages of mono-OH BA (LCA), di-OH BAs 
(MDCA, UDCA, HDCA, CDCA, and DCA), and tri-OH BAs (CA, HCA, and MCA) were 
calculated as the ratio of the concentration of the sum of the respective BAs in all their 
forms to the total concentration of BAs.  The ratio of primary to secondary BAs was 
calculated as the ratio of the sum of the concentrations of CDCA, CA, MCA, and HCA to 
the sum of the concentrations of DCA, LCA, UDCA, HDCA, and MDCA in all their forms.  
Similarly, ratio of 12α-OH: non-12α-OH was calculated as the ratio of the sum of the 
concentrations of DCA and CA to the sum of the concentrations of CDCA, HDCA, MCA, 
LCA, UDCA, HCA, and MCA in all their forms.  The Hydrophobicity index (HI) of the BA 
pool was calculated according to the Heuman index, based on the relative contributions 
of the individual BAs to the total BA pool and their hydrophobicity indices [58]. 
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1.3 Results  
1.3.1 BA Profiles in Plasma 
Table 1.1 shows plasma BA profiles in humans and in various animal species.  
The total plasma BA pool was highest in pig (31 µM) followed by rat (12 µM) and lowest 
(0.07 µM) in chimpanzee.  In all other species, the BA pool ranged from 1-5 µM.  The 
highest sulfation of BAs was 30-50% in human and chimpanzee followed by 5% in rabbit 
and it was less than 2% in all other species.  Also, tri-OH BAs (CA, MCA, and HCA) 
were the least sulfated (for example, <5% in human), mono-OH BAs (LCA) was the most 
sulfated (for example, 93% in human), while di-OH BAs (UDCA, CDCA, and DCA) had 
an intermediate sulfation (for example, 30-60% in human) across all species studied in 
this manuscript.  Amidation was highest (50-80%) in dog, chimpanzee, human, and CD-
1 and C57/BL6 mice, while it was 10-20% in all other species.  G-amidation was 
predominant in human, minipig, hamster, and rabbit, while it was lowest in dog and both 
strains of mice (<1%).  In contrast, T-amidation was predominant in both strains of mice, 
rat, dogs, while it was lowest in minipig and rabbit (<1%).  Glucuronidation was low (< 
0.5%) in all species across all BAs, with dog being the highest.  Also, similar to sulfation, 
glucuronidation was inversely proportional to the number of OH groups, with tri-OH BAs 
(CA, MCA, and HCA) being the lowest and mono-OH BA (LCA) being the highest 
glucuronidated BAs.  
 The percentage of mono-OH BAs (LCA) was highest in chimpanzee (52%) and 
rhesus monkey (26%), followed by human, cynomolgus monkey, dog, and rabbit (5-
10%), while it was less than 1% in all other species.  The percentage of Di-OH BAs was 
highest (50-75%) in human, rabbit, minipig, and both strains of monkeys and lowest (25-
35%) in hamster, rat and both strains of mice.  The percentage of Tri-OH BAs was 
highest in hamster, rat, dog and both strains of mice (50-75%), followed by monkey (25-
35%), and lowest in human, chimpanzee and rabbit (5-10%).  The contribution of 
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individual BAs to the overall composition of the plasma BA pools in the various species 
is shown in Figure 1.2.  The most abundant BAs were CA (37%) in cynomolgus 
monkey, dog (54%), hamster (56%), and SD rat (30%); LCA (26%), DCA (23%), and CA 
(22%) in rhesus monkey; HCA (33%) and HDCA (57%) in minipig; CA (41-46%) and 
MCA (28-36%) in mice; CDCA (33%) and DCA (27%)  in human; DCA in rabbit (43%);  
and LCA (51%) in chimpanzee.    
The ratio of primary (sum of CDCA, CA, MCA and HCA) to secondary (sum of 
DCA, LCA, UDCA, HDCA, and MDCA) BAs was lowest in rabbit (0.05), followed by the 
chimpanzee (0.18) and minipig (0.59) because these species have the highest 
concentrations of the secondary BAs DCA, LCA, and HDCA, respectively (Table 1.1).  In 
contrast, this ratio was highest in mice (4.5) and cynomolgus monkey (3.84) because of 
the high concentrations of the primary BAs, CA, and MCA, respectively.  CA: CDCA ratio 
was highest (6-15) in mice, dog, and hamster, and it was lowest in minipig and human 
(0.04 and 0.3).  Similarly, the ratio of 12α-OH (sum of DCA and CA): non-12α-OH (sum 
of CDCA, HDCA, MCA, LCA, UDCA, HCA, and MCA) BAs was highest (2-4.4) in dog, 
hamster, and mice, while it was lowest in minipig, chimpanzee and human (0.002, 0.2, 
and 0.7). 
HI was lowest (-0.1 to -0.2) in minipig and in both strains of mice because these 
species have the lowest concentrations of LCA (the most hydrophobic BA) and they 
have the highest concentrations of the hydrophilic BAs, MCA and HCA, respectively.  In 
contrast, highest HI values were found in the rabbit (0.6) and rhesus monkey (0.55) 
because of the high concentrations of the secondary BAs, DCA, and LCA, respectively.   
1.3.2 BA Profiles in Urine 
 Table 1.2 shows urine BA profiles in humans and in the various species.  The 
total urine BA pool was highest in pig (205 µM) followed by rat and CD-1 mouse (21 µM) 
and was lowest (0.2-0.7 µM) in chimpanzee, monkeys, hamster, and rabbit.  In all other 
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species, the BA pool ranged from 5 to 21 µM.  The highest sulfation of BAs was 85% in 
human followed by 50-70% in chimpanzee, rabbit, and mice, while it was 25% in monkey 
and less than 10% in all other species.  Amidation was highest (85%) in human and 
rabbit followed by 55-70% in chimpanzee, dog and mice, while it was 30% in monkey 
and lowest in hamster (3%).  BA amidation in minipig, human, chimpanzee, rhesus 
monkey, and rabbit was primarily with glycine (50-80%), whereas it was primarily with 
taurine (55-75%) in rat, mice, and dog.  Glucuronidation was low (< 0.5%) in all species 
across all BAs, with dogs being the highest.   
 The percentage of mono-OH BA (LCA) was highest in chimpanzee (30%), 
followed by human and rhesus monkey (10-12%), while it was less than 5% in all other 
species.  The percentage of Di-OH BAs was highest (50-75%) in human, monkey, rabbit, 
and minipig and was lowest (3-7%) in dog, and mice.  The percentage of Tri-OH BAs 
was highest in hamster, rat, dog and mice (70-95%) and was lowest in human and 
monkey (12-29%).  The contribution of individual BAs to the overall composition of the 
urine BA pool is shown in Figure 1.3.  The most abundant BAs were CA in chimpanzee 
(36%) and mice (66-76%); MCA (56%) in rat; MCA and CA in hamster (41 and 37%) and 
dog (49 and 40%); HCA (32%) and HDCA (28%) in minipig; CA (33%) and CDCA (29%) 
in rabbit; DCA (36%) in rhesus monkey; DCA (30%) and CA (22%) in cynomolgus 
monkey; and CDCA (28%) and DCA (27%) in human.     
 The ratio of primary to secondary BAs was lowest in monkey and human (0.5-
0.8) because they have the highest concentration of the secondary BAs, DCA (Table 
1.2). In contrast, this ratio was highest in mice (15-18) and dog (10) because of the high 
concentrations of the primary BAs, CA and MCA.  CA: CDCA ratio was highest (> 100) 
in mice followed by dog (35), rat (30), and hamster (29), while it was lowest in minipig 
and human (0.3-1).  Similarly, the ratio of 12α-OH: non-12α-OH BAs was highest (2.2-
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3.8) in hamster, and mice, while it was lowest in minipig, rat, and human (0.11, 0.15, and 
0.55). 
 HI was lowest (-0.2 to -0.6) in mice, rat, minipig, and dog because these species 
have the lowest concentrations of LCA (the most hydrophobic BA) and they have the 
highest concentrations of the hydrophilic BAs, CA, MCA, and HCA, respectively.  In 
contrast, highest HI values were found in the rhesus monkey (0.52) because of the high 
concentrations of the secondary BAs, DCA.   
1.3.3 Identification of Ursodeoxycholic acid (UDCA) Metabolites Generated by 
Hepatocyte S9 fractions   
1.3.3.1 Triple quadrupole tandem mass spectrometry 
For metabolite identification, incubations of 1:1 unlabeled:stable isotopically 
labeled (2H4) UDCA  were carried out with hepatocyte S9 fractions from 12 different 
species.  Table 1.4 shows optimized cofactor concentrations in our S9 fraction in vitro 
system to maximize assay sensitivity at relevant physiological concentrations.  Thirteen 
metabolites of UDCA were formed and detected in the hepatocyte S9 fractions from 
these species (Figure 1.4).  Detected metabolites were assigned based on the following 
criteria: 1) Mass shifts of metabolites relative to parent compound, 2) metabolites should 
not be detected in the control sample (0 min), 3) by matching the retention times of 
metabolites with available authentic standards, 4) by characterizing the MS/MS 
fragmentation patterns from the enhanced product ion (EPI) spectra of metabolites, and 
5) detections of pairs of isotopic peaks with mass difference of 4 Da due to the use of 
the mixture of 1:1 unlabeled:stable isotopically labeled UDCA (2H4) in the incubations.  
Representative EPI spectra of the UDCA metabolites generated by S9 fractions and 
their fragmentation patterns are shown in Figure 1.5.   
UDCA produced three metabolites (M1, M2, and M3) at m/z 567 corresponding 
to glucuronide conjugation (Figure 1.4 B).  UDCA has three possible sites for 
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glucuronidation, two hydroxyl group at C3 and C7 (O-glucuronide) and one free carboxyl 
group on side chain (acyl glucuronide).  Fragmentation patterns of M1 and M2 
metabolites (Figure 1.5 A) showed sequential loss of two H2O and one carbonate (-
H2CO3) moieties.  They also showed a fragment corresponding to the intact parent 
molecule at 391 m/z.  Characteristic fragments (m/z 175 and 113) of the glucuronide 
moiety were also observed.  In contrast, the fragmentation pattern of M3 metabolite 
(Figure 1.5 B) did not show sequential loss of two H2O moieties or a carbonate (-H2CO3) 
moiety.  However, it showed a characteristic fragment of glucuronide anion at m/z 193, 
which was not present in the EPI spectra of M1 and M2 metabolites.  Collectively, these 
data suggest that M1 and M2 are O-glucuronide, whereas M3 is an acyl-glucuronide 
conjugate of UDCA.  This is also supported by the longer retention time for acyl-
glucuronide (M3 at 7.4 min) compared to O-glucuronides (M1:3.5 and M2:4.3 min).  O-
glucuronides are more polar than acyl glucuronides due to the presence of one extra 
free carboxyl group, which cause them to elute earlier than acyl glucuronides.  However, 
the exact position of the O-glucuronidation, i.e. C3 vs. C7 could not be confirmed due to 
the identical MS/MS spectra of both metabolites and the lack of authentic standards.   
Two metabolites, M4 and M5, corresponding to sulfate conjugates were 
observed for UDCA at retention times of 4.1 and 7.4 min, respectively (Figure 1.4 C).  
There are two possible sites for sulfate conjugation at the hydroxyl groups at C3 and C7.  
Fragmentation of the deuterated (2H4) sulfate conjugates showed major fragments at m/z 
98 and 97 for M4 and M5, respectively (Figure 1.5 C and 1.4 E).  The sulfate ion (m/z 
97) is generated when the proton from the β carbon is transferred to the sulfate moiety, 
and the C-O bond is broken (Figure 1.5 D).  For the 3-O-sulfate metabolites, the proton 
from the β carbon is deuterated; and therefore, forms a m/z 98 rather than the m/z 97 
fragment resulting from the 7-O-sulfates.  These data suggest that M5 is a UDCA sulfate 
conjugate at the C3 position and M6 is a sulfate conjugate at the C7 position.  
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UDCA produced one metabolite (M6) at m/z 680 corresponding to a glutathione 
conjugate (Figure 1.4 D).  EPI spectra of the glutathione conjugate (Figure 1.5 E) 
showed characteristic fragments of glutathione at m/z 306, 272, 254, 210, 179, and 128.  
Four metabolites representing single-step hydroxylation into tri-OH metabolites, 
(M7, M8, M9, and M10; m/z 407) at retention times 2.5, 4.3, 5.2 and 7.4 min, 
respectively, were detected (Figure 1.4 E).  M10 was assigned as β-muricholic acid (β-
MCA) because its retention time and fragmentation pattern matched with the authentic 
standard of β-MCA.   EPI spectra were similar between all hydroxylated metabolites 
(M7-M10), with a common feature of loss of two consecutive H2O molecules (Figure 1.5 
F).  Due to the lack of authentic standards, the positions of the hydroxyl groups of M7, 
M8 and M9 were not assigned at this stage. 
Glycine (G) and taurine (T) amidates of UDCA were observed at m/z 448 (M11) 
and 498 (M12), respectively (Figure 1.4 F and G).  EPI spectra of G-UDCA (Figure 1.5 
G) produced intact G (m/z 74) and [M-H-COO-] (m/z 404) fragments.  EPI spectra of T-
UDCA (Figure 1.5 H) produced intact T (m/z 124) and two T fragments (m/z107 
[C2H3SO3-] and 80 [SO3-]).  G-UDCA and T-UDCA metabolite assignments were 
confirmed by matching their retention times with authentic standards. 
 One metabolite at m/z 514 (M13), corresponding to the combination of mono-
hydroxylation and T amidation, was observed (Figure 4 H).  EPI spectrum of M13 
(Figure 5 I) showed the loss of H2O and the production of intact T (m/z 124) and two T 
fragments at m/z of 107 [C2H3SO3-] and 80 [SO3-].  M13 was confirmed as T-MCA by 
matching the retention time with authentic standard.  
1.3.3.2 High resolution mass spectrometry (HRMS) analysis 
High resolution MS/MS was used to confirm the structural identification of the in-
vitro UDCA metabolites to confirm the low-resolution triple quadrapole MS/MS data by 
matching the MS/MS fragmentation patterns of metabolites with BA standards.  First, the 
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fragmentation patterns of the available authentic BA standards were characterized.  
Exact mass analyses of parent BA standards and their MS/MS fragments are shown in 
Table 1.3.  Proposed structures of MS/MS fragments are given in Figure 1.6.  
Tri-OH BAs (CA, HCA, α-MCA, β-MCA and ω-MCA) produced common 
fragments at m/z 405.2636, 389.2684, 387.2530, and 371.2585.  However, CA can be 
identified among all isomeric tri-OH BAs by the presence of unique MS/MS fragments at 
m/z 363.2894, 353.2479, 345.2788, 327.2684, 325.2528, 289.2166 and, 251.2010.  
MCA isomers (α-MCA, β-MCA and ω-MCA) can be identified by the presence of one 
unique MS/MS fragment at m/z 369.2429.  In addition, for the MCA isomers, α-MCA, and 
ω-MCA showed similar MS/MS spectra characterized by unique fragments at m/z 
377.2687 and 375.2530, which were not produced by β-MCA.  In contrast, HCA did not 
produce any unique MS/MS fragments that allow its distinction from the other tri-OH 
BAs.    
For the di-OH isomers (UDCA, CDCA, MDCA, HDCA, DCA, and isoDCA), 
UDCA, CDCA, MDCA, and HDCA produced common fragments at m/z 389.2688, 
373.2739 and 371.2583, whereas DCA and isoDCA produced different fragments at m/z 
355.2637, 347.2950, 345.2796, 329.2846, and 327.2690.  The two mono-OH BAs 
isomers (LCA and isoLCA) could not be distinguished and produced common fragments 
at m/z 357.2789 and 355.2635.   
All G- and T-amidates produced G (m/z 74.2048) and T (m/z 124.0074, 
106.9808, 79.9574) fragments, respectively.  All S-conjugates produced a common 
fragment (SO3-) at m/z 96.9602.  
After determining the fragmentation patterns of authentic BA standards, they 
were compared with the fragmentation patterns of in-vitro UDCA metabolites.  The 
metabolites of interest were isolated from UDCA incubation with hepatocyte S9 fractions 
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for 60 min.  Fractions collected from several injections were pooled to produce about 10 
µg quantity of metabolites before MS/MS analyses.  Exact mass analyses of the isolated 
metabolites and their MS/MS fragments are shown in Table 1.4.  In general, the 
fragmentation patterns of glucuronide, sulfate, glutathione conjugates (M1-M6), and G 
and T-amidates (M11-M13) of UDCA were similar in both the low-resolution triple quad 
(Figure 1.4) and HRMS Orbitrap MS systems (Table 1.4).  In addition, M10 was 
assigned as β-MCA because it shared the same retention time and fragmentation 
pattern with the authentic standard (Table 1.3 and Figure 1.6).  However, fragmentation 
patterns of other oxidative (M7-M9) metabolites did not match with any of the available 
authentic standards of tri-OH BAs.  Therefore, the positions of hydroxylation of M7-M9 
were not assigned but they could be excluded from being CA, HCA, α-MCA, β-MCA, or 
ω-MCA, because their retention times did not match with that from any of these 
authentic standards.   
1.3.4 Biosynthesis and NMR-quantification of UDCA Metabolites  
 Authentic standards are required for the absolute quantification of analytes using 
ESI-LC-MS.  When authentic standards are not available, the parent drug standards are 
used to quantify the metabolites after adjusting their MS responses with a MS response 
factor (RF) from a global detector with a uniform response detector that accounts for the 
ratio of the metabolite/parent MS sensitivity.  We used NMR to establish this MS-RF.  
First, metabolites are biosynthesized, separated, and isolated.  UDCA metabolites were 
isolated from hepatocyte S9 fraction incubations by collecting fractions that contain 
individual chromatographic peaks from the HPLC column.  Fractions collected from 
several injections were pooled to produce about 10 µg quantities of individual 
metabolites.  To generate a UDCA NMR calibration curve, a unique proton signal is 
needed.  To identify this unique proton, the 1H NMR spectra of fractions collected from 
blank versus UDCA incubations were compared.  Proton signal at 0.6 ppm was not 
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observed in the blank incubation and was selected as a unique proton for UDCA 
quantification (Figure 1.7).  To confirm the response uniformity between parent UDCA 
and its metabolites and since metabolite standards were not available, we used 
structural analogs of UDCA including LCA and T-UCDA to prove that various structural 
modifications of UDCA did not change its NMR response (Figure 1.8).  Therefore, it can 
be concluded that structural modifications due to metabolism will also not affect the 
signal of this proton, i.e. a uniform NMR response for parents and their metabolites.  
Accordingly, concentrations of metabolites in the fractions isolated from S9 fraction 
incubations were determined by NMR using UDCA calibration curves.  Figure 1.9 shows 
an example for the determination of UDCA-3-S concentration in a HPLC fraction 
collected from UDCA hepatocyte S9 fraction incubation.  After determining their 
concentrations by NMR, metabolite and parent LC fractions were diluted to equal 
concentrations and were analyzed by LC-MS/MS.  A response factor (RF), calculated as 
the ratio of the metabolite/parent MS signal at equal concentrations was determined.  A 
metabolite concentration can be calculated in any in vivo or in vitro sample using a 
parent calibration carve after adjusting the metabolite peak area with RF.  This RF 
approach for LC-MS/MS quantification was validated by comparing UDCA metabolite 
concentrations measured by this approach versus direct LC-MS/MS quantification using 
metabolites authentic standards for representative UDCA metabolites, for which 
authentic standards were available (Figure 1.10).  Results from both approaches were < 
15% different.   
1.3.5 Species Differences of BA Metabolism by Hepatocyte S9 fractions 
The species differences of BA metabolism was studied for four representative 
BAs (LCA, UDCA, CDCA, and CA) using the optimized S9 fractions in vitro system 
(Table 1.5). 
1.3.6.1 LCA 
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 Table 1.6 shows the various metabolic pathways of LCA, UDCA, CDCA, and CA 
in hepatocyte S9 fractions obtained from different species.  The highest sulfation of LCA 
was observed in chimpanzee (52%) and human (18%) and it was < 5% in all other 
species.  Amidation was higher than 70% in all species except in dog and chimpanzee, 
where it was 9% and 36%, respectively.  BA amidation in minipig (89%) and rabbit (65%) 
was primarily with G, whereas it was primarily with T in mice (70%), hamster (52%), 
chimpanzee (25%), rat (15%), and dog (9%).  The rest of the species had similar G- vs. 
T- amidation rates.  Oxidation was highest in rat (80%) followed by mice, hamster and 
rabbit (~30%), while it was 5-10% in all other species.  Table 1.7 shows the relative 
formation of various hydroxylated metabolites as a result of LCA oxidation.  In general, 
and for all species, except in dog, LCA oxidation occurs at the C6 position resulting in 
the formation of HDCA (C6-α-OH) and MDCA (C6-β-OH).  Among the hydroxylated 
metabolites, MDCA was predominant in rabbit, rat and mice, while HDCA was 
predominant in human, chimpanzee, monkey, pig, and hamster.  Glucuronidation was 
highest in dog (75%) followed by rhesus monkey (11%), while it was < 5% in all other 
species.  Glutathione conjugation (< 5%) was a minor pathway in all species. 
1.3.6.2 UDCA  
The highest sulfation of UDCA was observed in chimpanzee and human (20-
27%) followed by hamster and rabbit (9-12%), while it was < 1% in all other species.  
Amidation was highest (95%) in minipig, while it was lowest in the dog (20%).  BA 
amidation in minipig (91%) and rabbit (62%) was primarily with G, whereas it was 
primarily with T in CD-1 and C57/BL6 mouse (>70%), rat (~40%), hamster (50%), dog 
(19%), and chimpanzee (44%).  The rest of the species had similar G- vs. T- amidation 
rates.  Oxidation was highest in rat (60%), while it was lowest (5-10%) in human and 
minipig.  In general, UDCA oxidation occurs primarily at the C6-β position in 
chimpanzee, pig, hamster, rat, and mice, which lead to the formation of β-MCA (Table 
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1.7).  The remaining species hydroxylation primarily occurs on other positions that we 
did not identify.  Glucuronidation was highest in dog (56%), while it was < 5% in all other 
species. Glutathione conjugation (< 5%) was a minor pathway in all species. 
1.3.6.3 CDCA 
 The highest sulfation of CDCA was observed in human, chimpanzee, and rabbit 
(14-22%) followed by hamster, minipig, and rhesus monkey (5-8%), while it was < 3% in 
all other species.  Amidation was highest (70-75%) in minipig and cynomolgus monkey, 
and it was lowest in the dog and rat (22-25%).  BA amidation in minipig (65%) and rabbit 
(62%) was primarily with G, whereas it was primarily with T in mice (50-60%), 
chimpanzee (44%), rat (25%), and dog (19%).  The rest of the species had similar G- vs. 
T- amidation rates.  The highest oxidation was observed in rat (70%) followed by mice 
and dog (40-50%), while it was lowest (12%) in human.  CDCA oxidation occurred 
primarily at the C12-α position (CA) for human, chimpanzee, monkey, and dog, while it 
was primarily at the C6-β position (α-MCA) for rat and mice and at the C6-α position 
(HCA) in pig (Table 1.7).  Glucuronidation was highest in the dog (27%), while it was < 
3% in all other species. Glutathione conjugation (< 5%) was a minor pathway in all 
species. 
1.3.6.4 CA 
The highest sulfation of CA was observed in human (5%) and it was < 5% in all 
other species.  Amidation was 90-95% in all species except in dog, rat, and mice it was 
80%.  BA amidation in minipig (94%) and rabbit (95%) was primarily with G, whereas it 
was primarily with T in mice (80%), dog (80%), human (60%), and chimpanzee (62%).  
The rest of the species had similar G- vs. T- amidation rates.  Oxidation was highest in 
rat, mice, and hamster (10-20%), while it was <5% in all other species.  Oxidation of CA 
results in the formation of unidentified tetra-OH BAs.  Glucuronidation was highest in dog 
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(10%), while it was < 2% in all other species.  Glutathione conjugation (< 5%) was a 
minor pathway in all species. 
1.4 Discussion 
 Because of their hepatotoxicity, intrahepatic accumulation of BAs can worsen 
and contribute to the pathogenesis of liver diseases [106, 107].  Similar to liver diseases, 
BA accumulation due to alterations of various aspects of their homeostasis by some 
drugs, is proposed to be one of the major mechanisms underlying DILI [108, 109].  
However, currently used in vitro and in vivo preclinical models of BA homeostasis fail to 
predict DILI in humans [137].    The marked differences in BA composition and 
homeostasis between preclinical safety models and humans may play a major role in the 
poor prediction of DILI at earlier stages of drug discovery and development.  Major 
species differences in the susceptibility to BA-induced hepatotoxicity were previously 
reported, which may be explained by species differences in BA homeostasis.  For 
example, CDCA produces severe hepatic toxicity in species that lack BA sulfation 
capabilities including rhesus monkeys [122, 123], rabbits [124], guinea pigs  [125], and 
dogs [126].  However, in humans and chimpanzees, where sulfation is a primary 
metabolic pathway of BAs, CDCA administration is not associated with hepatic injury 
[122, 127-130].  Collectively, strong evidence exists that species susceptibility to BA 
toxicity may be determined by their capability to efficiently metabolize BAs.  Therefore, 
this work aimed to quantify the species differences in BA metabolism in vitro and in vivo 
to identify preclinical species that are most similar to humans in regards to BA 
metabolism and therefore are more relevant to in vivo testing of DILI.  Furthermore, we 
developed an in vitro model that represents the in vivo metabolism of BAs in humans 
and in various animal species.   
1.4.1 In-vivo BA Profile  
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We observed major species differences in multiple aspects of the plasma BA 
profiles.  Similar to previous data our data showed that highest total concentrations of 
plasma BAs were observed in rat and pig [86, 138-140] and that G-amidation was 
predominant in human and pig [86, 139, 141, 142], while T-amidation was predominant 
in rat, mice, and dog [91, 135, 138, 142-146].  Furthermore, in-line with previous data we 
found that the BA pool in plasma was primarily composed of Di-OH BAs in human, while 
tri-OH BAs were the main components in rat, mice, and hamster (Table 1.1).   
BA hydrophobicity is influenced by both the BA nucleus and the side chain 
structures [54].  Amidation increases the acidity of unconjugated BAs, where pKa is 
reduced from about 5.5 for the unamidated BAs to 4.5 and 1.5 for those with G- and T-
amidation, respectively [51].  This increases BA ionization and solubility at physiological 
pH.  There is an inverse relationship between the number of OH groups present on 
steroid nucleus and lipophilicity.  The mono-OH BA (LCA) is more hydrophobic than di-
OH BAs (CDCA, and DCA), which in turn are more hydrophobic than tri-OH BAs (CA, 
MCA, and HCA).  Hydrophobicity is also determined by the position and stereochemistry 
of hydroxyl groups.  For example, the 7β, 6α, and 6β- OH substitutions result in the 
formation of more hydrophilic BAs.  These hydroxyl groups are equatorial to the plane of 
the steroid ring system and they are more resistant to the loss of associated water than 
is a 7α-hydroxyl group, causing these hydroxyl groups to be intrinsically more hydrophilic 
[55, 56].  Therefore, UDCA (contains 7β-OH) is the most hydrophilic among all other di-
OH BAs, and MCA (contains 6β-OH) and HCA (contains 6α-OH) are more hydrophilic 
than other tri-OH BAs such as CA (contains 12α-OH) [56, 58].  The term hydrophobicity 
index (HI) was introduced to describe the hydrophilic- hydrophobic balance of BAs 
based on their relative retention time and capacity factor in C18 reversed-phase HPLC.  
HI of BAs ranges from +1.46 for the most hydrophobic BA (LCA) to -0.94 for the most 
hydrophilic BA (T-UDCA) [58, 59, 147].  HI of individual BAs ranged from +1.46 for the 
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hydrophobic BA (LCA) to -0.94 for the hydrophilic BA (T-UDCA).  The lower the 
composite HI value of the overall BA pool in any species, the higher the concentrations 
of the more hydrophilic BAs and the less cytotoxic is the BA pool [94, 148, 149].   
We observed that HI was lowest in minipig and mice because more than 90% of 
the plasma BA pool in minipig was consisted of hydrophilic BAs (HDCA and HCA), while 
the hydrophobic BA, LCA, comprised less than 1% of the plasma BA pool (Figure 1.2).  
Similarly, in mice, the hydrophilic BAs (MCA and CA) constituted 75% of the total BA 
pool, while LCA comprised less than 1% (Figure 1.2).  Furthermore, in mice 70-85% of 
the total BA pool was conjugated with taurine, which is more hydrophilic than G-
amidated or unamidated BAs (Table 1.1).  In contrast, higher HI values were observed 
for rhesus monkey and rabbit, primarily due to higher LCA composition (26%) in rhesus 
monkey and higher DCA composition (43%) in rabbit (Figure 1.2).  This is in accordance 
with previous reports, where composite HI for mice and pigs ranged from -0.37 to -0.05 
in different matrices including plasma [86, 139, 141, 150], liver [139, 151], and bile [135, 
152-154], while it was 0.45 for rabbit [155-157].   
In general, BA toxicity is highly correlated with hydrophobicity, where the most 
hydrophobic BAs, LCA and DCA, are more cytotoxic than the more hydrophilic BAs, CA, 
UDCA, MCA, and HCA [158-160].  Therefore, mice [131] and rats  [132] are more 
resistant to LCA and CDCA hepatotoxicity due to efficient BA hydroxylation and taurine 
amidation compared to humans [97, 133-135].  LCA is also hepatotoxic in rabbits, a 
species in which the toxic BA, DCA, is dominant and it lacks both BA sulfation and 
hydroxylation capabilities [84, 124, 152].   
Most of the previous reports on BA profiling in various species did not include 
sulfated BAs because of the challenges associated with their analysis.  In accordance 
with previous reports, we found sulfation to be a minor pathway of BA metabolism in rats 
and mice (Table 1.1).  No to very small percentages of exogenous doses of LCA [132, 
34  
161], DCA [162], CDCA, or CA [163, 164] were sulfated in rats and mice.  Furthermore, 
less than 5% of plasma BAs were detected in the sulfated form in rats and mice [87, 
151, 165].  In baboons [129, 166] and rabbits [124] less than 10% of CDCA and LCA 
exogenous doses were sulfated, and 15% was sulfated in rhesus monkey [95, 122].  
Also, less than 1% of plasma BAs are present in the sulfate form in cat [90] and hamster 
[167].  In contrast, we found sulfation to be the highest in human and chimpanzee.  
Similarly, it was previously reported that 63% of administered LCA was sulfated in 
chimpanzee and human [95, 168]. Among the individual BAs, sulfation was highest in 
LCA, followed by di-OH-BAs, and lowest in CA, which is consistent with previous data 
[169-175].      
 Lowest ratios of primary to secondary BAs were observed in rabbit followed by 
chimpanzee and minipig (Table 1.1).  Secondary BAs are produced in the intestine as a 
result of bacterial biotransformation of primary BAs, including deamidation, 
dehydroxylation, epimerization, dehydrogenation, and desulfation [6, 24].  Rabbit has a 
large intestinal lumen, full of anaerobic bacteria, and the prolonged retention of colonic 
contents provide ample opportunity for secondary BAs to be formed and absorbed [84] 
which results in extensive conversion into secondary BAs [155].  Furthermore, 
coprophagy causes recirculation of secondary BAs, which increases their systemic 
concentrations [176, 177] in minpig and chimpanzee.  This  is in  agreement with 
previous reports where lowest primary: secondary BA ratios were observed in rabbit (1.1 
fold [155]) and pig (1.2 fold [139, 141]), while it was highest in mice (2.6-8.6 fold [86, 
145, 150]), rat (2.1-7 fold [86, 138, 146]), and hamster (5.4 fold [155]).  
 CYP8B1 catalyzes 12α-hydroxylation of CDCA to CA and the CA: CDCA ratio or 
the ratio 12α-BAs (sum of DCA and CA) to non-12α BAs (sum of CDCA, HDCA, MDCA, 
LCA, UDCA, HCA, and MCA) are used as probes for CYP8B1 activity [178, 179].  We 
observed that both ratios were highest in mice, dog, and hamster, and were lowest in 
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human, chimpanzee, and pig.  This is in line with previous reports, where CA: CDCA 
ratio was in the range of 9 to 28 in mice [86, 135, 145, 150], 5.1 to 6.2 in dog [91, 144] 
and 5.9 in hamster [155].   Similarly, 12α: non-12α BAs ratio were high (6 - 7.6) in dog 
[91, 144] and hamster [155].  In contrast, CA: CDCA ratio was low (0.3 - 0.6) in human 
[86, 91, 142, 180-185] and 0.024 in pig [139, 141].  Similarly, 12α-OH: non-12α-OH BAs 
ratio was 0.7, 0.4, and 0.004 in human [86, 91, 142, 180-185], pig [139, 141], and rat 
[86, 138, 141, 143, 146], respectively. 
In general, the absolute total concentration of BAs in urine was higher than 
plasma in all species except monkeys, hamster, and rabbit.  However, urine BAs 
showed similar patterns to these in plasma.  For example, and similar to plasma, highest 
total BA concentration in urine was observed in minipig, while it was lowest in 
chimpanzee.  In addition, amidation with glycine in urine was predominant over taurine in 
minipig, human, chimpanzee, rhesus monkey, and rabbit, whereas it was primarily with 
taurine in rat, mice, and dog.  This is in agreement with previous reports [163, 186, 187], 
which showed 65-95% of urinary BAs are conjugated with glycine in human, while it was 
conjugated with taurine in mice and rat.  However, in urine percentage amidation in urine 
was higher compared to plasma.   
  The percentage of BAs excreted in the sulfated form in urine was more than 
that in plasma across all species.  For example, in human, 85% of urinary BAs and were 
sulfated, compared to 32% in plasma, indicating the role of sulfation in enhancing the 
urinary excretion of BAs.   However, species that do not sulfate BA efficiently, had <5% 
of their urinary BAs in the sulfated form, which was also shown previously [135, 188-
190].  Similar to plasma, the percentage of BAs present in the sulfated form was 
inversely proportional to the number of OH group, where 99% of LCA, 97-98% of UDCA, 
CDCA and DCA, and 55% of CA were sulfated in human urine.  Previous reports for the 
% sulfation of BAs varied markedly, where 50–100% for LCA, 13–100% for UDCA, 86–
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100% for CDCA, 56–100% for DCA, and 1.2–59% for CA in human urine were reported 
[169-171, 191, 192]. 
Similar to plasma the highest percentage of mono-OH BAs was observed in 
chimpanzee, the percentage of Di-OH BAs was highest in human, monkey, rabbit, and 
minipig, while the percentage of Tri-OH BA was highest in hamster, rat, dog, and mice.  
In general, the percentage of tri-OH BAs in urine (12-94%) was higher than that in 
plasma (4-75%) across all species (Table 1.1 and 1.2), while the percentage of mono-
OH BAs was lower in urine (0.01 to 19%) compared to plasma (0.06 to 52%), also 
indicating the role of hydroxylation in enhancing the urinary excretion of BAs.   
 The ratios of primary to secondary BAs, CA: CDCA, and 12α-OH-BAs: non-12α-
OH-BAs were higher in urine compared to plasma due to the higher concentrations of 
primary and 12α-OH-BAs in urine compared to plasma across all species except human 
and monkey.  For example, 95% and 86% of plasma BAs were secondary BAs in rabbits 
and chimpanzees, respectively, while in urine it was BAs were 36% and 51% in the 
same species.  This is expected due to the relatively higher hydrophilicity and therefore 
urinary excretion of these BAs [151, 159, 193, 194].  
Collectively, the urinary BA pool was more hydrophilic than the plasma BA pool 
across all species.  This was due to the presence of more tri-OH, amidated, sulfated, 
and primary BAs, in urine compared to plasma.  This can also be demonstrated using 
the HI values, where it was 5-10 folds lower in urine than plasma across all species 
except in minipig, hamster, and rhesus monkey where HI was similar in both urine and 
plasma. 
1.4.2 Literature Summary of BA Profiles in Different Species 
 Table 1.8 shows a literature summary of plasma BA profiles in different 
species.  Data reported from different laboratories are extremely variable for the same 
species, which is expected due to the variability in the analytical techniques and more 
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importantly due to the high inter-and intra-variability of BAs associated with feeding 
status, gender, age, etc. [43].  However, trends can be depicted regarding the species 
differences of the plasma BA profiles and the contributions of the various metabolic 
pathways.  Total plasma BA pool was highest in cow (93 µM) followed by rat (3.6-38 µM) 
and pig (6.6-31 µM).  In all other species, the BA pool ranged from 1-10 µM.  BA 
amidation in pig and human was primarily with glycine whereas it was primarily with 
taurine in rat, mice, dog, and horse. Cow plasma showed similar glycine to taurine 
amidation.  LCA is a minor BA (~1%) in the plasma of all species except in humans, 
where it ranged between 0.5 and 8%.  The BA pool in plasma was primarily composed 
of di-OH BAs in human and horse (65-85%), while tri-OH BAs were the main 
components in rat, mice, hamster, and cow (50-90%).  The most abundant BAs were 
CDCA in human (29-75%) and horse (68%), DCA (44%) and CA (45%) in rabbit, HDCA 
(57%) in pig, and CA (60-84%) in dog, hamster, and cow.  Also, CA (14-63%) and MCA 
(13-59%) were the major BAs in rat and mouse.  The ratio of primary to secondary BAs 
was highest in horse (15 fold), cow (6.5 fold), hamster (5.4 fold), mice (2.6-8.6 fold), and 
rat (2.1-17 fold), while it was lowest in rabbit (1.1 fold), human (0.74-1.9 fold), and pig 
(1.26 fold).  CA: CDCA ratio was highest (9-31) in mice and cow followed by dog (5.1-
6.2), rabbit (6.3), and hamster (5.9), and it was lowest in pig (0.024) and human (0.3-
0.6).  Similarly, 12α: non-12α BAs ratio was highest (27) in cow followed by dog (6-7) 
and hamster (7.6) and it was lowest in pig (0.004).  HI was low in mice, pig and rat, while 
it was high in human, cow, and horse. 
 Table 1.9 shows a literature summary of biliary BA profiles of different species.  
Total BA pool in bile was highest in rabbit (72-358 mM) followed by pig (35-208 mM) and 
hamster (52-133 mM), while it was lowest in rat (16-25 mM).  Similar to plasma, BA 
amidation in pig, human, hamster, and rabbit was primarily with glycine whereas it was 
primarily with taurine in rat and mice.  The percentage of mono-OH BAs (LCA) was 
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highest 22% in cat, while it was less than 5% in all other species except in hamster it 
was 1-15%.  The percentage of Di-OH BA was highest (82-91%) in rabbit followed by 
50-84% in pig, while it was lowest in mouse (2.5%) and cat (15%).  Tri-OH BAs was 
highest (72-86%) in rat and mice, while it was lowest (3-10%) in rabbit.  The most 
abundant BAs were CDCA in human (46%), while it was CA (40-70%) in mouse, rat, 
hamster, and cat; it was DCA (80-89%) in rabbit and HDCA (55%) in pig.  The ratio of 
primary to secondary BAs was lowest in rabbit (0.03-0.1) and human (0.5-0.8), while it 
was highest in mice (8-45) and rat (5-9). CA: CDCA ratio was highest (80) in mice 
followed by cat (14), rat (5.3-10), and rabbit (6.7), while it was lowest in human (0.75).  
12α: non-12α BAs ratio was highest (50-250) in rabbit and it was lowest in human (0.91).  
HI was low in mice, pig and rat, while it was high in human and hamster. 
 Table 1.10 shows a literature summary of liver BA profiles of different species.  
Total BA pool in liver was highest (150-226 µM) in mice and hamster, while it was lowest 
in bovine (2.54 µM).  The percentage of mono-OH BAs (LCA) was highest 7% in pig, 
while it was less than 2% in all other species.  The percentage of Di-OH BA was highest 
(89%) in pig followed by rat (50-64%) and hamster (32%), while it was lowest (6-11%) in 
mouse and bovine.  Tri-OH BAs was highest (90%) in mice and bovine followed by 
hamster (68%) and rat (35-49%), while it was lowest (6.4%) in pig.  The most abundant 
BAs were MCA (50%) in mice, CA in bovine (94%), hamster (67%), and rat (50%) and 
HDCA in pig (47%).  The ratio of primary to secondary BAs was highest (10-30) in mice, 
hamster and bovine, while it was lowest (0.5-1.5) in pig and rat.  CA:CDCA ratio was 
highest (20-40) in mice and bovine, while it was lowest (0.29) in pig.  12α: non-12α BAs 
ratio was highest (46) in bovine and it was lowest in pig (0.22).  HI was low in mice and 
rat, while it was high in hamster, pig, and bovine. 
1.4.3 Biosynthesis of UDCA Metabolites and Quantification Using NMR 
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 LC-MS is the method of choice for quantitative analysis due to its superior 
sensitivity, selectivity, and speed.  In LC-MS, analytes are ionized in the ion source, 
before mass-separation by the MS analyzer.  Atmospheric pressure ionization (API) is 
one of the most common ionization sources in mass spectrometry because it allows 
direct coupling of the LC flow into the MS system.  Electrospray ionization is a subtype of 
API that utilizes a high-electric field and high temperature to evaporate and produce 
charged droplets from sprayed solution.  However, due to differences in ionization 
efficiencies, analytes at equal concentrations can produce different MS responses [195-
197].  Therefore, authentic standards are required for the absolute quantification of 
analytes using ESI-LC-MS.  Although reference standards are available for the parent 
drugs, it is usually difficult, time consuming, and expensive to produce authentic 
standards for the metabolites.  Hence, it is unlikely to have authentic standards for 
metabolites available in early stages of drug discovery and development to facilitate their 
absolute quantification.   
 When authentic standards are not available, the parent drug standards are used 
to quantify the metabolites after adjusting with a response factor (RF) that accounts for 
the ratio of the metabolite/parent MS sensitivity.   To establish this RF without metabolite 
authentic standards, a universal detector, which response is independent of chemical 
structure is needed.  Several universal detection techniques such as nanospray 
ionization-mass spectrometry (NSI-MS) [198, 199], chemiluminescence nitrogen 
detection (CLND) [200-202], evaporative light scattering detection (ELSD) [203, 204], 
accelerator mass spectrometry (AMS) [205], charged aerosol detector (CAD) [206], 
radiometric detection [207], and ultraviolet detection (UV) [208] and nuclear magnetic 
resonance (NMR) detection [209-211] can be used for this purpose.  NSI-MS is a 
sensitive technique and it utilizes low LC flow rates and small sample volume. However, 
because of the complexity of operation and lack of reproducibility, NSI has not been 
40  
used extensively [199].  CLND is coupled with LC flow for high throughput analysis to 
produce a uniform response for most analytes, regardless of their physical and chemical 
properties.  However, CLND is limited to nitrogen-containing compounds and all LC 
mobile-phase components must be free of nitrogen to keep baseline noise to a 
minimum. Furthermore, it requires longer method run time because endogenous 
nitrogen containing compounds should be separated from analytes [200-202].  ELSD is 
used as an alternative to UV detection for non-UV absorbing compounds and it is 
compatible with gradient elution.  However, this technique is less sensitive than UV and 
it does not have robust linear responses [204, 212].  Advantages of AMS are the much 
greater sensitivity of the measurement and sample size is thus typically 1000 times 
smaller.  The major limitation of  AMS is the cost of instrumentation, which makes it of 
limited availability [205].  CAD offers a universal response for diverse structures with low 
nanograms sensitivity. However, changes in the solvent composition in gradient elution 
used for the separation of metabolites affect the uniform CAD response [206].  UV and 
fluorescence are widely available detection techniques.  However they can only be used 
if the metabolites maintain the parent chromophore intact, i.e. no modification of the 
parent chromophore as a result of metabolism [208].   
 Among all the universal detectors, NMR is the most commonly used for 
metabolite quantification, when authentic standards are not available [209-211].   NMR 
requires the separation and isolation of metabolites, which was accomplished by the 
fraction collection of metabolites, generated by hepatocyte biosynthesis, after their 
chromatographic separation.   Concentrations of biosynthesized metabolites in these 
collected fractions were determined by NMR analyses using parent drug calibration 
curves.  Metabolites and parent drugs are then injected in LC-MS to calculate RF that 
accounts for the ratio of the metabolite/parent MS sensitivity.   
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 To quantify UDCA metabolites, we isolated these metabolites from hepatocyte 
S9 fraction incubations using fraction collections of the HPLC column effluents.  To 
generate a UDCA NMR calibration curve, a unique proton signal, which does not exist in 
any of the endogenous components of the samples and is not modified by metabolism is 
needed.  Therefore, this unique proton should have a uniform response for the parent 
and its metabolites should not produce any response in blank S9 fraction incubations, 
and it should not be affected by metabolism.  Proton signal at 0.6 ppm (Figure 1.8) was 
identified as unique proton for quantification and its response for structurally different 
compounds was uniform (Figure 1.9).  The concentrations of metabolites in the fractions 
isolated from S9 incubations were determined using UDCA calibration curves.  After 
determining their concentrations by NMR, the metabolites and parent LC fractions were 
diluted to equal concentrations and were injected in LC-MS/MS.  A response factor (RF), 
calculated as the ratio of the metabolite/parent MS signal at equal concentration was 
determined.  A metabolite concentration can be calculated in any in vivo or in vitro 
sample using a parent calibration curve after adjusting the metabolite peak area with RF 
(Figure 1.10).  This RF approach for LC-MS/MS quantification was validated by 
comparing UDCA metabolite concentrations measured by this approach versus direct 
LC-MS/MS quantification using metabolites authentic standards for representative 
UDCA metabolites, for which authentic standards were available.  Using this 
combination of NMR and LC-MS/MS, we were able to detect and quantify BA 
metabolites from all major and minor pathways known to be involved in BA metabolism 
in the various species including sulfation, amidation, glucuronidation, and hydroxylation.   
1.4.4 Optimization of Hepatocyte S9 Incubation Conditions 
 Various in vitro systems including hepatocyte microsomes, cytosol fractions, S9 
fractions, intact hepatocytes, and recombinant metabolizing enzymes are used to 
characterize biotransformation of compounds  [213].  Hepatocyte S9 fractions offer 
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unique advantages among these systems including capability to study both phase I and 
phase II metabolism, feasibility to study individual, gender-, and species-specific 
biotransformation, and affordability.  Hepatocyte S9 fractions often require 
supplementation with exogenous cofactors for the various metabolic pathways including 
oxidation, glucuronidation, sulfation, glutathione conjugation, and amidation at 
physiological concentrations.  Previous in vitro systems were always supplemented with 
cofactors at more than 10-fold higher than physiological concentrations.  Therefore, we 
optimized cofactor concentrations in our S9 fraction in vitro system to maximize assay 
sensitivity at relevant physiological concentrations (Table 1.5).  This optimized S9 in 
vitro system was subsequently used to study the species differences in metabolism of 
BAs metabolism. 
1.4.5 Species Differences in BA Metabolism by Hepatocyte S9 fractions 
 Species differences in BA metabolism was studied for four BAs (LCA, UDCA, 
CDCA, and CA) using optimized hepatocyte S9 fractions in vitro system.  Overall data 
from our in-vitro system showed that sulfation of BAs was highest in human and 
chimpanzee followed by rabbit and hamster, and it was lowest in all other species, for all 
four BAs (LCA, UDCA, CDCA, and CA).  Previous in-vitro studies also showed low 
sulfation affinity in rodents.  In rat primary hepatocytes, very low [214, 215] or no [216] 
BA sulfation activity was detected.  Furthermore, sulfation of LCA by rat liver was shown 
to be more than a 100-fold less than that of humans [217].  In addition, rat and hamster 
sulfotransferase has lower affinity for BAs compared with human [218, 219].  Also, our 
current data showed that the tri-OH BA (CA) had the lowest sulfation, while LCA had the 
highest sulfation among all tested BAs, which agreed with previous reports, where Km for 
LCA, CDCA and CA sulfation by human liver sulfotransferase was 2.5, 25, 71 µM [218] 
and sulfation activity for G/T-LCA was 4-5 times higher than G/T-CDCA  by rat 
sulfotransferase [219].  Similarly, we have also previously reported that the Km of LCA, 
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DCA, UDCA, and CDCA sulfation by SULT2A1 were 2.0, 8.9, 12.9, and 15.7 µM, 
respectively, whereas, the Km of CA could not be determined as no CA-S formation was 
detected [174].  A common observation among all these studies is that the extent of 
sulfation is inversely related to the hydrophobicity or the number of hydroxyl groups of 
BA species, with mono-OH BA species (LCA) being almost 100% sulfated, and tri-OH 
BAs showing the lowest sulfation.  These results indicate that sulfation acts as a 
protective mechanism for detoxifying the more toxic BAs such as LCA [6].  We also 
found species differences in the position of BA sulfation, where sulfation was primarily at 
C3 in human, chimpanzee, monkey, pig, and rabbit, while it was primarily at C7 in mice 
and hamster.   
 Amidation was the major pathway of all four BAs and across all species, but with 
different preferences toward G vs. T amidation.  Amidation was primarily with glycine in 
minipig and rabbit, primarily with taurine in human, chimpanzee, dog, hamster, rat, and 
mice, while it was similar all other species.  Also, CA had the highest G or T amidation 
across all species.  
Overall, oxidation was highest in rat and mice followed by hamster, while it was 
lowest in human, chimpanzee, and minipig.  Also, CA had the lowest oxidation among all 
BAs across all species.  In general, oxidation was predominant at the 6-β position in rat 
and mice, while it was at the 6-α position in pig, and at the 12-α position in human, 
chimpanzee, monkey, and dog.  Previous reports showed 6-β hydroxylation of LCA and 
CDCA to MDCA and α-MCA, respectively, by rat liver microsomes and hepatocytes 
[220, 221].  Also 6-α hydroxylation of LCA and T-LCA to HDCA  [222] and T-HDCA [223, 
224] was minimal compared to12-α hydroxylation of CDCA into CA [225].   
Glucuronidation was highest in dog, while it was minor pathway in all other 
species.  Acyl glucuronidation was predominant in all species except in pig and rabbit, 
where it was primarily hydroxyl glucuronidation.  Also, similar to sulfation, 
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glucuronidation was inversely proportional to the number of OH groups, with CA being 
the lowest and LCA being the highest glucuronidated BAs across all species. This is in-
line with previous reports which showed glucuronidation of LCA was 8-9 times higher 
than CDCA and 2 times higher than DCA and UDCA by rat liver glucuronyltransferase.  
Furthermore, affinity (km) for glucuronidation by human liver microsomes was highest for 
LCA (0.019 µM) followed by DCA (0.11 µM) and UDCA (0.29 µM) [226, 227]. 
Glutathione conjugation was minor for all BAs across all species. This is in-line with 
previous in-vivo reports where only 0.02% of GSH conjugates was observed in rat bile 
[228, 229].  
1.4.6 In-vivo and In-vitro Correlation   
We compared data obtained from our in vitro system vs. in vivo plasma BA 
profiles on the contributions of the different metabolic pathways across various species.  
For sulfation, the extent of in-vivo sulfation was higher than that in-vitro across all 
species for all BAs.  For example, in-vivo sulfation of LCA in plasma was 91-93%, 
whereas it was 18-52% in our in-vitro system for both human and chimpanzee.  
However, both in-vivo and in-vitro data showed that sulfation of BAs was highest in 
human and chimpanzee followed by rabbit, and hamster, while it was very low for all 
other species across all BAs.  In addition, both sets of data showed that the extent of 
sulfation of individual BAs was inversely proportional to the number of OH groups, with 
the tri-OH BA (CA) is the least sulfated vs. the mono OH BA (LCA) is the most sulfated.   
There was a dissociation between the extent of amidation in vivo vs. in vitro of 
total and individual BAs for both monkey species, minipig, hamster, rabbit, and rat, 
where extent of amidation was markedly higher in vitro (75-95%) vs. in vivo (10-30%).  In 
contrast, extent of amidation was lower in vitro compared to in vivo for dog, chimpanzee, 
and mice.  The rate determining step in determining extent of amidation by G and T is 
not solely determined by the affinity of BAs to the bile acid-coenzyme A: amino acid N-
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acyltransferase (BAT) enzyme, but it is also depended on the intracellular availability of 
G and T in peroxisomes [7, 10, 230, 231].  Amidation of BAs with T and G via BAT takes 
place in the peroxisomes.  There are known species differences in the intra-peroxisomal 
concentrations of T and G, possibly due to species differences in the peroxisomal 
synthesis of glycine catalyzed by alanine:glyoxylate aminotransferase (AGT), which 
convert glyoxylate to glycine [10, 232].  Since this is not a cellular system, our S9 
fraction in vitro system is not expected to capture the effects of intra-peroxisome 
concentrations of G and T.  However, this in-vitro system was still predictive of in vivo 
data in terms of comparing the contribution of amidation to BA metabolism between the 
various species, where amidation was the highest in human, chimpanzee, and mice, and 
lowest in rats in both in vitro and in vivo systems.  In addition, both sets of data showed 
G-amidation was predominant in minipig and rabbit, while T-amidation was predominant 
in dog, rat, and mice across all BAs.   
Among the different in-vitro oxidative metabolites C6-β oxidation was highest in 
rat and mice and it was lowest in human and chimpanzee.  In agreement with the in vitro 
data, MCA, a BA with a C6-β OH group, was highest in rat and mice (22-36%) and 
lowest in human and chimpanzee (<1%).  In-vitro, oxidation at the C6-α position was 
predominant in pig.  Similarly, HCA, a C6-α-OH BA, and its metabolite (HDCA) 
constituted 90% of the BA pool in pig plasma.  In-vitro, oxidation at the C12-α position 
was predominant in hamster and rabbit.  Similarly, CA and DCA, both are BAs with an 
OH group on the C12-α position, represent 70% and 50% of the BA pool in hamster and 
rabbit plasma, respectively.  Therefore, both in vitro and in vivo data showed that 
hydroxylation on the C6-α and C6-β positions are primary pathways that produce the 
most hydrophilic and least toxic BAs, HCA in pig and MCA in rat and mice, respectively. 
For glucuronidation, both sets of data showed glucuronidation was a minor 
pathway in all species across all BAs, except in dog where glucuronidation was 
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detectable in vivo and it was also the highest in-vitro.  In addition, similar to sulfation, 
both sets of data showed that the extent of glucuronidation of individual BAs is inversely 
proportional to the number of OH groups, with the tri-OH BA (CA) is the least 
glucuronidated, while the mono OH BA (LCA) is the most glucuronidated.   
1.5 Conclusions 
There is a major gap in our knowledge regarding the differences in BA 
metabolism between preclinical species used in drug safety testing and humans, which 
prevents extrapolation of preclinical safety data from the various in-vivo and in-vitro 
hepatotoxicity models.  In this study, we filled this gap by quantifying and comparing the 
in-vivo plasma BA profiles and of the in-vitro BA metabolism across various species.     
In summary, plasma BA profiles showed that only two species (human and 
chimpanzee) could efficiently sulfate BAs.  BAs were preferentially amidated with glycine 
in human, minipig, hamster, and rabbit, while it was primarily amidated with taurine in 
mice, rat, and dogs. Composition of BAs consisted primarily of tri-OH BAs in hamster, 
rat, dog, and mice, di-OH BAs in human, rabbit, and minipig. While it primarily consisted 
of mono-OH BA (LCA) in chimpanzee. As a results, plasma BA profiles comprised 
primarily hydrophilic and less toxic BAs (CA, MCA, HCA, and HDCA) in mice, rat, pig, 
and hamster, while it primarily comprised hydrophobic and more toxic BAs (DCA, CDCA) 
in human, and rabbit, and chimpanzee.  Glucuronidation and amidation were minor 
pathways in all species   
In-vitro, sulfation predominated in human and chimpanzee, while oxidation 
predominated in rat, mice, rabbit, and hamster.  Species differences were also observed 
in the position of sulfation and oxidation, where C6-β oxidation was predominant in rat 
and mice, while it was at C6-α position in pig.  For sulfation 3-O-sulfate was predominant 
in human and chimpanzee, while rodents and monkeys showed 3-O- and 7-O- sulfates.  
Amidation was the major metabolic pathway in all species.  G-amidation was 
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predominant in minipig and rabbit, while T-amidation was predominant in dog, rat, and 
mice.  Glucuronidation and glutathione conjugation were minor pathways in all species, 
except dog.  
  The absolute extent of metabolism by the various pathways was different 
between the in-vitro and in-vivo data.  For example, sulfation and oxidation were lower in 
in-vitro vs. in-vivo across all species for all BAs whereas, extent of amidation was higher 
in monkeys, minipig, hamster, rabbit, and rat and lower in dog, chimpanzee, and mice in-
vitro compared to in-vivo.  However, the trends and the patterns of relative contributions 
of the various metabolic pathways in vivo were preserved using our in vitro system.  For 
sulfation, both in-vivo and in-vitro data showed that human and chimpanzee were the 
only species that efficiently sulfate BAs. Amidation was the highest in human, 
chimpanzee, and mice and lowest in rats in both in vitro and in vivo systems.  In 
addition, both sets of data showed G-amidation was predominant in minipig and rabbit, 
while T-amidation was predominant in dog, rat, and mice across all BAs. Similarly, both 
sets of data showed C6-α and C6-β positions were the primary position of oxidation that 
produces the most hydrophilic and least toxic HCA in pig and MCA in rat and mice, 
respectively. Finally, both sets of data showed that glucuronidation and glutathione 
conjugation were minor pathways in all species across all BAs.  Therefore, our 
hepatocyte S9 fraction in vitro system can reliability predict the in vivo metabolism of 
BAs, and could be used for the early screening of the effect of compounds on BA 
homeostasis as a part of the screening for DILI. 
48  
 
Bile acid R1 R2 R3 R4 
Tri-OH BAs     
Cholic acid (CA) H OH H OH 
α-Muricholic acid (α-MCA) β-OH OH H H 
β-Muricholic acid (β-MCA) β-OH H OH H 
ω- Muricholic acid (ω-MCA) α-OH H OH  
Hyocholic acid (HCA) α-OH OH H H 
Di-OH BAs     
Chenodeoxycholic acid (CDCA) H OH H H 
Deoxycholic acid (DCA) H H H OH 
Ursodeoxycholic acid (UDCA) H H OH H 
Mono-OH BAs     
Lithocholic acid (LCA) H H H H 
R5 
Unamidated BAs OH       
Glycine-amidated BAs (G-BAs) NH2CH2COOH Taurine-amidated BAs (T-BAs) NH2CH2CH2SO3H     
R6 
Unsulfated BAs H       
Sulfated BAs (S-BAs) SO3H        
Figure 1.1 Chemical structures of major BAs and their glycine (G), taurine (T), and sulfate (S) conjugates.  
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Figure 1.2 Individual BA contributions to the overall composition of plasma BA pools in humans and in various animal species.
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 Figure 1.3 Individual BA contributions to the overall composition of urine BA pools in humans and in various animal species.
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Figure 1.4 Extracted ion chromatograms (EIC) of detected metabolites obtained after incubation of UDCA with hepatocyte S9 fractions from different species for 60 min.  A) parent-UDCA (m/z 391), B) M1 to M3: glucuronide conjugates (m/z 567), C) M4 and M5: sulfate conjugates (m/z 471), D) M6: glutathione conjugate (m/z 680), E) M7 to M10: hydroxylation into tri-OH BA metabolites (m/z 407), F) M11: glycine (G) amidate (m/z  448), G) M12: taurine (T) amidate (m/z 498), and H) M13: combination of hydroxylation and taurine amidation into T-MCA (m/z 514). 
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Figure 1.5  Representative enhanced product ion (EPI) spectra of UDCA metabolites.  A) M1 
and M2: O- glucuronide conjugate, B) M3: acyl-glucuronide conjugate, C) M4: 3-O-sulfate 
conjugate, D) M5: 7-O-sulfate conjugate, E) M6: glutathione conjugate, F) M7 to M10: 
hydroxylation into tri-OH BA metabolites G) M11: glycine (G) amidate H) M12: taurine (T) 
amidate, and I) M13: combination of hydroxylation and taurine amidation into T-MCA. 
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Figure 1.6 Proposed structures of MS/MS fragments produced by HRMS analyses of various BA standards. 
C24H37O5-405.2647 C24H37O4
-
389.2697 C24H35O4
-
387.2541 C23H37O4
-
377.2697
C23H35O4-375.2541 C24H35O3
-
371.2592
C24H33O3-369.2435
C23H39O3-363.2905 C23H31O3-355.2279
C24H33O2-353.2486 C23H37O2
-
345.2799
C23H35O2-343.2643
C23H35O-327.2693 C23H33O-325.2537
C19H29O2-289.2173
C16H27O2-251.2017
C24H37O3-373.2748
C24H35O2-355.2643
C23H39O2-347.2956 C23H37O
-
329.2850 C24H37O2-357.2799
C25H40NO3-402.3014
C25H40NO2-386.3065
C2H4NO2-74.2048 C2H6NO3S-124.0074 C2H3O3S
-
106.9808
SO3-79.9574 HSO4-96.9602
55  
 
Figure 1.7 Identification of a unique proton signal by comparing 1H NMR spectrum of 1) blank 
hepatocyte S9 fraction incubation and B) UDCA neat standard. 
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Figure 1.8 Uniform 1H NMR responses of the 0.6 ppm proton for A) 0.2 mM LCA, B) 0.2 mM T-
UDCA, and C) 0.2 mM UDCA 
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Figure 1.9 Quantification of UDCA-3S by 1H NMR using UDCA calibration curve: (A) UDCA-3-S 
1H NMR spectrum showing the AUC of the unique 0.6 ppm proton obtained from hepatocyte S9 
fractions incubation, (b) a UDCA calibration curve using the same proton. 
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Figure 1.10 (A) LC-MS Chromatogram of equal concentrations of UDCA and its representative 
metabolites (UDCA-3-S, β-MCA, and G-UDCA) at 0.5 µM.  RF is calculated from the ratio of 
metabolite: parent peak areas at equal concentrations, (B) comparison of metabolite 
concentrations calculated using the RF approach vs. direct analysis using authentic standards. 
59  Table 1.1 Plasma BA profiles in humans and in various animal species.  Human  Chimpanzee Cynomolgus Monkey Rhesus Monkey Beagle Dog Gottingen Minipig Syrian Hamster New Zealand Rabbit 
SD Rat CD-1 Mouse C57/BL6 Mouse 
Total BA (µM) 3.9 0.074 3.5 5.3 1.4 31.0 1.6 2.9 12 2.2 3.1 Total LCA (µM) 0.36 0.034 0.22 0.63 0.029 0.016 0.038 0.083 0.051 0.001 0.004 Total UDCA (µM) 0.34 0.013 0.009 0.024 0.022 0.024 0.014 0.16 0.17 0.019 0.06 Total CDCA (µM) 1.4 0.003 0.78 1.2 0.08 1.1 0.21 0.032 2.2 0.093 0.12 Total DCA (µM) 0.99 0.015 0.75 0.72 0.254 0.000 0.24 1.4 0.55 0.415 0.52 Total HDCA (µM) 0.069 0.005 0.28 0.17 0.021 16.2 0.066 0.504 0.84 0.071 0.053 Total MDCA (µM) 0.093 0.000 0.015 0.057 0.003 0.16 0.000 0.047 0.059 0.003 0.016 Total CA (µM) 0.56 0.003 1.3 2.4 0.95 0.022 0.90 0.055 3.5 0.99 1.2 Total MCA (µM) 0.025 0.000 0.016 0.000 0.011 0.075 0.008 0.014 2.8 0.60 1.2 Total HCA (µM) 0.02 0.001 0.002 0.003 0.000 11.2 0.011 0.001 0.019 0.002 0.003 Total Unamidated BA (µM) 1.4 0.037 3.0 4.8 1.1 26.0 1.3 2.7 9.5 0.38 1.1 Total G-BA (µM) 2.1 0.019 0.16 0.23 0.001 4.8 0.19 0.21 0.76 0.007 0.009 Total T-BA (µM) 0.43 0.018 0.33 0.21 0.34 0.13 0.055 0.000 1.9 1.8 2.1 Total Unsulfated BA (µM) 2.8 0.043 3.4 5.2 1.4 30.9 1.6 2.8 12.2 2.2 3.1 Total Sulfated BA (µM) 1.1 0.031 0.046 0.031 0.000 0.077 0.026 0.078 0.021 0.000 0.003 %Sulfation of total BA 32% 50% 1.4% 0.9% 0.01% 0.5% 1.6% 4.8% 0.2% 0.0% 0.2% %Amidation of total BA 65% 62% 15% 13% 52% 20% 12% 11% 22% 86% 71% %G-amidation of total BA 54% 33% 5.4% 7.6% 0.03% 20% 8.5% 11% 7% 0.3% 0.3% %T-amidation of total BA 12% 29% 10% 5.6% 52% 0.5% 3.1% 0.00% 15% 86% 71% % Glucuronidation of total BA 0.01% 0.2% 0.0% 0.0% 0.5% 0.0% 0.0% 0.1% 0.1% 0.1% 0.2% %Mono-OH BA 12% 52% 7.1% 26% 5.9% 0.06% 2.3% 4.8% 0.5% 0.03% 0.1% %Di-OH BA 74% 41% 53% 48% 39% 61% 34% 72% 33% 26% 23% %Tri-OH BA 12% 8% 38% 23% 55% 34% 58% 3.6% 52% 74 % 77% Total Primary BA (µM) 2.0 0.010 2.1 3.6 1.1 12.4 1.1 0.10 8.5 1.7 2.5 Total Secondary BA (µM) 1.9 0.070 1.3 1.7 0.36 18.6 0.45 2.8 3.7 0.51 0.67 % Primary BA 45% 14% 59% 36% 63% 37% 69% 5% 7% 78% 80% % Secondary BA 55% 86% 41% 64% 37% 63% 31% 95% 30% 22% 20% Primary/secondary 1.1 0.18 3.8 2.0 2.0 0.59 2.5 0.050 2.3 4.2 4.5 Total 12α-OH BA (µM) 1.6 0.020 2.1 3.1 1.2 0.060 1.2 1.7 4.1 1.4 1.7 Total non-12α-OH BA (µM) 2.3 0.060 1.4 2.2 0.20 31.0 0.42 1.2 8.1 0.80 1.5 % 12α-OH BA 38% 17% 59% 46% 80% 0.2% 75% 56% 35% 65% 57% % non-12α-OH BA 62% 83% 41% 54% 20% 99% 25% 44% 65% 35% 43% 12α-OH/ non-12α-OH BA 0.69 0.23 1.6 1.1 4.4 0.002 3.2 1.4 0.55 2.0 1.4 CA/CDCA 0.34 0.87 1.7 1.2 8.5 0.040 6.1 1.9 1.7 17.8 13.7 HI 0.45 0.10 0.41 0.55 0.30 -0.19 0.29 0.60 0.24 -0.06 -0.09 
60  Table 1.2 Urine BA profiles in humans and in various animal species.  Human  Chimpanzee Cynomolgus Monkey Rhesus Monkey Beagle Dog Gottingen Minipig Syrian hamster New Zealand Rabbit 
SD Rat CD-1 Mouse C57/BL6 Mouse 
Total BA (µM) 9.2 0.3 0.7 0.2 11.6 205 0.4 0.3 20.6 21.4 4.3 Total LCA (µM) 1.2 0.080 0.031 0.009 0.002 0.29 0.004 0.010 0.062 0.003 0.005 Total UDCA (µM) 1.4 0.008 0.069 0.002 0.078 6.8 0.004 0.035 0.28 0.039 0.008 Total CDCA (µM) 2.7 0.030 0.059 0.013 0.18 15.3 0.005 0.11 0.058 0.016 0.008 Total DCA (µM) 2.6 0.047 0.23 0.10 1.23 6.9 0.029 0.055 0.94 0.44 0.11 Total HDCA (µM) 0.004 0.000 0.030 0.011 0.14 80.3 0.012 0.000 1.2 0.089 0.037 Total MDCA (µM) 0.047 0.004 0.021 0.020 0.023 6.8 0.008 0.004 0.11 0.011 0.009 Total CA (µM) 0.61 0.15 0.18 0.063 7.7 19.6 0.13 0.092 1.8 14.0 3.3 Total MCA (µM) 0.36 0.015 0.034 0.003 1.0 9.9 0.17 0.004 11.5 5.9 0.78 Total HCA (µM) 0.033 0.000 0.006 0.000 0.007 39.2 0.000 0.000 0.19 0.026 0.005 Total Unamidated BA (µM) 1.1 0.072 0.52 0.19 10.1 85.2 0.37 0.03 9.1 5.6 1.2 Total G-BA (µM) 7.5 0.17 0.10 0.04 0.01 109.8 0.007 0.25 0.12 0.039 0.011 Total T-BA (µM) 0.60 0.092 0.13 0.005 1.53 9.9 0.006 0.036 11.4 15.8 3.08 Total Unsulfated BA (µM) 1.2 0.16 0.53 0.21 11.6 202.5 0.38 0.12 20.5 8.1 1.2 Total Sulfated BA (µM) 8.0 0.17 0.22 0.03 0.00 2.4 0.00 0.19 0.14 13.2 3.1 %Sulfation of total BA 85% 52% 27% 24% 0.0% 7.3% 2.1% 55% 0.7% 63% 72% %Amidation of total BA 86% 69% 30% 31% 53% 49% 3% 88% 56% 73% 72% %G-amidation of total BA 80% 47% 14% 26% 0.0% 45% 2.0% 78% 0.6% 0.2% 0.3% %T-amidation of total BA 6.6% 22% 16% 5.4% 53% 3.6% 1.4% 10% 56% 73% 72% % Glucuronidation of total BA 0.01% 0.16% 0.01% 0.03% 0.54% 0.0% 0.01% 0.09% 0.06% 0.13% 0.28% %Mono-OH BA 12% 29% 4.6% 10% 0.0% 0.1% 1.1% 3% 0.27% 0.02% 0.12% %Di-OH BA 73% 28% 54% 67% 7% 46% 17% 57% 13% 2.6% 4.0% %Tri-OH BA 12% 42% 29% 21% 89% 44% 78% 35% 65% 94% 94% Total Primary BA (µM) 3.7 0.20 0.30 0.10 8.9 84 0.30 0.20 13.5 19.9 4.1 Total Secondary BA (µM) 5.5 0.10 0.50 0.20 2.7 121 0.10 0.10 7.1 1.5 0.26 % Primary BA 40% 49% 35% 30% 90% 51% 80% 64% 66% 94% 94% % Secondary BA 60% 51% 65% 70% 10% 49% 20% 36% 34% 6.4% 6.0% Primary/secondary BA  0.80 1.7 0.57 0.44 10.1 1.3 3.9 2.0 1.9 18.0 16.5 Total 12α-OH BA (µM) 3.3 0.20 0.41 0.16 8.9 26.5 0.16 0.16 2.7 14.5 3.4 Total non-12α-OH BA (µM) 5.9 0.14 0.34 0.07 2.7 178.4 0.23 0.16 17.9 6.9 0.94 % 12α-OH BA 34% 54% 53% 55% 44% 9.8% 46% 53% 13% 68% 78% % non-12α-OH BA 66% 46% 47% 45% 56% 90% 54% 47% 87% 32% 22% 12α-OH/ non-12α-OH BA 0.55 1.6 1.2 2.0 1.6 0.11 0.97 1.3 0.15 2.2 3.8 CA/CDCA 0.3 5.0 3.5 4.4 35 0.99 29 2.1 30 1019 434 HI 0.04 0.24 0.29 0.52 -0.28 -0.19 0.23 0.09 -0.57 -0.60 -0.49 
61  Table 1.3 Exact mass analyses of various BA standards and their fragments using Orbitrap high resolution mass spectrometry (HRMS). Experimental mass Theoretical mass Mass difference (ppm) 
Formula Parent BAs that produce the fragment 
Tri-OH BAs (CA, HCA, α-MCA, β-MCA and ω-MCA) 407.2795 407.2803 1.96 C24H39O5- CA, HCA, α-MCA, β-MCA and ω-MCA 405.2636 405.2647 2.59 C24H37O5- CA, HCA, α-MCA, β-MCA, and ω-MCA 389.2684 389.2697 3.40 C24H37O4- CA, HCA, α-MCA, β-MCA, and ω-MCA 387.2530 387.2541 2.79 C24H35O4- CA, HCA, α-MCA, β-MCA, and ω-MCA 377.2687 377.2697 2.76 C23H37O4- α-MCA and ω-MCA 375.2530 375.2541 2.80 C23H35O4- α-MCA and ω-MCA 371.2585 371.2592 1.80 C24H35O3- CA, HCA, α-MCA, β-MCA, and ω-MCA 369.2429 369.2435 1.68 C24H33O3- α-MCA, β-MCA, and ω-MCA 363.2894 363.2905 2.95 C23H39O3- CA 355.2269 355.2279 2.70 C23H31O3- α-MCA and β-MCA 353.2479 353.2486 1.98 C24H33O2- CA 345.2788 345.2799 3.19 C23H37O2- CA 343.2638 343.2643 1.31 C23H35O2- CA and ω-MCA 327.2684 327.2693 2.87 C23H35O- CA  325.2528 325.2537 2.64 C23H33O- CA 289.2166 289.2173 2.59 C19H29O2- CA 251.2010 251.2017 2.55 C16H27O2- CA Di-OH BAs (UDCA, CDCA, MDCA, HDCA, DCA, and isoDCA) 391.2847 391.2854 1.79 C24H39O4- UDCA, CDCA, MDCA, HDCA, DCA, and isoDCA 389.2688 389.2697 2.31 C24H37O4- UDCA, CDCA, MDCA, HDCA and DCA 373.2739 373.2748 2.41 C24H37O3- UDCA, CDCA, MDCA, HDCA and DCA 371.2583 371.2592 2.42 C24H35O3- UDCA, CDCA, MDCA, HDCA and DCA 355.2637 355.2643 1.69 C24H35O2- DCA, and isoDCA 347.2950 347.2956 1.73 C23H39O2- DCA, and isoDCA 345.2796 345.2799 0.87 C23H37O2- DCA, and isoDCA 329.2846 329.2850 1.21 C23H37O- DCA, and isoDCA 327.2690 327.2693 0.92 C23H35O- DCA, and isoDCA Mono-OH BAs (LCA and isoLCA) 375.2902 375.2905 0.80 C24H39O3- LCA and isoLCA 357.2789 357.2799 2.80 C24H37O2- LCA and isoLCA 355.2635 355.2643 2.25 C24H35O2- LCA and isoLCA BA G-amidates (G-LCA, G-UDCA, G-CDCA, G-DCA, G-MDCA, G-CA, and G-HCA) 432.3109 432.2119 2.32 C26H42NO4- G-LCA 
62  448.3056 448.3068 2.68 C26H42NO5- G-UDCA, G-CDCA, G-DCA, and G-HDCA 464.3017 464.3018 0.22 C26H42NO6- G-CA and G-HCA 402.3001 402.3014 3.23 C25H40NO3- G-CA and G-HCA 386.3054 386.3065 2.85 C25H40NO2- G-UDCA, G-CDCA, G-DCA, and G-HDCA 74.2050 74.2048 1.35 C2H4NO2- G-CA, G-HCA, G-UDCA, G-CDCA, G-DCA, and G-HDCA, and G-LCA BA T-amidates (T-LCA, T-UDCA, T-CDCA, T-DCA, T-HDCA, T-CA, T-MCA, and T-HCA) 482.2940 482.2946 1.2 C26H44NO5S- T-LCA 498.2882 498.2895 2.61 C26H45NO6S- T-UDCA, T-CDCA, T-DCA, and T-HDCA 514.2797 514.2797 0.00 C26H45NO7S- T-CA , T-MCA, and T-HCA 
124.0075 124.0074 -0.81 C2H6NO3S- T-CA, T-MCA, T-HCA, T-UDCA, T-CDCA, T-DCA, and T-HDCA 
106.9809 106.9808 -0.93 C2H3O3S- T-CA, T-MCA, T-HCA, T-UDCA, T-CDCA, T-DCA, and T-HDCA 
79.9576 79.9574 -2.50 SO3- T-CA, T-MCA, T-HCA, T-UDCA, T-CDCA, T-DCA, and T-HDCA BA S-conjugates (CA-S, G-CA-S, T-CA-S, UDCA-S, CDCA-S, DCA-S, G-CDCA-S, T-CDCA-S, T-UDCA-S, T-CDCA-S, T-DCA-S, G-LCA-S, and TLCA-S 594.2422 594.2412 -1.68 C26H44NO10S2- T-CA-S 544.2575 544.2586 2.02 C26H42NO9S- G-CA-S 487.2374 487.2371 -0.62 C24H39O8S- CA-S 578.2464 578.2463 -0.17 C26H44NO9S2- T-UDCA-S, T-CDCA-S, and T-DCA-S 528.2637 528.2642 0.95 C26H42NO8S- G-CDCA-S, and G-DCA-S 471.2418 471.2422 0.82 C24H39O7S- UDCA-S, CDCA-S, and DCA-S 96.9601 96.9602 1.03 HSO4- CA-S, G-CA-S, T-CA-S, UDCA-S, CDCA-S, DCA-S, G-CDCA-S, T-CDCA-S, T-UDCA-S, and T-CDCA-S, T-DCA-S 
63  Table 1.4 HRMS analysis of UDCA metabolites and their fragments.  Each biotransformation product is described by molecular formula [M-H]-, exact m/z shift (compared to the parent), and MS/MS fragments.  
 
Modification  Exact m/z shift Formula  [M-H]- Experimental mass Theoretical mass Mass difference (ppm) Fragment of UDCA (Parent) - C24H39O4- 391.2849 391.2854 1.28 - UDCA-Glucuronide (M1-M3) 176.0325 (+C6H8O6) C30H47O10- 567.3174 567.3175 0.18 M1-M3   C30H45O9- 549.3063 549.3069 1.09 M1 and M2 C29H47O8- 523.3271 523.3276 0.96 M1 and M2 C29H45O7- 505.3166 505.3171 0.99 M1-M3 C24H39O4- 391.2849 391.2854 1.28 M1-M3 C6H9O7- 193.0354 193.0354 0.00 M3 C6H7O6- 175.0245 175.0248 1.71 M1-M3 UDCA-Sulfate (M4-M5) 79.9562 (+SO3) C24H39O7S- 471.2422 471.2416 1.27 M4-M5   HO4S- 96.9601 96.9602 1.03 M4-M5 UDCA-Glutathione conjugate (M6) 289.0733 (+C10H15N3O5S) C34H54N3O9S- 680.3582 680.3586 0.59 M6   C34H52N3O8S- 662.3461 662.3481 3.02 M6 C10H16N3O6S- 306.0764 306.0765 0.33 M6 C10H14N3O6- 272.0887 272.0888 0.37 M6 C10H14N3O5- 254.0781 254.0782 0.39 M6 C9H12N3O3- 210.0885 210.0884 -0.48 M6 C5H6NO3- 128.0353 128.0353 0.00 M6 Oxidation (M7-M10) 15.9946 (+O) C24H39O5- 407.2795 407.2803 1.96 M7-M10   C24H37O5- 405.2639 405.2647 1.85 M7 and M10 C24H37O4- 389.2689 389.2697 2.13 M7-M10 C24H35O4- 387.2533 387.2541 2.01 M7-M10 C23H35O4- 375.2533 375.2541 2.08 M7 C24H35O3- 371.2584 371.2592 2.07 M7-M10 C24H33O3- 369.2424 369.2435 2.98 M10 C23H39O3- 363.2896 363.2905 2.39 M7 C22H33O4- 361.2377 361.2384 1.94 M7 and M8 C23H31O3- 355.2272 355.2279 1.89 M8 and M10 C24H33O2- 353.2480 353.2486 1.70 M8 C22H35O3- 347.2586 347.2592 1.73 M7-M9 C23H37O2- 345.2792 345.2799 2.03 M9 C23H35O2- 343.2637 343.2643 1.60 M7-M9 C20H31O4- 335.2222 335.2280 1.79 M7-M9 C21H31O3- 331.2273 331.2279 1.72 M8 and M9 C22H33O2- 329.2481 329.2486 1.52 M8 and M9 C20H29O3- 317.2117 317.2122 1.58 M7-M9 G-UDCA (M11) 57.0211 (+C2H3NO1) C26H42NO5- 448.3060 448.3068 1.78 M11   C25H40NO2- 386.3055 386.3065 2.59 M11 C2H4NO2- 74.2049 74.2048 -1.35 M11 T-UDCA (M12) 107.0042 (+C2H5NO2S) C26H44NO6S- 498.2891 498.2895 0.80 M12 T-UDCA+Oxidation (T-MCA; M13) 122.9987(+O+C2H5NO2S) C26H45NO7S- 514.2800 514.2794 -0.58 M13   C2H6NO3S- 124.0076 124.0074 -1.61 M12 and M 13 C2H3O3S- 106.9809 106.9808 -0.93 M12 and M 13 SO3- 79.9575 79.9574 -1.25 M12 and M 13 
64  Table 1.5 Physiological concentrations of biotransformation cofactors for various metabolic pathways in human liver and biological fluids, and in previously and currently used in vitro metabolism systems.  Cofactors  Metabolic Pathway Human liver Human biological fluids Previous in vitro systems Current in vitro system  Taurine T-amidation 0.3-3.6 mM [233-236] Bile: 0.2 mM [233]; WBC: 0.02-0.035 mM [233]; Plasma: 0.068 mM [235]  
20-30 mM [10, 237]  5 mM 
Glycine G-amidation 1.5-3.8 mM [235, 236]  Plasma: 0.23 mM [235] 20-30 mM [10, 237] 5 mM GSH Glutathione conjugation 1 mM [238]  Plasma: 0.0034-0.026 mM [239, 240], blood: 0.85-1.8 mM [239, 241]; Lymp 11 -21.5 nmol/mg protein [242]  
1.5-10 mM [243-245] 5 mM 
PAPS Sulfation 0.023 mM [246] - 0.04-1 mM [174, 244, 247-250]  0.1 mM UDPGA Glucuronidation 0.29 mM [251] - 1-5 mM [250, 252-255] 0.4 mM CoA G and T Amidation 0.065-0.1 mM [256] - 0.4-2 mM [10, 237]  0.4 mM ATP  G and T Amidation 1-10 mM [257] Plasma: 0.000028 mM [258]  5-7 mM [10, 237]  1 mM NADPH Oxidation 0.2-0.3 mM [259] RBC:0.02 mM [241]  1 mM [260-262] 1 mM 
65  Table 1.6  LCA, UDCA, CDCA, and CA metabolism by hepatocyte S9 fractions from humans and various animal species Species % Metabolized %  Sulfation % Amidation % G-Amidation % T-Amidation % Oxidation % Glucuronidation % Glutathione conjugation LCA Human 25% 18 % 76 % 23 % 53 % 4.6 % 0.8 % 0.0 % Chimpanzee 19% 52 % 36 % 10% 25% 9.6% 2.7% 0.2 % Cynomolgus Monkey 25% 1.3 % 86 % 44% 42% 8.0% 4.4% 0.2 % Rhesus Monkey 26% 2.1 % 75 % 40% 35% 11% 11.3% 0.5 % Beagle Dog 21% 0.1 % 9 % 0% 8.8% 13% 75% 2.9 % Gottingen Minipig 54% 0.2 % 96 % 89% 7.2% 3.7% 0.1% 0.0% Syrian Hamster 33% 0.7 % 71 % 19% 52% 25% 3.2% 0.2% New Zealand Rabbit 27% 2.1 % 70 % 65% 4.2% 27% 1.0% 0.1% SD Rat 46% 0.2 % 16 % 1.1% 15% 80% 3.8% 0.1% CD-1 Mouse 47% 0.0 % 72 % 0.4% 71% 28% 0.1% 0.1% C57/BL6 Mouse 33% 0.1 % 70 % 0.4% 69% 30% 0.2% 0.1% UDCA Human 23% 19% 70% 28% 43% 9.5% 0.3% 0.7% Chimpanzee 11% 27% 55% 11% 44% 15% 2% 0.4% Cynomolgus Monkey 30% 0.4% 77% 39% 37% 22% 0.8% 0.2% Rhesus Monkey 21% 0.15% 79% 42% 37% 19% 1.3% 0.2% Beagle Dog 8% 0.01% 19% 0.0% 19% 25% 56% 0.4% Gottingen Minipig 62% 0.04% 96% 91 % 5.3% 3.6% 0.0% 0.15% Syrian Hamster 16% 9% 70% 20% 50% 20% 1.0% 0.01% New Zealand Rabbit 16% 12% 64% 62% 2.3% 20% 0.5% 0.05% SD Rat 23% 0.0% 40% 0.9% 39% 59% 0.5% 0.02% CD-1 Mouse 39% 0.0% 76% 0.32% 75% 24% 0.03% 0.1% C57/BL6 Mouse 20% 0.0% 72% 0.42% 71% 28% 0.12% 0.02% CDCA Human 25% 22% 64% 24% 40% 12% 1.1% 0.6% Chimpanzee 9% 14% 61% 17% 44% 22% 1.9% 1% Cynomolgus Monkey 31% 2.1% 73% 35% 38% 24% 0.8% 0.4% Rhesus Monkey 21% 5.4% 65% 31% 34% 26% 1.5% 1.4% Beagle Dog 12% 0.0% 22% 2.7% 19% 48% 27% 3.3% Gottingen Minipig 80% 5.7% 68% 65% 3.1% 25% 0.5% 0.2% Syrian Hamster 28% 7.5% 60% 32% 28% 31% 1.5% 0.8% New Zealand Rabbit 15% 14% 64% 62% 2.4% 20% 2.9% 0.0% SD Rat 22% 1.3% 26% 1.0% 25% 70% 1.6% 0.6% CD-1 Mouse 34% 0.0% 50% 0.5% 50% 49% 0.7% 0.4% C57/BL6 Mouse 26% 0.0% 60% 0.5% 59% 39% 0.8% 0.4% CA Human 16 % 4.8% 93% 26% 66% 2.1% 0.1% 0.5% Chimpanzee 2.0% 0.5% 90% 29% 62% 7.6% 0.3% 1.2% Cynomolgus Monkey 17% 0.04% 98% 61% 36% 2.1% 0.2% 0.1% Rhesus Monkey 9.0% 0.06% 97% 61% 36% 2.1% 0.6% 0.3% Beagle Dog 2.0% 0.00% 81% 0.0% 81% 4.8% 9.7% 4.3% Gottingen Minipig 68% 0.02% 98% 94% 4% 1.6% 0.0% 0.0% Syrian Hamster 20% 0.3% 89% 42% 48% 10% 0.5% 0.0% New Zealand Rabbit 6.0% 1.4% 98% 95% 3% 0.6% 0.2% 0.2% 
66  SD Rat 6.0% 0.04% 81% 33% 48% 18% 0.6% 0.4% CD-1 Mouse 19% 3.5% 81% 0.5% 81% 13% 1.0% 1.2% C57/BL6 Mouse 7.0% 2.0% 80% 0.7% 79% 16% 1.1% 1.3%  
67  Table 1.7 BA oxidation into hydroxylated metabolites by hepatocytes S9 fractions. 
  LCA  UDCA CDCA  6-β-OH (MDCA) 6-α-OH (HDCA) Other* 6-β-OH (MCA) Other 6-β-OH (MCA) 12-α-OH (CA) 6-α-OH (HCA) Other Human 12% 59% 29% 44% 56% 7% 73% 7% 12% Chimpanzee 7% 68% 25% 55% 45% 12% 56% 6% 27% Cynomolgus Monkey 13% 38% 49% 4.8% 95% 11% 63% 12% 14% Rhesus Monkey 13% 41% 47% 16% 84% 10% 58% 14% 18% Beagle Dog 3% 4% 93% 9.2% 91% 20% 57% 7% 16% Gottingen Minipig 3% 36% 61% 64% 36% 1% 0.7% 97% 1.6% Syrian Hamster 6% 71% 23% 89% 11% 10% 69% 3% 18% New Zealand Rabbit 93% 2% 5% 8.9% 91% 0% 65% 15% 19% SD Rat 94% 3% 2% 94% 5.5% 95% 1.2% 1.7% 2.1% CD-1 Mouse 65% 3% 32% 94% 6.4% 93% 2.9% 1.3% 2.5% C57/BL6 Mouse 67% 2% 31% 89% 11% 92% 3.3% 1.5% 2.7% *Other:  Sum of metabolites resulting from hydroxylation of various overlapping position excluding 6-α, 6-β, and 12-α position. 
68  Table 1.8 Literature summary of plasma BA profiles in different species.  Human [86, 91, 142, 180-185] 
Mouse [86, 135, 142, 145] Rat [86, 138, 141, 143, 146] 
Beagle dog [91, 144] Syrian Hamster [155] 
New Zealand Rabbit [155] 
Pig [139, 141] Cow [91] Horse [91] 
Total BA (µM) 0.9 - 4.4 1.3-9.0 3.6-38 2.4-5.0 - - 6.6-31 93 3.64 Total LCA (µM) 0.01 - 0.3 0.004-0.02 0.01-0.11 0.0-0.02 - - 0.02-0.04 0.84 0.00 Total UDCA (µM) 0.02 - 0.51 0.01-0.5 0.04-0.73 0.04-0.12 - - 0.02-2.9 0.00 0.23 Total CDCA (µM) 0.15 - 4.2 0.008-0.4 0.3-2.8 0.28-0.51 - - 1.0-1.1 2.5 2.5 Total DCA (µM) 0.13 - 0.96 0.09-1.0 0.3-4.1 0.66-1.24 - -  11.6 0.00 Total HDCA (µM) 0.002-0.18 0.02-0.1 0.2-4.8 - - - 16.2 - - Total MDCA (µM) 0.0 - 0.0001 0-0.5 0.0-0.05 - - - 0.16 - - Total CA (µM) 0.09-1.26 0.44-4.5 1-19 1.4-3.1 - - 0.02-0.03 78 0.92 Total MCA (µM) 0.003-0.026 0.65-4.5 0.4-7.6 0 - - 0.07 - - Total HCA (µM) 0.004-0.032 0-0.02 0.0-0.08 - - - 2.7-11.2 - - Total G-BA (µM) 0.7 - 2.7 0.02-0.04 0.03-0.9 - - - 3.0 29 0.25 Total T-BA (µM) 0.06 - 0.57 1-5.3 0.6-10 2.3-4.8 - - 0.0 23 3.1 Total Unsulfated BA (µM) 0.7 - 4.4 1.3-9.0 3.6-24 2.4-5.0 - - - - - Total Sulfated BA (µM) - - - - - - - - - %Sulfation of Total BA - -   -  - - - - - - %Amidation of Total BA 36%-72% 18%-82% 9%-73% 94-95% - - 45% 56% 92% %G-amidation of Total BA 31%-66% 0%-0.2%   0.7%-4% 0% - - 42% 31% 7.0% %T-amidation of Total BA 2.7%-12% 18%-82% 5%-72% 94-95% - - 2.7% 25% 85% %Mono-OH BA 0.5%-8% 0%-0.4% 0.15%-1.5% 0-1% 1.40% 3.1% 0.1-0.5% 0.9% 0.0% %Di-OH BA 65%-85% 1%-40% 12%-50% 37-40% 25% 52% 59% 15% 75% %Tri-OH BA 12%-28% 50-90% 50%-87% 58-62% 73% 45% 40% 84% 25% %LCA 0.5%-8% 0%-0.4% 0.15%-1.5% 0-1% 1.40% 3.1% 0.1-0.5% 0.9% 0.0% %UDCA 1.8%-20% 1%-7% 0.7%-10% 1.7-2.3 2.10% 1.4% 0.2-44% 0.0% 6.3% %CDCA 29%-75% 0.8%-5% 5%-29% 10-12% 11% 7.0% 3-15% 2.7% 68% %DCA 9.2%-36% 0.5-26% 0.8%-11% 25-27% 12% 44% 0.00% 12.5% 0.0% %HDCA 0.09%-5.5% 0%-2.6% 1%-27% - - - 57% - - %MDCA 0% 0-1% 0.0-0.2% - - - - - - %CA 9%-28% 14%-63% 27%-56% 58-63% 73% 45% 0.38% 84% 25% %MCA 0.12%-0.8% 13%-59% 18%-42% 0%   0.6 - - %HCA 0.2%-5.7% 0%-0.32% 0.0%-0.4% 0%   33-40%   Total Primary BAs (µM) 0.23-2.85 1.1%-4.9% 2.7-28 1.7-3.7 - - 3.70 81 3.4 Total Secondary BAs (µM) 0.13-1.53 0.13%-2.3% 1-9.2 0.7-1.35 - - 2.94 12 0.23 % Primary BAs 40%-65% 58%-90% 68-95% 70-73% - - 56% 87% 94% % Secondary BAs 9.2%-56% 10%-40% 5.5-32% 27-30% - - 44% 13% 6.3% Primary/secondary 0.74-1.9 2.6-8.6 2.1-17 2.3-2.7 5.4 1.1 1.3 6.5 14.9 Total 12α-OH BAs (µM) 0.22-1.81 0.5-5.5 1-24 2.1-4.4   0.03 90 0.92 Total non-12α-OH BAs (µM) 0.22-2.5 0.7-3.6 2.6-14 0.3-0.6 - - 6.61 3.4 2.7 % 12α-OH BAs 21%-49% 35%-78% 28-59% 85-88% - - 0.38% 96% 25% 
69  % non-12α-OH BAs 29%-61% 23%-65% 37-72% 12-14% - - 99% 3.6% 75% 12α-OH/ non-12α-OH BAs 0.7-1.7 0.8-2.1 0.4-1.4 6.0-7.0 7.6 1.1 0.004 27 0.34 CA/CDCA 0.3-0.6 9-28 1.7-9 5.1-6.2 5.9 6.3 0.024 31 0.37 HI 0.3-0.54 -0.32- -0.1 -0.09-0.22 0.19-0.22 - - -0.18 0.17 0.30 
70  Table 1.9 Literature summary of biliary BA profiles in different species.  Human [263-265] Mouse [88, 135, 266] Rat [153, 155, 267] Syrian Hamster [268-270] Pig [140, 153, 154, 157] New Zealand Rabbit [90, 155-157] 
Cat [90] 
Total BA (µM) 14,000-99,000 57,100-64,000 16,000-25,700 52,076-133,000 35,759-208,000 72,824-358,000 52,131 Total LCA (µM) 2172 0 3.2-8.2 1414 25 244-269 11,344 Total UDCA (µM) 8554 571 1400-3500 - 176-255 - - Total CDCA (µM) 76,144 0 1100-2700 7844 19,278-20,379 - 2258 Total DCA (µM) 22,022 856.5 750-1150 7060 241-595 60,204-64,640 5711 Total HDCA (µM) - - - - 4825-41005 - - Total MDCA (µM) - - - - - - - Total CA (µM) 56,883 35,230 14,800-11,198 35,758 242 2222-7333 14,003 Total MCA (µM) - 13,532 1,500-3,900 - - -  Total HCA (µM) - 286 - - 11,612-26,112 - - Total G-BA (µM) - 26 - - 42,820 - - Total T-BA (µM) - 63,737 - - 7395 -  Total Unsulfated BA (µM) - - - - - - - Total Sulfated BA (µM) - - - - - - - %Sulfation of Total BA - - - - - - - %Amidation of Total BA - - 96-99% -  - - %G-amidation of Total BA 80% 0.04% 5-14% 64-82% 73-82% 92% - %T-amidation of Total BA 20% 99% 86-95% 17-35% 15-27% 8% - %Mono-OH BA 1-1.3% 0.00-0.01% 0.01-0.05% 1.1-15% 2.1% 0.4-1.2% 22% %Di-OH BA 64-67% 2.5-4.4% 19-27% 29-57% 50-84% 82-91% 15% %Tri-OH BA 34-35% 86-95% 72-80% 38-69% 20-52% 3-10% 60% %LCA 1-1.3% 0-0.01% 0.01-0.05% 1.1-15% 2.1% 0.4-1.2% 22% %UDCA 5.2-6.0% 1-2.5% 6-14% 8.0-13% 0.35-14% - - %CDCA 46-48% 0.6-2.3% 6-11% 15-38% 14-38% 0.7-1.2% 4% %DCA 13% 0.9-3.5% 3.0-6.0% 5-15% 0.33% 80-89% 11% %HDCA - - - 0% 55% - - %MDCA - - - - - - - %CA 34-35% 46-62% 57-70% 38-68% 20% 3-10% 60% %MCA - 24-49% 09-15% - - - - %HCA - 0.50% - 0% 16% - - Total Primary BAs (µM) 133,028 49,049-62,626 13,770-21,507 43602 31,990-45,390 2222-7333 16261 Total Secondary BAs (µM) 32,748 1372-1428 2300-4256 8475 4825-41,501 60,449-64,909 17,056 % Primary BAs 80-83% 50-86% 83-90% 68-83% 43-90% 8-10% 64% % Secondary BAs 20% 3-6% 10-16% 16-30% 55-65% 82-90% 33% Primary/secondary 4.1-4.3 8.1-45 5-8.6 2.2-9.2 0.55-0.77 0.03-0.1 1.96 Total 12α-OH BAs (µM) 78,906 30,265-36,087 12,094-17,389 42,818 241-837 66,882-67,538 19,714 Total non-12α-OH BAs (µM) 86,871 14,389-33,732 3984-10205 9259 50212-73250 244-269 13,602 % 12α-OH BAs 48% 47-63% 60-75% 51-82% 0-0.3% 92-97% 71% % non-12α-OH BAs 52% 25-52% 24-40% 18-49% 99% 0.33-2.1% 26% 
71  12α-OH/ non-12α-OH BAs 0.87-0.91 0.9-1.4 1.5-3.04 1.1-4.6 2.25 50-250 2.7 CA/CDCA 0.73-0.75 20-80 5.3-10 1.25-4.56 1.43 6.7 14 HI 0.27-0.4 -0.28 - -0.37 -0.03-0.11 0.23 -0.05 - - 
72  Table 1.10 Literature summary of liver BA profiles in different species. Species Human [271] Mice [151] Rat [271, 272] Hamster [273] Pig [139] Bovine [139] Total BA (µM) 62 170-226 9-70 151 6.5 2.54 Total LCA (µM) 1.5 0.4-0.7 0.1-6.8 1 0.6 0 Total UDCA (µM) 2 3.9-4.1 2.0-2.7 1.9 0.8 0 Total CDCA (µM) 31 4.1-4.6 0.6-2.5 36 1.4 0.06 Total DCA (µM) 6.2 7.4-8.1 1.3-7 10.3 0.92 0.1 Total HDCA (µM)  1.9-2.8 0.02-0.11 - 2.24 0 Total MDCA (µM)  2.2-2.3 - - - - Total CA (µM) 21 70-91 5-23 102 0.63 2.4 Total MCA (µM)  80-112 0.05-5.9 - - - Total HCA (µM)  0.3-0.4 7.2 - - - Total G-BA (µM)  0.1 0.65-0.69 - - - Total T-BA (µM)  135-163 6.4-8.5 - - - Total Unsulfated BA (µM)  170-226 7.3-9.4 - 6.5 2.54 Total Sulfated BA (µM)  - - - - - %Sulfation of Total BA  - - - - - %Amidation of Total BA  73-80% 96-98% - - - %G-amidation of Total BA  0.04-0.06% 7.3-8.9% - - - %T-amidation of Total BA  72-79% 87-91% - - - %Mono-OH BA 4.5% 0.2-0.3% 1-13% 0.7% 6.8% 0% %Di-OH BA 67% 9.5-11% 50-64% 32% 89% 6% %Tri-OH BA 28% 88-90% 35-49% 68% 6.4% 94% %LCA 4.5% 0.2-0.3% 1-13% 0.7% 6.8% 0% %UDCA 4.6% 1.7-2.4% 3.8-36% 1.3% 8.5% 0% %CDCA 46% 2.0-4.0% 4.7-10% 24% 21% 2.3% %DCA 16% 3.5-4.5% 14-18% 6.8% 10% 3.7% %HDCA  1.1-1.3% 0.2-13% - 47% 0% %MDCA  1-1.3% - - - - %CA 29% 40-41% 35-49% 67% 6.4% 94% %MCA  47-49% 0.1-11% - - - %HCA  0.2% - - - - Total Primary BAs (µM) 52 155-208 3.2-30 138 2.0 2.44 Total Secondary BAs (µM) 9.7 15-17 3.8-23 13 4.5 0.1 % Primary BAs 75% 90-92% 43-59% 91% 28% 96% % Secondary BAs 25% 7.5-8.6% 41-57% 9% 72% 4% 
73  Primary/secondary 3.03 11-12 0.8-1.5 11 0.4 33 Total 12α-OH BAs (µM) 27 77-99 3.8-29 112 1.6 2.5 Total non-12α-OH BAs (µM) 35 92-125 3.5-24 39 4.9 0.06 % 12α-OH BAs 44% 44-45% 52-63% 74% 17% 98% % non-12α-OH BAs 56% 54-56% 37-48% 26% 83% 2% 12α-OH/ non-12α-OH BAs 0.80 0.8 1.1-1.7 2.89 0.22 46 CA/CDCA 0.62 17-19 4.4-8.7 2.83 0.29 45 HI  -0.24 -0.02 0.28 0.41 0.16 
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CHAPTER 2 
 Bile Acids as Potential Novel Biomarkers for Organic Anion-Transporting 
Polypeptides 
2.1 Introduction 
It is now accepted that organic anion-transporting polypeptides (OATPs) mediate 
the active uptake of numerous drugs into hepatocytes and hence govern their 
pharmacokinetic profile and liver (free)-to-plasma (free) concentration ratio.  OATPs can 
also serve as the loci of important drug-drug interactions (DDIs) leading to changes in 
systemic and local drug concentrations, possibly resulting in altered efficacy and toxicity 
profiles [1, 2].  Consequently, tools have been developed to facilitate OATP inhibition 
screening in vitro, drive model-based DDI in vitro-in vivo extrapolations, and support 
OATP DDI risk assessment prior to human dosing [3-6].  The latter is particularly 
important because OATP activity and expression is also known to be impacted by 
genotype and liver disease [7, 8]. 
More recently, it has been envisioned that OATP biomarkers will greatly facilitate 
clinical phenotyping and DDI studies, while possibly deferring more formal studies 
employing drug probes [9, 10].  For example, Lai et al (2016) recently evaluated plasma 
bilirubin, bilirubin glucuronide, and coproporphyrin isomers (I and III) as OATP 
biomarkers in human subjects following a single dose of rifampicin (RIF) [9]. The authors 
noted a 4.0- and 3.3-fold increase in the coproporphyrin I and III area under the plasma 
concentration-time curve (AUC), respectively, consistent with in vitro data [11, 12].  
Likewise, Yee et al (2016) identified the 3-O-sulfate conjugates of 
glycochenodeoxycholic acid (GCDCA-S), glycodeoxycholic acid (GDCA-S),  
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and taurolithocholic acid (TLCA-S) as candidate OATP biomarkers after dosing of 
SLCO1B1 genotyped subjects with cyclosporine [10].    Because of the high sequence 
identity with human OATPs, the cynomolgus monkey has been used increasingly as a 
model to study OATP inhibition in vivo [13-15]. The utility of the cynomolgus monkey has 
extended also to the search for OATP biomarkers, which has involved the administration 
of a single RIF dose and reporting its impact on the plasma bilirubin, bilirubin 
glucuronide, coproporphyrins (I and III), non-sulfated bile acids (BAs) and 
dehydroepiandrosterone (DHEA) 3-O-sulfate [12, 16, 17].  
As described, an attempt was made to extend the work of Chu et al by profiling 
30 different BAs in cynomolgus monkey plasma following single oral doses of RIF (1, 3, 
10 and 30 mg/kg) [16]. It was possible to prepare synthetic standards of numerous BA 3-
O-sulfates and apply a liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
method that has been used successfully to profile non-sulfated and sulfated BAs in 
human serum and urine [18].  It should be noted that at the time of the study, BA 
sulfation in the cynomolgus monkey was not well characterized, although the putative 
hydroxysteroid sulfotransferase (SULT2A1) that catalyses BA sulfation in humans was 
known to be expressed in monkey liver [19-21].  It was also known that DHEA 3-O-
sulfate was detectable in cynomolgus monkeys following DHEA administration [22].  
In the present study, animals also received a single i.v. dose of 2H4-pitavastatin 
to ensure that OATP was inhibited by RIF in a dose-dependent manner [14].  In addition, 
the plasma concentrations of RIF were determined at each of the four dose levels. 
Sulfated BAs are known to be cleared renally in humans [18, 21]; therefore BA profiling 
was extended to include urine of control and RIF-dosed cynomolgus monkeys. The 
different BAs were then assessed in terms of their utility as OATP biomarkers: (a) 
detectability in control animals; (b) magnitude of the RIF dose response; and (c) 
detectability in human serum. Based on these criteria, seven sulfated BAs (GCDCA-S, 
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GDCA-S, glycolithocholate 3-O-sulfate [GLCA-S], TLCA-S, taurochenodeoxycholate 3-
O-sulfate [TCDCA-S], taurodeoxycholate 3-O-sulfate [TDCA-S], and deoxycholate 3-O-
sulfate [DCA-S]) were identified as potential OATP biomarkers. For GCDCA-S, GDCA-S, 
and TLCA-S, the results are consistent with human plasma metabolomic data from a 
recent OATP1B1 (SLCO1B1) genome-wide association study and earlier reports 
describing TLCA-S as an OATP substrate in vitro [10, 23, 24].  The present study also 
included an in vitro assessment of BA sulfation by cynomolgus monkey liver cytosol, as 
well as uptake studies with GDCA-S, GCDCA-S, DCA-S, and TDCA-S (cynomolgus 
monkey plated primary hepatocytes) in order to phenotype both in terms of OATP- and 
sodium-taurocholate co-transporting polypeptide (NTCP)-mediated active uptake. 
2.2 Materials and Methods  
2.2.1 Chemicals and Reagents  
3'-Phosphoadenosine-5'-phosphosulfate (PAPS), simvastatin, rifamycin SV 
(RIFsv), and rifampicin (RIF) were purchased from Sigma-Aldrich (St Louis, MO, USA). 
Deuterium labeled RIF (2H8-RIF) were obtained from ALSACHIM (Illkirch, Graffenstaden, 
France). Pitavastatin was purchased from Sequoia Research Products Ltd. (Oxford, 
UK). Deuterium labeled pitavastatin (2H4-pitavastatin) was purchased from Clearsynth 
(Ontario, Canada). InVitroGro-HT and CP hepatocyte media were purchased from Celsis 
IVT (Baltmore, MD). Collagen I coated 24-well plates were obtained from BD 
Biosciences (Franklin Lakes, NJ). Cryopreserved cynomolgus monkey hepatocytes were 
purchased from In vitro ADMET Laboratories, LLC (Columbia, Maryland). BCR protein 
assay kit was purchased from PIERCE (Rockford, IL). RIPA protein lysis buffer was 
purchased from TEKNOVA (Hollister, CA). Methanol, acetonitrile, water, ammonium 
hydroxide were obtained from Fisher Scientific (Fair Lawn, NJ, USA).  
Cholic acid (CA), glycocholic acid (GCA), taurocholic acid (TCA), deuterium 
labeled taurocholic acid (2H4-TCA), chenodeoxycholic acid (CDCA), deuterium labeled 
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chenodeoxycholic acid (2H4-CDCA), taurochenodeoxycholic acid (TCDCA), deoxycholic 
acid (DCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), 
taurodeoxycholic acid (TDCA), lithocholic acid (LCA), glycolithocholic acid (GLCA), 
taurolithocholic acid (TLCA), ursodeoxycholic acid (UDCA), tauroursodeoxycholic acid 
(TUDCA), glycoursodeoxycholic acid (GUDCA), and deuterium labeled glycodeoxycholic 
acid 3-O-sulfate (2H4-GDCA-S) were purchased from IsoSciences (King of Prussia, PA, 
USA). Lithocholic acid 3-O-sulfate (LCA-S), glycolithocholic acid 3-O-sulfate (GLCA-S), 
chenodeoxycholic acid 3-O-sulfate (CDCA-S), glycochenodeoxycholic acid 3-O-sulfate 
(GCDCA-S), and deuterium labeled glycochenodeoxycholic acid 3-O-sulfate (2H5-
GCDCA-S) were purchased from Toronto Research Chemicals (Toronto, Ontario, 
Canada). Ursodeoxycholic acid 3-O-sulfate (UDCA-S) was obtained from ALSACHIM 
(Illkirch, Graffenstaden, France). Deuterium labeled glycochenodeoxycholic acid (2H4-
GCDCA) was purchased from C/D/N isotopes, Inc. (Pointe-Claire, Quebec, Canada). 
Taurolithocholic acid 3-O-sulfate (TLCA-S) was purchased from Sigma-Aldrich (St Louis, 
MO, USA). 
2.2.2 Animal Handling, Dosing, Plasma Draws, and Urine Collection  
All experiments involving animals were conducted at the Pfizer Groton 
(Connecticut) facilities (Association for Assessment & Accreditation of Laboratory Animal 
Care-accredited) and were reviewed and approved by the Pfizer Institutional Animal 
Care and Use Committee. Male cynomolgus macaque Mauritian monkeys 
(approximately 6 to 8.5 years of age) were used for these studies.  A cross-over study 
design was employed, where the same four animals were dosed over a series of five 
studies, following a minimum one-week wash-out period between each study.  One 
exception was the 3 mg/kg RIF dose group, where one of four monkeys was dosed only 
in that single study. 
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Animals were provided a normal food schedule the day before the study (meals 
at 8:00 am and 11:00 am, with one treat daily) and were allowed free access to water. 
On the day of the study, monkeys were fed at approximately 1h and 3h post-dose and 
allowed water ad libitum.  RIF was administered via oral gavage at 0 (blank vehicle), 1, 
3, 10, and 30 mg/kg.  RIF was given at a dose volume of 2 ml/kg in a 0.5% (w/v) 
methylcellulose (in water) suspension.  Approximately one hour and 15 minutes 
following the oral RIF administration, 2H4-pitavastatin was administered via an 
intravenous (i.v.) bolus (cephalic vein), at dose of 0.2 mg/kg, in a dosing volume of 0.2 
ml/kg; 2% DMSO (v/v) and 98% of TRIS-buffered saline (pH ~7.7).  All i.v. formulations 
were sterile filtered prior to administration.  Serial blood samples were collected via the 
femoral vein before dosing into K2EDTA tubes and then at 0.083, 0.25, 0.5, 0.75, 1, 2, 3, 
5, 6, and 24 hours post i.v. dosing.  Blood samples were stored on wet ice prior to being 
centrifuged to obtain plasma (3000 RPM, 10 minutes at 4 ◦C; Jouan BR4i refrigerated 
centrifuge).  Urine was also collected (metabolism cages), on wet ice, pre-dose and at 
intervals of 0 to 6 hours and 6 to 24 hours post-dose.  Due to instability and possible 
inter-conversion of lactone to pitavastatin, each plasma and urine sample was equally 
divided into two aliquots prior to being stored frozen.  The first was untreated matrix, 
while the second was added to an equal volume of 0.1 M sodium acetate buffer (pH 4) to 
stabilize pitavastatin.  All urine and plasma samples, treated and untreated, were kept 
cold during collection, after which they were stored frozen at -20°C.  It is known that BAs 
undergo enterohepatic recirculation, but no attempt was made to collect portal vein 
blood from the different cynomolgus monkeys.  Following LC-MS/MS analysis of femoral 
vein-derived plasma, it was apparent that the concentration (plasma total) of the various 
BA sulfates was low (≤ 30 nM).  For some of the BA sulfates (TCDCA-S, GCDCA-
S,TDCA-S, and GDCA-S), unbound fraction in cynomolgus monkey plasma was 
determined (~0.016); maximal free plasma concentration ~0.5 nM.  It is assumed that 
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even if free BA sulfate concentrations were 100-fold higher in the portal vein, such 
concentrations would still likely be below the apparent Km for cynomolgus monkey 
OATPs.  As described in Results, RIF dosing brought about robust (≥ 10-fold) dose-
dependent increase in the area under the plasma concentration-time curve (AUC) for a 
number of BA sulfates (LCA-S, GLCA-S, TLCA-S, GCDCA-S, TCDCA-S, DCA-S, 
GDCA-S, TDCA-S).  Such a result is consistent with low substrate concentration-to-
OATP Km ratios in vivo. 
2.2.3 Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis  
2.2.3.1 Analysis of BAs and their 3-O-sulfate conjugates  
Plasma and urine concentrations of BAs and their 3-O-sulfate conjugates were 
measured in untreated matrices by LC-MS/MS, as described previously with some 
modifications (Bathena et al., 2013).  Briefly, a Waters ACQUITY ultra performance 
liquid chromatography (UPLC) system (Waters, Milford, MA) coupled to an 5500 Q 
TRAP® quadrupole linear ion trap hybrid mass spectrometer (MS) with an electrospray 
ionization (ESI) source (Applied Biosystems, MDS Sciex, Foster City, CA) was used. 
Chromatographic separations were performed with an ACQUITY UPLC®BEH C18 
column (1.7 μm, 150 × 2.1 mm) maintained at 25°C and equipped with an in-line pre-
column filter. The mobile phase consisted of 7.5 mM ammonium bicarbonate, adjusted 
to pH 9.0 using ammonium hydroxide (mobile phase A), and 30% acetonitrile in 
methanol (mobile phase B), at a total flow rate of 0.2 ml/min.  The gradient profile was 
held at 52.5% mobile phase B for 12.75 min, increased linearly to 68% in 0.25 min, held 
at 68% for 8.75 min, increased linearly to 90% in 0.25 min, held at 90% for 1 min, and 
finally brought back to 52.5% in 0.25 min followed by 4.75 min re-equilibration (total run 
time of 28 min per sample).  Ten μl of sample was injected for analysis. Quantitative 
data were acquired in multiple reaction monitoring (MRM)-negative ESI mode.  MRM 
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transitions and MS parameters for the different BAs and their respective 3-O-sulfate 
conjugates are shown in Supplemental Table 1. 
For preparation of calibration curves blank plasma and urine were obtained by 
charcoal stripping as described previously [18].  Fourteen-point calibration curves were 
prepared in stripped matrices by spiking ten μl of appropriate standard solution at final 
concentrations ranging from 0.5 to 2500 ng/ml.  For extraction of plasma samples, 1 ml 
of ice-cold alkaline ACN (5% NH4OH) containing 2H4-GCDCA and 2H4-CDCA as 
internal standards was added to 100 μl of samples.  Samples were then vortex mixed 
and centrifuged at 16,000 × g for 10 min and the supernatants were aspirated, 
evaporated, and reconstituted in 100 μl of 50% MeOH solution. Urine samples were 
extracted similar to plasma samples except that Tween 20 was added (final 
concentration of 0.2% v/v) to reduce non-specific binding. 
3.2.3.2 Analysis of 2H4-pitavastatin and RIF  
The plasma concentrations of RIF and 2H4-pitavastatin were measured in plasma 
samples treated with 0.1 M sodium acetate buffer (pH 4) using the LC-MS/MS system 
listed above. All standards and QCs were made in blank monkey plasma mixed with an 
equal volume of 0.1 M sodium acetate buffer (pH 4). Standard and QC mixtures of the 
analytes were made to encompass a range of concentrations (0.1 to 500 ng/ml, 2H4-
pitavastatin; 1 to 5,000 ng/ml, RIF).  Samples were diluted to be measured in the linear 
range of the instrument responses; with the high specificity of MRM (no interference in 
the blank matrixes) and a wide dynamic range for each analyte, the dilution integrity was 
confirmed by independent analysis of the drugs in the samples in separate assays. 
Aliquots of 50 μl of standards, QCs and plasma samples were prepared by protein 
precipitation using 200 μl of acetonitrile containing an internal standard mixture of 
simvastatin and 2H8-RIF (100 ng/ml).  The plates were vortexed for 2 minutes, 
centrifuged at 3000 rpm for 10 minutes, and 100 μl supernatants of the mixture were 
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transferred for LC-MS/MS analysis.  Chromatographic separation was accomplished on 
a Waters Acquity UPLC HSS T3 C18 column (1.8μm, 2.1 × 50 mm) maintained at 40 °C. 
The mobile phase consisted of two solvents, solvent A (0.1% formic acid in water) and 
solvent B (0.1% formic acid in acetonitrile).  The total run time for each injection was 3 
minutes.  The flow rate was 0.6 ml/min.  The gradient was maintained at 5% B for 0.3 
min, followed by a linear increase to 95% B in 1.8 minutes, and kept at 95% B for 0.3 
min then a linear decrease to 5% in 0.3 minutes. The column was equilibrated at 5% B 
for 0.3 min.  A Valco VICI valve (Valco Instruments Co., Houston, TX) was used to divert 
the first 0.3 min and the last 0.5 minutes of HPLC effluent to waste.  The injection 
volume was 2 μl. The analytes were monitored using MRM with settings listed in 
Supplemental Table 2. 
2.2.4 Determination of Uptake Clearance in the Presence of Cynomolgus Monkey Plated 
Primary Hepatocytes   
Thawing and seeding procedure for cynomolgus monkey hepatocytes was the 
same as that described previously for human hepatocytes [25].  In brief, cryopreserved 
cynomolgus monkey primary hepatocytes (male animal; Lot number 10106012; In vitro 
ADMET Laboratories, LLC. Columbia, Maryland) were thawed and seeded into 24-well 
collagen coated plates using In Vitro-HT and In Vitro-CP hepatocyte media at a density 
of 0.35 x 106 cells/well (0.5 ml/well).  After culturing for 6 hours, the uptake study was 
conducted.  To assess the rate of uptake and passive diffusion, the cells were pre-
incubated with and without (DMSO only) RIFsv (1 mM) or RIF (5 μM) at 37 °C for 10 
minutes. The uptake was initiated by the addition of 0.5 ml containing 2H4-TCDCA-S (0.1 
μM), 2H4-TDCA-S (0.1 μM), 2H4-DCA-S (0.1 μM), 2H5-GCDCA-S (0.1 and 0.5 μM), 2H4-
GDCA-S (0.1 and 0.5 μM), 2H4-TCA (0.1 and 0.5 μM), and non-labeled pitavastatin (0.1 
μM). To determine the effect of sodium on substrate uptake, the cells were pre-
incubated in Krebs-Henseleit buffer (KHB) without sodium (NaCl and NaHCO3 replaced 
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with choline chloride and choline bicarbonate, respectively) at 37 °C for 10 minutes [26].  
In all cases, incubations were terminated at 0.5, 1, 2 and 5 minutes by washing the cells 
three times with ice-cold HBSS buffer. The cells were then lysed with 100% methanol 
containing internal standard (diclofenac), centrifuged, and dried down under nitrogen 
and reconstituted in 50/50 methanol/water. Chromatography was performed on a Waters 
Acquity UPLC System (Milford, MA). The autosampler and column were kept at 10°C 
and 50°C, respectively. Separation was achieved with a Waters BEH C18 column 
(2.1x50mm, 1.7 μm), and a gradient of 7.5 mM ammonium bicarbonate (Mobile Phase 
A) and 70/30 methanol/acetonitrile (Mobile Phase B) at a flow rate of 0.2 ml/min. An 
initial mobile phase composition of 50% B was held for 2 minutes, then ramped to 95% 
in 1.5 minutes, held at 95% for 1 minute, and then returned to initial 50% B for 0.5 
minute re-equilibration. The total analysis time for each sample was 5 minutes. Data 
were collected on an AB Sciex API5500 (QTRAP) mass spectrometer (Foster City, CA, 
USA) using negative Turbo IonSpray™ electrospray ionization (ESI) and multiple 
reaction monitoring (MRM) mode with the following transitions: 290.6/96.8 (2H4-TDCA-
S), 475.2/96.8 (2H4-DCA-S), 533.3/453.4 (2H5-GCDCA-S), 532.3/452.3 (2H4-GDCA-S), 
and 514.2/79.8 (2H4-TCA).  Data acquisition and processing was carried out with Analyst 
software version 1.6.2. (Applied Biosystems/MDS Sciex, Canada) Analysis of 
pitavastatin was performed as described above.  Stability of the various sulfated BA 
substrates was confirmed after their addition to assay buffer and incubation for 5 mins at 
37 °C. 
2.2.5 Pharmacokinetics Analysis  
2.2.5.1 BAs 
For each BA, the plasma AUC from 0 to 24 hour (AUC0-24,plasma) was derived from 
the concentration-time profile for each individual animal (trapezoidal rule, Microsoft 
Office Excel). Renal clearance (CLrenal) was calculated by dividing the amount excreted 
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in urine from 0 to 24 hour (Ae0-24,urine) by the AUC0-24,plasma. AUC0-24,plasma ratios 
(AUCRplasma) were determined by dividing the AUC0-24,plasma after RIF treatment by 
the vehicle alone AUC0-24,plasma. The CLrenal ratio was determined by dividing the CLrenal 
after RIF treatment by the vehicle alone CLrenal. 
2.2.5.2 RIF and pitavastatin 
 The non-compartmental analyses of 2H4-pitavastatin and RIF plasma 
concentration-time data were performed using Watson LIMSTM version 7.4.1 (Thermo 
Fisher Scientific Inc, Waltham, MA ), which supported the generation of the various 
pharmacokinetic parameters; AUC, T1/2 (half-life), CL (clearance), Vdss (volume of 
distribution), Cmax (peak plasma concentration), and Tmax (time to peak plasma 
concentration).  As for the different BAs, 2H4-pitavastatin AUCRplasma values were 
determined by dividing the AUC0-24,plasma after RIF treatment by the vehicle alone AUC0-
24,plasma. For RIF, it was possible to calculate RIF plasma free Cmax based on a plasma 
unbound fraction of 0.265. 
In turn, in vitro IC50s for RIF with cynomolgus monkey OATP and NTCP [13, 16] were 
used to calculate % inhibition; % inhibition = 100 * {[I]/([I] + IC50)}. It is assumed that IC50 
~ Ki (when substrate concentration < Km).  [I] represents plasma Cmax of RIF (total or 
free). Consideration of free and total plasma Cmax is consistent with [5]; in the absence 
of i.v. RIF pharmacokinetic data, it was not possible to derive an absorption rate 
constant for RIF and estimate its liver inlet (portal) concentration in the cynomolgus 
monkey. 
2.2.6 Statistical Analysis of RIF Dose Response  
Plasma: Plasma profiles over time for each animal were collapsed into an AUC 
using the trapezoidal rule and a Cmax score. The analyses were then conducted using a 
linear mixed model, such that the within-animal correlations were accounted for in the 
model. The R computing language was used for these calculations (R Core Team, 
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2014). Outcomes were analyzed on the log (base 2) scale to make the residuals more 
normal. Concentrations were entered into the model on the same scale and the p-value 
for the linear trend is based on an F-statistic using Satterthwaite's approximation 
(Burghoff, 2016). False discovery rate (FDR) estimates were computed using the 
Benjamini and Hochberg procedure (Benjamini and Hochberg, 1995).  
Urine: Renal clearance (CLrenal) values (ml/min/kg) of zero were treated as 
missing and analytes with greater than five missing values were excluded. As such, 18 
of the 30 BAs were analyzed. As described for plasma, the analysis was conducted 
using a linear mixed model such that the within-animal correlations were accounted for 
in the model. The BAs were analyzed on the natural log scale to make the residuals 
more normal. Similar to plasma, the p-value for the linear trend is based on an F-statistic 
using Satterthwaite's approximation and FDR estimates were computed using the 
Benjamini and Hochberg procedure. 
2.3 Results 
2.3.1 Pharmacokinetics of RIF in Cynomolgus Monkeys 
As expected, a dose-dependent increase in RIF AUC0-24,plasma, and plasma Cmax 
was observed over the dose range of 1 to 30 mg/kg (Table 2.1 and Supplemental Fig. 
1). However, at the RIF doses of 3, 10 and 30 mg/kg, there was evidence for a greater 
than proportional increase in AUC0-24,plasma (11-, 71- and 243-fold versus AUC at 1 mg/kg) 
and plasma Cmax (12-, 45-, and 137-fold versus Cmax at 1 mg/kg).  For RIF, plasma 
unbound fraction was 0.265 and so the calculated free Cmax was 0.057, 0.659, 2.57 and 
7.79 μM at 1, 3, 10 and 30 mg/kg, respectively.  Such concentrations exceed the 
reported in vitro IC50 values (0.14 to 1.7 μM) for RIF with cynomolgus monkey OATP1B1 
and OATP1B3 [13, 16].  
2.3.2 Impact of RIF on 2H4-Pitavastatin Pharmacokinetics 
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The pharmacokinetic parameters of 2H4-pitavastatin, an accepted cynomolgus 
monkey OATP probe drug [14], were determined after dosing of an i.v. bolus (0.2 mg/kg) 
to vehicle control and RIF-dosed cynomolgus monkeys (Table 2.2, Supplemental Fig. 
1).  Compared with the vehicle control, 2H4-pitavastatin CL was decreased 21%, 58%, 
73%, and 76% with RIF treatment at 1, 3, 10, and 30 mg/kg dose levels, respectively.  
However, the change was only statistically significant at the 3 top RIF doses.  
Furthermore, 2H4-pitavastatin AUC0-24,plasma was increased 1.2-, 2.4-, 3.8-, and 4.5-fold at 
1, 3, 10 and 30 mg/kg RIF, respectively.  Both the Vdss and T1/2 of 2H4-pitavastatin were 
decreased (~70 %) at the three highest RIF doses.  At all the RIF dose levels, recovery 
of unchanged 2H4-pitavastatin in urine was less than 5% of the dose.  Overall, the impact 
of the lowest RIF dose on 2H4-pitavastatin pharmacokinetics was not statistically 
significant. 
2.3.3 Profiling of Plasma BAs at Different Doses of RIF 
As with 2H4-pitavastatin, the plasma levels of various BAs, as well as their 
corresponding 3-O-sulfate conjugates, were measured in cynomolgus monkeys following 
increasing doses of RIF.  In total, 30 different BAs were monitored.  Sulfated BAs, in 
particular GDCA-S, TDCA-S, GCDCA-S, TCDCA-S, GLCA-S, and TLCA-S, presented a 
marked dose-dependent increase in their plasma concentration-time profile (Figure1.1, 
Supplemental Table 3).  In contrast, the plasma concentration-time profile of non-
sulfated BAs, particularly DCA, GDCA, TDCA, GCDCA, TCDCA, UDCA, GUDCA, 
TUDCA, CA, GCA, and TCA, showed a relatively weak increase at the RIF doses of 10 
and 30 mg/kg (Supplemental Figure 2).  Chu et al. have also reported a weak increase 
in non-sulfated BAs after an oral RIF dose of 18 mg/kg [16].  RIF treatment did not cause 
significant changes in LCA, GLCA and TLCA. Unfortunately, GUDCA-S, TUDCA-S, CA-
S, TCA-S, and GCA-S plasma levels were low and remained undetectable even after 
RIF treatment.  Overall, the presence of various sulfo-conjugates in plasma was 
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indicative of BA sulfation in the cynomolgus monkey.  However, the pool of cynomolgus 
monkey BAs in circulation was distinct from that reported for human subjects; the 
percentages of sulfated (1.3% versus 28.4%) and amidated (21.5% versus 75.4%) BAs 
were low for monkey versus human, respectively (Supplemental Table 4).  To 
complement the in vivo studies, the sulfation of six representative BAs (GCDCA, 
GUDCA, LCA, GLCA, GCA, and TLCA) was investigated after incubation with 
cynomolgus monkey liver cytosol (Supplemental Figure 3); the availability of authentic 
standards supported the identification of the 3-O-sulfate as the major product of PAPS-
fortified monkey liver cytosol.  Although a good correlation was obtained between human 
and cynomolgus monkey (R2 = 0.905), a low activity ratio (cynomolgus monkey-to-
human) was obtained for the formation of LCA-S, GLCA-S, TLCA-S, and GUDCA-S 
(0.20, 0.25, 0.36, and 0.37, respectively). In comparison, GCDCA-S (activity ratio = 0.89) 
and GCA-S (activity ratio = 3.0) rendered higher activity ratios comparable to those of 
DHEA 3-O-sulfate (activity ratio of 1.3). Importantly, RIF (up to 100 μM) was shown not 
to inhibit cynomolgus monkey liver cytosol-catalyzed BA sulfation (Supplemental Fig. 
4). 
2.3.4 Assessment of RIF Dose Response 
AUCRplasma values for the various BAs after RIF treatment are shown in Figure 
2.2.  The highest AUCRplasma (≥ 78) was observed for GDCA-S and GCDCA-S, followed 
by TDCA-S, DCA-S and TCDCA-S (~50) and GLCA-S and TLCA-S (~30).  A relatively 
modest AUCRplasma (5 to 10) was observed for CA, GCA and TCA. The remaining non-
sulfated BAs presented low AUCRplasma values (2 to 5).  Fold changes in plasma Cmax 
after RIF treatment are shown in Figure 3. Similar to the AUC changes, the highest (50- 
to 80-) fold increase was observed for DCA-S, GDCA-S, TCDCA-S, TDCA-S, and 
GCDCA-S followed by a 20-fold increase for GLCA-S and TLCA-S at RIF dose of 30 
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mg/kg.  AUC0-24,plasma and plasma Cmax values at each RIF dose and vehicle control are 
shown in Supplemental Table 3.  
Statistical analysis for linear trend in AUC0-24,plasma, and Cmax and FDR for each BA 
are shown in Table 2.3.  Overall, with the exception of CA-S, all BA 3-O-sulfates were 
characterized by a significant linear trend (p-value < 0.01) with a slope of more than 
0.6700 and a FDR less than 10% for AUC0-24,plasma. GDCA-S, GCDCA-S, TDCA-S, 
TCDCA-S, GLCA-S, and TLCA-S were the most significant sulfate conjugates with a p-
value for the linear trend of less than 0.001, a slope of more than 0.7500 and FDR less 
than 1% for AUC0-24,plasma as well as Cmax.  In contrast, most of the non-sulfated bile acids 
did not show a statistically significant linear trend and FDR was more than 10% for 
AUC0-24,plasma and Cmax. Only TCA and TDCA showed a p-value less than 0.01 and ~ 10% 
FDR. 
Importantly, the plasma AUCRplasma values showed a good linear correlation (R2 
> 0.7000) between pitavastatin and GDCA-S, TDCA-S, GCDCA-S, TCDCA-S, GLCA-S, 
and TLCA-S (Figure 2.4). Similarly, a good linear correlation (R2 > 0.7500) between RIF 
plasma free Cmax and 2H4-pitavastatin, GDCA-S, TDCA-S, GCDCA-S, TCDCA-S, 
GLCA-S, and TLCA-S AUCRplasma was observed (Figure 2.5). 
As described previously, an effort was made to administer RIF over a dose range that 
generated a wide range of plasma total (0.2 to 29 μM) and free (0.06 to 7.8 μM) Cmax 
values (Table 2.1). In so doing, it was possible to investigate the dose-dependent 
inhibition of OATPs and NTCP. Based on in vitro IC50 data, dose-dependent inhibition of 
OATP1B1 (16% to ≥ 96%) and OATP1B3 (<10% to ≥ 85%) was expected, with less 
inhibition of OATP2B1 (<10% to 31%) and NTCP (<10% to 29%) anticipated 
(Supplemental Table 5 and 6). Despite the effort to ensure dose-dependent inhibition, 
however, the AUCRplasma values for the various BA sulfates differed markedly. The 
highest maximal AUCRplasma values (≥ 78) were obtained with GDCA-S and GCDCA-S, 
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followed by TDCA-S, DCA-S and TCDCA-S (AUCRplasma ~ 50) and GLCA-S and TLCA-S 
(AUCRplasma ~ 30). 
2.3.5 Impact of RIF on BA Renal Clearance 
Because the 3-O-sulfate conjugates of the various BAs are recovered in human 
urine [18, 27, 28], the present study was extended to include the profiling of urine of 
control and RIF-dosed cynomolgus monkeys.  In this regard, a dose-dependent increase 
in the amounts of GDCA-S, TDCA-S, GCDCA-S, TCDCA-S, GLCA-S, and TLCA-S 
excreted in urine was observed (Supplemental Table 3).  CLrenal ratios and statistical 
analysis for each BA are shown in Figure 2.6 and Table 2.3, respectively.  A weak 
dose-dependent increase in CLrenal was observed for UDCA, GDCA, and DCA.  
However, there was no statistically significant effect of RIF treatment on the CLrenal of 
sulfated and non-sulfated bile acids.  For the former, this is in marked contrast to the 
changes in plasma AUC and Cmax following RIF treatment. 
2.3.6 Incubation of GCDCA-S, GDCA-S, DCA-S, TDCA-S, TCA and Pitavastatin with 
Cynomolgus Monkey Plated Hepatocytes 
Based on the availability of deuterium-labeled material and RIF-dependent AUCRplasma 
values in vivo, four sulfated BAs (GCDCA-S, GDCA-S, DCA-S, and TDCA-S) were 
chosen for study as solute carrier (SLC) substrates in vitro after incubation with plated 
cynomolgus monkey primary hepatocytes (Figures 7 and 8).  TCA and pitavastatin were 
also incubated as representative cynomolgus monkey NTCP (> OATP) and OATP 
(>NTCP) substrates, respectively [14, 16].  To discern the role of NTCP versus OATPs, 
incubations were performed in the presence and absence of sodium (NTCP is sodium-
dependent). In addition, RIF (5 μM) and RIFsv (1 mM) were deployed as cynomolgus 
monkey OATP-selective and pan-SLC inhibitors, respectively (Supplemental Table 5; 
[13, 16]).  
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When incubated with RIFsv, the uptake of TCA, GDCA-S, GCDCA-S, and 
pitavastatin was markedly inhibited (≥ 92%). For the four substrates, such a result is 
consistent with relatively high rates of active (versus passive; ≤ 8%) uptake (Figure 
2.7A).  As shown in Figure 2.7B, the uptake of GCDCA-S and GDCA-S was minimally 
impacted by the removal of sodium. By contrast, uptake of TCA (74%) and pitavastatin 
(~44%) was decreased in the presence of sodium-free buffer.  As expected, RIF elicited 
relatively weak inhibition of TCA uptake when compared to pitavastatin (14% versus 
58%). Uptake of both GCDCA-S (69% inhibition) and GDCA-S (82% inhibition) was 
sensitive to RIF.  Although the exact contribution of OATP1B1 and OATP1B3 was not 
determine, in the absence of selective inhibitors and established relative activity factors 
for cynomolgus monkey transporters, it is concluded that uptake of both GCDCA-S and 
GDCA-S (0.5 μM) in the presence of cynomolgus monkey hepatocytes is dominated by 
OATPs and that their profile is distinct from that of TCA.  Based on the results presented 
in Figure 2.8, the same can be said for two additional BA sulfates (TDCA-S and DCA-
S).  In this instance, RIF (5 μM) was shown to inhibit the uptake of TCA, pitavastatin, 
GCDCA-S, GDCA-S, TDCA-S and DCA-S (0.1 μM) by 21%, 73%, 92%, 83%, 95% and 
80%, respectively. 
2.4 Discussion and Conclusion 
Metabolism of various BAs is complex and involves oxidation, amidation, 
glucuronidation, and sulfation.  Once conjugated, BAs are also subjected to transporter-
mediated uptake (e.g., OATP and NTCP) and efflux [23, 28-32].  Therefore, the BA pool 
of most species is complex, and subject to enterohepatic recirculation and renal 
clearance. This means that the BA profiling requires robust LC-MS/MS methods with 
access to a large number of authentic standards [18].  To support the present study, 
therefore, authentic standards of a number of non-commercially available BA 3-O-
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sulfates were prepared and 30 different BAs were profiled in cynomolgus monkey 
plasma and urine.  
Although in vivo sulfation of DHEA has been reported in cynomolgus monkeys 
[22], and SULT2A1 (human sulfotransferase involved in BA 3-O-sulfation) is known to be 
expressed in cynomolgus monkey liver [19-21], there have been no reports describing 
the BA sulfation in the cynomolgus monkey.  For the first time, it was possible to report 
that DHEA and various BAs undergo sulfation in vitro (Supplemental Figure 3).  
Importantly, the presence of BA sulfates in cynomolgus monkey urine is consistent with 
human data [18, 28].  However, the fraction of the BA pool in circulation as the sulfated 
species was low in cynomolgus monkey versus human (28.4% versus 1.3%; 
Supplemental Table 4), and likely reflects species differences in CLrenal and formation 
clearance. In agreement, the CLrenal of GCDCA-S is lower in humans (31 versus 0.05 
ml/min per kg) (Supplemental Table 3; [28]) and the rate of BA sulfation in vitro was 
lower in the presence of cynomolgus monkey cytosol (Supplemental Figure 3). A 
species difference in OATP-mediated hepatic uptake clearance is also a possibility. 
GCDCA-S has been shown to undergo active renal secretion and has been 
proposed as a biomarker for human organic anion transporter 3 (OAT3) [28].  Although 
the cynomolgus monkey OAT3 has been expressed and characterized, nothing is known 
of its ability to transport BA sulfates and its inhibition by RIF [33].  Therefore, as part of 
the present study, it was important to assess the impact of RIF on BA sulfation and renal 
clearance. This ensured that any observed changes in BA AUC0-24,plasma were reflective of 
hepatic transporter inhibition. In vitro data indicated that RIF (up to 100 μM) did not 
inhibit liver cytosol-catalyzed BA sulfation (Supplemental Figure 4).  Likewise, profiling of 
cynomolgus monkey urine supported calculation of CLrenal for the different BAs and it was 
determined that the impact of RIF was minimal (Table 2.3; Supplemental Table 3).  
Importantly, there is evidence indicating that BA sulfates also serve as substrates of 
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human canalicular multidrug resistance-associated protein (MRP) MRP2 and basolateral 
MRP3 and MRP4 [23, 29-31].  The possibility that single dose RIF can inhibit 
cynomolgus monkey MRP2 has already been considered by Chu et al (2015). In this 
instance, the authors showed that RIF is a relatively weak inhibitor of cynomolgus 
monkey MRP2 (IC50 = 118 μM) and argued for relatively minimal inhibition based on 
estimated free RIF liver levels (~10 μM).  Although no RIF inhibition data are available 
for monkey MRP3 and MRP4, given that robust AUCRplasma values for the various BA 
sulfates it is assumed that neither transporter is inhibited. Alternatively, RIF could induce 
MRP3 and MRP4 and compromise the interpretation of the data [34, 35].  However, it 
can be argued that significant and sustained induction of both MRP proteins is unlikely 
following a single RIF dose. Importantly, BA sulfate plasma concentration-time profiles 
were consistent with relatively rapid (within 6 hr) dose-dependent inhibition of hepatic 
uptake.  Moreover, plasma concentrations for five of the six BA sulfates were trending 
towards pre-RIF dose levels by 24 hr (Figure 2.1). 
To date, efforts to inhibit cynomolgus monkey OATP in vivo have involved oral 
administration of a single RIF dose that generates a plasma total Cmax of ~10 μM [13, 14, 
16].  As described, it was possible to administer RIF at four dose levels of 1, 3, 10, and 
30 mg/kg and obtain mean plasma total Cmax values of 0.2, 2.5, 9.7, and 29 μM, 
respectively; corresponding to a plasma free Cmax of 0.06, 0.67, 2.57 and 7.79 μM, 
respectively (Table 2.1).  Evidently, the pharmacokinetic profile of RIF in the cynomolgus 
monkey was non-linear, likely reflecting saturation of first pass, and consistent with 
human data [36].  Despite the non-linearity, there was a good linear correlation (R2 > 
0.9332) between RIF plasma Cmax and AUCRplasma for a number of BA sulfates (Fig. 5) 
and, because expression of hepatic OATP2B1 is relatively low in cynomolgus monkey, 
such a dose response is more likely reflective of OATP1B1 and OATP1B3 inhibition [37].  
Based on the in vitro IC50s reported for both OATPs (≤ 1.7 μM; Supplemental Table 5), 
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and assuming that RIF plasma concentrations support estimates of inhibition [5], up to 
>85% (RIF free Cmax) and >96% (RIF total Cmax) inhibition is anticipated (Supplemental 
Table 6). In agreement, a clear RIF dose-dependent increase in 2H4-pitavastatin 
AUCRplasma (1.2, 2.4, 3.8 and 4.5) was evident (Figure 2.5). Because of weaker inhibition 
by RIF (IC50 ≥ 35.1 μM, Supplemental Table 5), less NTCP inhibition (10% to 29%) is 
expected (Supplemental Table 6).  This is an important consideration, because certain 
BAs are known to favor NTCP over OATPs [38-41].  For example, the uptake of TCA by 
primary cynomolgus monkey hepatocytes was shown to be highly sodium dependent 
and relatively refractory to RIF (Figures 7 and 8). Although no formal in vitro-in vivo 
exercise was attempted, it assumed that the RIF dose-dependent AUCRplasma values for 
TCA (1.2, 2.0, 1.8 and 5.4) are largely reflective of NTCP inhibition (Supplemental 
Tables 3 and 6). On the other hand, GCDCA-S, GDCA-S, TDCA-S and DCA-S behaved 
as OATP substrates in the presence of cynomolgus monkey hepatocytes (Figures 2.7 
and 2.8), consistent with reports of a fifth sulphated BA (TLCA-S) presenting as an 
OATP substrate in vitro [23, 24]. 
As described, five sulfated BAs in plasma responded robustly to RIF in a dose-
dependent manner (maximal AUCRplasma ≥ 50). Two additional BA sulfates, GLCA-S and 
TLCA-S, were also found to respond to RIF (maximal AUCRplasma ~ 30) (Figure 2.2). 
From the standpoint of detectability in control animals, magnitude of the RIF dose 
response, and detectability in human plasma, these seven BA sulfates (GCDCA-S, 
TCDCA-S, DCA-S, GDCA-S, TDCA-S, GLCA-S and TLCA-S) all present as potential 
sensitive OATP biomarkers. Importantly, the RIF dose-response obtained was far 
greater than the increases (<10-fold) reported for cynomolgus monkey plasma bilirubin, 
bilirubin glucuronide, coproporphyrin (I and III), non-sulfated BAs, and DHEA sulfate [12, 
16, 17]. 
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Although the results presented herein showcase various BA sulfates as sensitive 
cynomolgus monkey OATP biomarkers, it cannot be assumed that the results translate 
directly to human subjects. For example, the balance of OATP- versus NTCP-mediated 
liver uptake, and the contributions of individual OATPs, may not be the same across 
species. Despite the caveats, the results of the present work are consistent with plasma 
metabolomic data from a recent OATP1B1 (SLCO1B1) genome-wide association study 
that identified GCDCA-S, GDCA-S and TLCA-S as potential OATP1B1 biomarkers [10].  
Such BA sulfates could potentially serve as sensitive human OATP biomarkers and 
provide the necessary dynamic range to support perpetrator differentiation (weak, 
moderate, versus potent inhibition), enable the study of OATP genotype-phenotype 
associations, and facilitate phenotyping of hepatobiliary diseased subjects [7, 8].  In this 
regard, sulfated BAs could be superior human OATP biomarkers when compared to 
plasma coproporphyrin I and III (AUCRplasma ~4.0) [9].  As discussed previously, because 
circulating sulfated BAs are substrates of renal transporters also, they may serve as dual 
liver OATP and renal OAT3 biomarkers. In agreement, an increase in “urinary sulfated 
bile acids” has been reported in patients with various hepatobiliary diseases, which may 
in part reflect altered liver OATP function [27, 42, 43].  Consistent with human data, the 
amount of sulfated BAs in cynomolgus monkey urine increased with RIF dose 
(Supplemental Table 3).  
Based on the results of the present study, it is concluded that the cynomolgus 
monkey can form BA sulfates that comprise only ~1% of the plasma BA pool and 
present as sensitive hepatic OATP biomarkers. Given the number of similarly sulfated 
BAs that are detectable in human serum [18], it is envisioned that they will be 
increasingly studied as human OATP substrates and compared to other biomarkers 
such as coproporphyrin I and III. 
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Figure 2.1 Plasma concentration-time profile of (A) GDCA-S, (B) TDCA-S, (C) GCDCA-S, (D)  TCDCA-S, (E) GLCA-S and (F) TLCA-S in male cynomolgus monkeys after oral administration of vehicle alone (open squares), and RIF 1 mg/kg (open circles), 3 mg/kg (closed triangles), 10 mg/kg (closed circles) and 30 mg/kg (closed squares).  Data are presented as mean ± SD of n = 4 animals.  
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Figure 2.2 Fold change in AUC0-24,plasma of (A) un-sulfated bile acids and (B) bile acid 3-O-sulfates at increasing doses of RIF in male cynomolgus monkeys. 
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Figure 2.3  Fold change in plasma Cmax of (A) un-sulfated bile acids and (B) bile acid 3-O-sulfates at increasing doses of RIF in male cynomolgus monkeys. 
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Figure 2.4  Linear regression of plasma AUC ratio (AUCRplasma) between pitavastatin and bile acid 3-O-sulfates for (A) GDCA-S, (B) TDCA-S, (C) GCDCA-S, (D)  TCDCA-S, (E) GLCA-S and (F) TLCA-S.  For pitavastatin and bile acids, AUCRplasma is calculated by dividing AUC0-24,plasma obtained with RIF (1, 3, 10 and 30 mg/kg) by the AUC0-24,plasma for vehicle control. 
 
 
(A) GDCA-S (B) TDCA-S 
(C) GCDCA-S (D) TCDCA-S 
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Figure 2.5  Linear regression between free RIF plasma Cmax (µM) at 1,  3, 10 and 30 mg/kg and bile acid 3-O-sulfate AUCRplasma for (A) GDCA-S, (B) TDCA-S, (C) GCDCA-S, (D)  TCDCA-S, (E) GLCA-S, (F) TLCA-S, and (G) pitavastatin.  AUCRplasma as defined in the legend to Figure 2.4.  
(A) GDCA-S 
R2 = 0.9957
(B) TDCA-S 
R2 = 0.9332
(C) GCDCA-S 
R2 = 0.9919
(D) TCDCA-S 
R2 = 0.9893
(E) GLCA-S 
R2 = 0.9974
(F) TLCA-S 
R2 = 0.9618
(G) Pitavastatin
R2 = 0.7353
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Figure 2.6  Fold change in CLrenal of (A) un-sulfated bile acids and (B) bile acid 3-O-sulfates at increasing doses of RIF in male cynomolgus monkeys. 
 
 
 
117  
 
Figure 2.7 Impact of RIF and RIFsv (A) and sodium removal (B) on the uptake of 2H5-GCDCA-S (0.5 mM), 2H4-GDCA-S (0.5 mM), 2H4-TCA (0.5 mM), and non-labeled pitavastatin (0.1 mM) by plated cynomolgus monkey primary hepatocytes. RIF and RIFsv were added at a final concentration of 5 mM and 1 mM, respectively. Data for individual duplicates are shown.  The mean % decrease is shown also and calculated as (VDMSO-Vi/ VDMSO)*100. VDMSO and Vi is the mean uptake rate in the presence of DMSO alone (plus sodium) and inhibitor (or minus sodium) respectively. 
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Figure 2.8 Impact of RIF on the uptake of 2H5-GCDCA-S (0.1 mM), 2H4-GDCA-S (0.1 mM), 2H4-TCA (0.1 mM), 2H4-TDCA-S (0.1 mM), 2H4-DCA-S (0.1 mM), and nonlabeled pitavastatin (0.1 mM) by plated cynomolgus monkey primary hepatocytes.  RIF was added at a final concentration of 5 mM.  Data for individual duplicates are shown. The mean % decrease is shown and was calculated as described in the legend to Figure 2.7. 
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Table 2.1 Pharmacokinetic parameters of pitavastatin in male cynomolgus monkeys after i.v. 
administration (0.2 mg/kg) with increasing doses of RIF 
 
Parameter 
Oral RIF Dose 
0 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 
AUC0-Tlast (ng.hr/ml) 192 ± 48.8 223 ± 40.5 459 ± 141 722 ± 190 862 ± 319 
AUC0-inf (ng.hr/ml) 194 ± 48.2 228 ± 44.3 469 ± 139 724 ± 190 871 ± 325 
C0 (ng/ml) 1200 ± 628 925 ± 278 1840 ± 579 1660 ± 355 1570 ± 577 
T1/2 (hr) 5.95 ± 0.854 7.21 ± 1.74 2.95 ± 1.86 3.77 ± 0.679 4.55 ± 0.594 
CL (ml/min/kg) 18 ± 4.62 14.2 ± 2.22 7.55 ± 2.0 4.80 ± 1.36 4.27 ± 1.61 
VdSS (l/kg) 1.79 ± 0.723 1.97 ± 0.498 0.466 ± 0.2 0.521 ± 0.164 0.546 ± 0.201  % Dose in urinea 1.77 ± 2.02 1.17 ± 0.595 1.23 ± 1.29 4.00 ± 2.02 2.89 ± 0.38 
a% of Total dose (as pitavastatin) recovered in urine over 24h.   
Data are presented as mean ± SD, n = 4 animals.  
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Table 2.2 Pharmacokinetic parameters of RIF after oral administration to male cynomolgus monkeys  RIF Dose 
Parameter 1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 
AUC0-Tlast (ng.hr/ml) 985 ± 396 11300 ± 3260 70100 ± 10800 240000 ± 73900 AUC0-inf (ng.hr/ml) 1010 ± 389 11400 ± 3300 72400 ± 8550 304000 ± 79100 Cmax(ng/ml) 176 ± 98.7 2050 ± 245 7980 ± 2480 24200 ± 14100 
Free Cmax (uM)a 0.057 ± 0.032 0.659 ± 0.079 2.57 ± 0.80 7.79 ± 4.54 
Tmax(hr) 2.70 ± 0.86 1.80 ± 0.36 1.70 ± 0.43 2.70 ± 0.58 
T1/2(hr) 5.18 ± 1.52 2.84 ± 0.202 4.56 ± 2.18 11.5 ± 6.26 
aTotal Cmax converted to µM and corrected for RIF plasma free fraction (0.265).  RIF plasma 
protein binding was determined using equilibrium dialysis with ascorbic acid as a stabilizer.  
Data are presented as mean ± SD, n = 4 animals. 
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Table 2.3 The p-value for the linear trend with RIF dose and false discovery rate (FDR) estimates for area under the plasma concentration-time curve (AUC0-24,plasma), maximum plasma concentration (Cmax,plasma) and renal clearance (CLrenal) for various bile acids and their respective 3-O-sulfate conjugates.  
  AUC0-24,plasma Cmax,plasma CLrenal 
Bile Acid Slopea p-value FDR Slope p-value FDR Slope p-value FDR 
CA-S 2.08 0.0218 0.2395 1.06 0.0589 0.5889 NAb NA NA 
DCA-Sc 1.44 < 0.0001 < 0.0001 0.9 < 0.0001 < 0.0001 -0.005 0.798 1 
TCA-S 1.2 0.0004 0.0067 1.07 0.0011 0.0193 NA NA NA 
GDCA-Sc 1.13 < 0.0001 < 0.0001 1.11 < 0.0001 0.0001 0.003 0.767 1 
GCA-S 1.1 0.0021 0.0373 0.89 0.0067 0.1067 NA NA NA 
TCDCA-Sc 1.09 < 0.0001 < 0.0001 1.04 < 0.0001 < 0.0001 0.01 0.2517 1 
GCDCA-Sc 1.07 < 0.0001 < 0.0001 0.97 < 0.0001 < 0.0001 -0.02 0.3157 1 
CDCA-S 0.99 0.0036 0.0619 0.61 0.094 0.6907 NA NA NA 
TDCA-Sc 0.91 < 0.0001 < 0.0001 0.89 < 0.0001 0.0001 0.01 0.4206 1 
GLCA-Sc 0.81 < 0.0001 < 0.0001 0.78 < 0.0001 < 0.0001 -0.003 0.7155 1 
TLCA-Sc 0.78 < 0.0001 < 0.0001 0.76 < 0.0001 < 0.0001 -0.003 0.7002 1 
UDCA-S 0.77 < 0.0001 < 0.0001 0.56 < 0.0001 0.0009 0.003 0.6382 1 
CA 0.72 0.0049 0.0737 0.49 0.0251 0.3264 -0.006 0.7236 1 
LCA-S 0.68 < 0.0001 < 0.0001 0.35 0.0013 0.0219 NAb NA NA 
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TCA 0.35 0.0071 0.092 0.35 0.0006 0.012 -0.03 0.0162 0.2434 
GCA 0.3 0.0971 0.8231 0.31 0.0767 0.6907 -0.005 0.6641 1 
DCA 0.25 0.0049 0.0737 0.18 0.0222 0.3107 0.04 0.0086 0.1369 
UDCA 0.24 0.0112 0.1343 0.19 0.0829 0.6907 0.04 0.004 0.0685 
TDCA 0.23 0.0045 0.0724 0.26 0.0004 0.0075 0.02 0.0485 0.6303 
GDCA 0.21 0.0622 0.6218 0.23 0.0346 0.4152 0.05 0.0027 0.0478 
GCDCA 0.17 0.2221 0.8884 0.18 0.1857 1 NA NA NA 
TCDCA 0.16 0.0915 0.8231 0.19 0.0073 0.1088 -0.03 0.0226 0.3161 
CDCA 0.16 0.1127 0.8231 0.09 0.3571 1 0.003 0.7522 1 
TUDCA 0.15 0.1343 0.8231 0.11 0.3341 1 NA NA NA 
GUDCA 0.1 0.2289 0.8884 0.05 0.5432 1 NA NA NA 
GLCA -0.06 0.413 0.8884 -0.03 0.669 1 NA NA NA 
LCA -0.1 0.1097 0.8231 -0.13 0.0434 0.4771 -0.009 0.5259 1 
aResults ranked in terms of slope (AUC0-24,plasma). bNo baseline (vehicle control) levels; NA: not applicable. cConsidered candidate OATP biomarkers (See Figure 3.2 and 3.3). 
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Figure S1 Plasma concentration-time profile of (A) 2H4-pitavastatin administered, intravenously (0.2 mg/kg), approximately one hour and 15 minutes after oral administration of vehicle (open circles), and rifampicin at 1 mg/kg (closed triangles), 3 mg/kg (open triangles), 10 mg/kg (open square) and 30 mg/kg (closed circles) and (B) rifampicin after oral administration at a dose of 1 mg/kg (open circles), 3 mg/kg (closed triangles), 10 mg/kg (open triangles) and 30 mg/kg (closed circles). Data are presented as the mean ± SD (n = 4 different cynomolgus monkeys).  
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Figure S2. Plasma concentration-time profile of (A) LCA, (B) GLCA, (C) TLCA, (D)  LCA-S, (E) UDCA, (F) GUDCA, (G) TUDCA, (H) UDCA-S, (I) GUDCA-S, (J)  TUDCA-S, (K) CDCA, (L) GCDCA, (M) TCDCA, (N) CDCA-S, (O) DCA, (P)  GDCA, (Q) TDCA, (R) DCA-S, (S) CA, (T) GCA, (U) TCA, (V)  CA-S, (W) GCA-S, and (X) TCA-S in cynomolgus monkeys (mean ± SD, n = 4 animals) after oral administration of dose vehicle (open squares), and RIF at 1 mg/kg (open circles), 3 mg/kg (closed triangles), 10 mg/kg (closed circles), and 30 mg/kg (closed squares).  
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Figure S3 Correlation of sulfation rate (pmol of bile acid sulfate formed per pmol of parent bile acid) between PAPS-fortified human liver and cynomolgus monkey liver cytosol (six different bile acids are considered).  Dotted line represents the line of identity. Under the same incubation conditions, the rate of DHEA sulfation in the presence of cynomolgus liver cytosol (0.35 pmol sulfate per pmol DHEA) was similar to that of PAPS-fortified human liver cytosol (0.27 pmol sulfate per pmol DHEA).  The ratio of sulfation (cynomolgus monkey-to-human) is 0.20, 0.25, 0.36, 0.37, 0.89 and 3.0 for LCA-S, GLCA-S, TLCA-S, GUDCA-S, GCDCA-S, and GCA-S, respectively.  
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Figure S4. Assessment of rifampicin as inhibitor of GDCA and GCDCA sulfation catalysed by PAPS-fortified cynomolgus monkey liver cytosol.  Substrate concentrations were 5 μM GDCA (A and B), 50 μM GDCA (C and D), 5 μM GCDCA (E and F), and 50 μM GCDCA (G and H).  Inhibitors (rifampicin and danazol) were studied at concentrations between 0.13 and 100 μM.  Danazol was used as positive control, assuming inhibition similar to that reported for human SULT2A1; IC50 = 4.2 µM. Rate of sulfation (mean ± SD; n = 6 determinations) for GDCA and GCDCA was 0.043 ± 0.018 and 0.045 ± 0.0051 pmol/min per mg (at 5 μM) and 0.34 ± 0.15, 0.26 ± 0.015 pmol/min per mg (at 50 μM), respectively. 
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Table S1 MRM transitions and MS parameters for bile acids and their 3-O-sulfate conjugates 
Analyte MRM transition DP (V) CE (eV) CXP (V) 2H4-GCDCA 452.2/74 -125 -75 -11 2H4-CDCA 395.2/395.2 -175 -20 -11 LCA 375.2/375.2 -200 -20 -11 GLCA 432.2/74 -130 -65 -7 TLCA 482.2/79.8 -130 -105 -13 LCA-S 455.2/96.8 -120 -90 -8 GLCA-S 512.2/432.2 -120 -44 -13 TLCA-S 280.6/96.8 -80 -37 -11 UDCA 391.2/391.2 -200 -20 -11 CDCA 391.2/391.2 -200 -20 -11 DCA 391.2/391.2 -200 -20 -11 GUDCA 448.2/74 -130 -65 -7 GCDCA 448.2/74 -130 -65 -7 GDCA 448.2/74 -130 -65 -7 TUDCA 498.2/79.8 -130 -105 -13 TCDCA 498.2/79.8 -130 -105 -13 TDCA 498.2/79.8 -130 -105 -13 UDCA-S 471.2/96.8 -120 -71 -13 CDCA-S 471.2/96.8 -120 -71 -13 DCA-S 471.2/96.8 -120 -71 -13 GUDCA-S 528.2/448.2 -120 -44 -13 GCDCA-S 528.2/448.2 -120 -44 -13 GDCA-S 528.2/448.2 -120 -44 -13 TUDCA-S 288.6/96.8 -70 -35 -7 TCDCA-S 288.6/96.8 -70 -35 -7 TDCA-S 288.6/96.8 -70 -35 -7 CA 407.2/407.2 -200 -20 -11 GCA 464.2/74 -130 -65 -7 TCA 514.2/79.8 -130 -105 -13 CA-S 487.2/96.8 -120 -80 -8 GCA-S 544.2/464.2 -120 -45 -13 TCA-S 296.6/96.8 -70 -35 -7  
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Table S2 MRM transitions and MS parameters for 2H4-pitavastatin, rifampicin, and internal standards 
Analyte MRM transition DP (V) CE (eV) CXP (V) 2H4-Pitavastatin 426.2/294.2 100 40 11 Rifampicin 823.4/791.7 100 17 7 
2H8-Rifampicin 831.4/799.7 100 17 13 Simvastatin 419.2/285.2 80 15 8  
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Table S3 Plasma AUC (AUC0-24,plasma), maximum concentration in plasma (Cmax,plasma), amount recovered in urine, and renal clearance (CLrenal) of bile acids in male cynomolgus monkeys (mean ± SD, N = 4 animals) following the oral administration of dose vehicle and rifampicin  (1, 3, 10, and 30 mg/kg)  
Bile acid  RIF dose (mg/kg) 
AUC0-24,plasma (ng.h/ml) Cmax,plasma (ng/ml) Amount recovered in urine (ng) 
CLrenal (ml/min/kg) 
LCA 
Vehicle 3211 ± 1120 183 ± 31 4768 ± 3892 0.20 ± 0.18 1 2767 ± 830 205 ± 80 5406 ± 5825 0.31 ± 0.40 3 2665 ± 1400 174 ± 91 3880 ± 3881 0.18 ± 0.18 10 2276 ± 472 162 ±30 6708 ± 6261 0.43 ± 0.42 30 1847 ± 537 117 ± 36 2745 ± 2385 0.20 ± 0.16 
GLCA 
Vehicle 434 ± 139 39 ± 17 -b - 1 511 ± 164 40 ± 14 - - 3 574 ± 346 46 ± 28 - - 10 424 ± 221 49 ± 29 - - 30 502 ± 326 39 ± 23 - - 
TLCA 
Vehicle 1473 ± 627 114 ± 41 - - 1 1521 ± 453 119 ± 42 - - 3 2765 ± 2088 230 ± 173 - - 10 1489 ± 656 161 ± 77 - - 30 1715 ± 870 143 ± 78 - - 
UDCA 
Vehicle 123 ± 51 12 ± 3.4 296 ± 228 0.35 ± 0.31 1 150 ± 116 16 ± 10 455 ± 391 0.37 ± 0.35 3 53 ± 11 6 ± 2 205 ± 297 0.52 ± 0.72 10 304 ± 256 27 ± 19 2304 ± 1066 1.41 ± 0.97 30 301 ± 316 25 ± 23 3062 ± 2012 1.79 ± 1.24 
GUDCA 
Vehicle 37 ± 25 3.7 ± 2.7 - - 1 73± 66 7 ± 6 - - 3 78 ± 66 6 ± 6 - - 10 208 ± 311 20 ± 28 - - 30 181 ± 277 15 ± 23 - - 
TUDCA 
Vehicle 57 ± 38 5.7 ± 4.0 - - 1 90 ± 81 10 ± 9 - - 3 106 ± 150 11 ± 13 - - 10 241 ± 350 26 ± 33 - - 30 225 ± 339 20 ± 33 38a 0.1 
CDCA 
Vehicle 4514 ± 3164 424 ± 304 4980 ± 1137 0.22 ± 0.14 1 3692 ± 1242 435 ± 236 4411 ± 2526 0.16 ± 0.06 3 4041 ± 2030 428 ± 203 6598 ± 3383 0.21 ± 0.07 10 4308 ± 2655 390 ± 266 7226 ± 3532 0.24 ± 0.11 30 6961 ± 3290 617 ± 372 10389 ± 5957 0.21 ± 0.13 
GCDCA 
Vehicle 1734 ± 845 157 ± 65 - - 1 2228 ± 1116 167 ± 73 - - 3 7148 ± 3525 644 ± 330 914 0.01 10 2555 ± 1434 262 ± 144 203 ± 406 0.01 ± 0.03 30 7196 ± 6668 549 ± 537 1960 ± 2255 0.05 ± 0.07 
TCDCA Vehicle 5669 ± 1245 508 ± 204 2642 ± 1385 0.07 ± 0.06 1 6730 ± 2826 582 ± 278 2195 ± 2224 0.07 ± 0.10 
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3 13775 ± 7288 1220 ± 629 2517 ± 1116 0.03 ± 0.03 10 7203 ± 3780 881 ± 457 2591 ± 1806 0.08 ± 0.10 30 14850 ± 4525 1233 ± 497 2056 ± 1005 0.02 ± 0.01 
DCA 
Vehicle 12777 ± 7593 908 ± 439 62899 ± 36723 0.80 ± 0.54 1 16146 ± 10141 1299 ± 631 61438 ± 26188 0.74 ± 0.56 3 15484 ± 8200 1273 ± 724 48696 ± 28035 0.64 ± 0.76 10 26893 ± 13094 2220 ± 799 237524 ± 143178 1.32 ± 0.94 30 30651 ± 14452 2018 ± 926 414830 ± 283148 2.10 ± 1.85 
GDCA 
Vehicle 4847 ±2410 441 ± 165 2289 ± 902 0.07 ± 0.02 1 5911 ±1655 484 ± 168 2067 ± 988 0.05 ± 0.03 3 16280 ±7205 1498 ± 644 3368 ± 273 0.03 ± 0.01 10 10026 ± 4738 1089 ± 525 11959 ± 2612 0.20 ± 0.13 30 18284 ± 15428 1517 ± 1233 22601 ± 10219 0.26 ± 0.24 
TDCA 
Vehicle 18868 ± 7292 1621 ± 705 5539 ± 2075 0.04 ±0.02 1 21692 ± 10093 1881 ± 1000 6402 ± 2843 0.04 ±0.02 3 40155 ± 25256 3453 ± 2092 14107 ± 9158 0.06 ± 0.03 10 35730 ± 19425 4108 ± 2161 28213 ±11709 0.12 ± 0.05 30 49375 ± 16320 4330 ± 1832 30438 ±16376 0.08 ± 0.03 
CA 
Vehicle 8917 ± 7730 938 ± 823 55637 ± 33210 1.28 ± 1.15 1 3021 ± 950 689 ± 297 49732 ± 51921 2.48 ± 3.00 3 11728 ± 8234 1570 ± 1099 102863 ± 96773 1.43 ± 0.98 10 9845 ± 6534 993 ± 745 259726 ± 250421 3.96 ± 3.80 30 61457 ± 53811 6430 ± 5519 604915 ± 653179 1.25 ± 0.96 
GCA 
Vehicle 2769 ± 1961 258 ± 150 29273 ± 19499 1.39 ± 0.33 1 3379 ± 1713 263 ± 134 21676 ± 9412 1.04 ± 0.57 3 13643 ± 6665 1258 ± 629 45482 ± 37342 0.44 ± 0.26 10 5261 ± 3918 523 ± 359 51524 ± 46370 1.58 ± 0.86 30 25737 ± 38285 1993 ± 2934 100389 ± 94136 0.91 ± 0.55 
TCA 
Vehicle 6208 ± 3826 579 ± 394 14751 ± 5320 0.43 ± 0.36 1 7745 ± 5022 801 ± 643 15075 ± 9524 0.60 ± 0.91 3 12639 ± 12969 1281 ± 1073 17752 ± 4358 0.33 ± 0.25 10 10995 ± 8702 1235 ± 925 24217 ± 11243 0.65 ± 0.90 30 33488 ± 26203 3038 ± 2347 28313 ± 15852 0.13 ± 0.07 
LCA-S 
Vehicle 29 ± 9.3 2.3 ± 0.9 - - 1 32 ± 10 4.4 ± 1.1 - - 3 87 ± 38 15 ± 6.6 352 ± 587 0.55 ± 0.90 10 179 ± 64 13 ± 5 511 ± 430 0.34 ± 0.30 30 342 ± 133 18 ± 7.1 1353 ± 1248 0.43 ± 0.41 
GLCA-S 
Vehicle 241 ± 43 18 ± 3.0 3875 ± 2302 2.27 ± 1.73 1 449 ± 93 30 ± 6 4328 ± 2647 1.38 ± 0.93 3 1293 ± 415 99 ± 28 7213 ± 2329 0.78 ± 0.46 10 3169 ± 1500 230 ± 101 33847 ± 15961 1.45 ± 0.58 30 8010 ± 4792 495 ± 307 67379 ± 34578 1.31 ± 0.65 
TLCA-S 
Vehicle 588 ± 163 41 ± 13 16638 ± 4659 4.05 ± 2.01 1 1066 ± 220 77 ± 20 20673 ± 10353 2.72 ± 1.54 3 3189 ± 2206 238 ± 149 36305 ± 13151 1.76 ± 0.82 10 7643 ± 867 576 ± 86 144452 ± 20699 2.52 ± 0.34 30 14035 ± 5468 954 ± 350 240905 ± 39793 2.48 ± 0.72 
UDCA-S Vehicle 59 ± 29 7.7 ± 4.2 3463 ± 1245 8.71 ± 4.45 1 49 ± 17 5.9 ± 1.6 2489 ± 2299 5.76 ± 5.18 
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3 111 ± 60 15 ± 10 5026 ± 2110 5.91 ± 1.17 10 437 ± 131 37 ± 9 23974 ± 5952 7.55 ± 1.66 30 547 ± 202 35 ± 11 33129 ± 15294 8.06 ± 2.00 
GUDCA-S 
Vehicle - - - - 1 - - - - 3 1.0 ± 1.6 0.6 ± 0.7 - - 10 - - - - 30 3.8 ± 6.0 0.3 ± 0.5 47 ± 68 1.92 ± 0.37 
TUDCA-S 
Vehicle - - - - 1 - - - - 3 23 ± 25 2.7 ± 2.8 - - 10 83 ± 54 6.5 ± 4.9 628 ± 500 1.02  ± 0.54 30 64 ± 75 4.7 ± 6.1 1087 ± 914 3.15 ± 2.11 
CDCA-S 
Vehicle 16 1.6 380 3.15 1 - - 478 - 3 9.1 ±  15 3.7 ± 2.6 1911 7.25 10 14 ± 17 0.6 ± 0.6 4100 14 30 93 ± 71 8.1 ± 9.0 2982 ± 3994 2.73 ± 2.69 
GCDCA-S 
Vehicle 13 ± 15 1.4 ± 1.2 1044 ± 621 31 ± 40 1 24 ± 13 1.8 ± 0.8 1138 ± 1115 6.59 ± 3.53 3 177 ± 118 13 ± 7.6 3996 ± 4059 2.51 ± 1.08 10 331 ± 100 17 ± 4.5 10920 ± 6717 4.04 ± 1.45 30 1024 ± 654 60 ± 32 30009 ± 19298 3.99 ± 1.48 
TCDCA-S 
Vehicle 32 ± 21 2.5 ± 1.3 1153 2.39 1 44 ± 15 3.4 ± 0.9 503 ± 630 1.34 ± 1.23 3 184 ± 101 14 ± 6.4 1333 ± 1247 0.79 ± 0.75 10 460 ± 162 36 ± 11 5474 ± 2767 1.56 ± 0.40 30 1844 ± 373 119 ± 12 24431 ± 9946 1.76 ± 0.51 
DCA-S 
Vehicle 6.5 ± 4.5 0.9 ± 0.1 2883 ± 1774 32 ± 31 1 2.4 ± 2.4 1.2 ± 0.9 2908± 3641 320 ± 585 3 25 ± 21 7.2 ± 6.8 3624 ± 2907 32 ± 35 10 79 ± 41 5.7 ± 2.9 54541 ± 54904 100 ± 80 30 368 ± 172 32 ± 20 127109 ± 108964 43 ± 22 
GDCA-S 
Vehicle 93 ± 31 7.6 ± 1.1 10422 ± 4527 18 ± 13 1 167 ± 27 12 ± 1.4 12513 ± 6656 10 ± 5.1 3 1117 ± 543 83 ± 38 35843 ± 12340 4.30 ± 1.71 10 2864 ± 956 221 ± 66 247858 ± 123183 12 ± 5.89 30 9958 ± 6998 640 ± 449 735541 ± 427431 12  ± 6.93 
TDCA-S 
Vehicle 253 ± 102 20 ± 6.9 22234 ± 7734 13 ± 7.52 1 388 ± 91 30 ± 6.4 26579 ± 13785 8.91 ± 4.38 3 4360 ± 736 332 ± 70 55389 ± 27684 1.51 ± 0.51 10 4952 ± 822 376 ± 66 328392 ± 95393 8.84 ± 2.27 30 12474 ± 4811 882 ± 307 811253 ± 222741 9.63 ± 4.86 
CA-S 
Vehicle - - - - 1 - - - - 3 3 0.89 - - 10 - - 318 ± 397 - 30 81 ± 43 8.0 ± 4.6 1746 ± 2024 1.91 ± 2.20 
GCA-S Vehicle - - 238 - 1 - - 196 - 
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aData from one animal only.  
bNot detectable. 
3 23 ± 20 2.2 ± 1.7 699 ± 1124 1.95 ± 2.89 10 37 ± 20 2.8 ± 1.3 2853 ± 1892 9.98 ± 3.40 30 289 ± 303 20 ± 22 17186 ± 13469 9.38 ± 4.60 
TCA-S 
Vehicle - - 263 - 1 - - 196 - 3 31 ± 22 3.1 ± 2.5 481 ± 572 1.62 ± 2.07 10 64 ± 32 5.4 ± 2.6 3673 ± 1699 7.94 ± 2.26 30 388 ± 171 28 ± 13 20401 ± 7389 7.61 ± 3.60 
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Table S4 Concentration (nM) of circulating bile acids in human and cynomolgus monkey (mean ± SEM) 
Bile acid Human Seruma Monkey Plasmab 
LCA 7.50 ± 0.38 (0.21%)c 353.9 ± 26.7 (7.62%) 
GLCA 10.7 ± 0.8 (0.29%) 12.5 ± 4.4 (0.27%) 
TLCA 1.64 ± 0.15 (0.05%) 43.4 ± 6.7 (0.93%) 
DCA 395.0 ± 19.9 (10.9%) 1627 ± 46.6 (35%) 
GDCA 283.1 ± 22.1 (7.78%) 71.4 ± 7.3 (1.54%) 
TDCA 79.3±16.9 (2.18%) 412.9 ± 18 (8.89%) 
CDCA 191.9 ± 21.0 (5.28%) 607.5 ± 26.8 (13.1%) 
GCDCA 580.3 ± 45.2 (16.0%) 41.3 ± 5.5 (0.89%) 
TCDCA 223.6 ± 22.3 (6.15%) 121.6 ± 10.7 (2.62%) 
UDCA 77.3 ± 7.7 (2.13%) 12.5 ± 3.7 (0.27%) 
GUDCA 106.1 ± 10.4 (2.92%) 0.9 ± 0.7 (0.02%) 
TUDCA 6.18 ± 0.90 (0.17%) 1.7 ± 0.90 (0.04%) 
CA 193.7 ± 26.6 (5.33%) 1039.6 ± 26.8 (22.4%) 
GCA 322.7 ± 50.3 (8.87%) 80 ± 7.8 (1.72%) 
TCA 126.9 ± 35.1 (3.49%) 159.4 ± 10 (3.43%) 
LCA-S 5.36 ± 0.54 (0.15%) 3.5 ± 2.1 (0.08%) 
GLCA-S 275.5 ± 15.0 (7.57%) 13.6 ± 4.5 (0.29%) 
TLCA-S 83.0 ± 5.1 (2.28%) 29.3 ± 9.0 (0.63%) 
DCA-S 0.82 ± 0.08 (0.02%) 0.7 ± 0.6 (0.02%) 
GDCA-S 203.0 ± 10.4 (5.58%) 3 ± 1.8 (0.06%) 
TDCA-S 29.3 ± 1.9 (0.81%) 6 ± 3.6 (0.13%) 
CDCA-S 5.10 ± 0.42 (0.14%) 0.3 ± 0.3 (0.01%) 
GCDCA-S 247.8 ± 12.9 (6.81%) 0.2 ± 0.3 (0.01%) 
TCDCA-S 13.9 ± 0.9 (0.38%) 0.5 ± 0.6 (0.01%) 
UDCA-S 18.2 ± 1.0 (0.50%) 3.9 ± 2.8 (0.08%) 
GUDCA-S 134.8 ± 7.3 (3.71%) -c 
TUDCA-S 3.15 ± 0.18 (0.09%) - 
CA-S 0.23 ± 0.03 (0.01%) - 
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GCA-S 1.35 ± 0.15 (0.04%) - 
TCA-S 10.1 ± 0.7 (0.28%) - 
% Sulfated 28.4%d 1.3% 
% Non-sulfated 71.6% 98.7% 
% Amidated 75.4% 21.5% 
% Non-amidated 24.6% 78.5% 
% Amidated + sulfated 27.2% 1.1% 
% Non-amidated + sulfated 0.8% 0.2% 
% Amidated + non-sulfated 47.8% 20.3% 
% Non-amidated + non-sulfated 23.8% 78.3% 
% Glycine amidated  59.5% 4.8% 
% Taurine amidated  15.9% 16.7% 
% Glycine amidated + sulfated 23.7% 0.4% 
% Glycine amidated + non-sulfated 35.8% 4.4% 
% Taurine amidated + sulfated 3.8% 0.8% 
% Taurine amidated + non-sulfated 12.0% 15.9% 
aBathena SP, Mukherjee S, Olivera M, and Alnouti Y (2013) The profile of bile acids and their sulfate metabolites in human urine and serum. J Chromatogr B Analyt Technol Biomed Life Sci 942-943:53-62. bPresent study. cNot detectable dPercent of circulating bile acids analysed.  
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Table S5 RIF and RIFsv as inhibitors of cynomolgus monkey OATPs  and NTCP expressed in HEK293 cells 
 Inhibitor  Substrate (µM) 
Reported IC50 (μM)a  Reference OATP1B1 OATP1B3 OATP2B1 NTCP 
RIFsv RSV (0.1) 0.05 ± 0.02 (100%) 0.45 ± 0.03 (100%) -
b -  
TCA (0.1) - - - 32.7 ± 0.9 (97%) RIF RSV (0.1) 0.42 ± 0.09 (92%) 1.7 ± 0.28 (75%) 69.1 ± 7.7 (7%) - (Shen et al., 2013) RSV (0.1) 0.25 ± 0.03 (95%) 1.3 ± 0.1 (79%) 61.7 ± 3.6 (7%) 83.5 ± 7.6 (6%) (Chu et al., 2015) ATV (0.01) 0.14 ± 0.01 (97%) 0.75 ± 0.08 (87%) 62.7 ± 10.7 (7%) 93.4 ± 10.4 (5%) E17G (1.0) 0.38 ± 0.02 (93%) 1.6 ± 0.1 (76%) - - TCA (1.0) - - - 35.1 ± 6.3 (13%)  Mean (all substrates)  
 0.3  1.3  64.5  70.7  
RSV, rosuvastatin; RIFsv, rifamycin SV; RIF, rifampicin; TCA, taurocholic acid; E17G, estradiol 
17β-D-glucuronide; ATV, atorvastatin. 
aMean ± SD.  Data in parentheses represent % inhibition based on the reported IC50 and a final 
RIF and RIFsv inhibitor concentration [I] of 5 μM and 1 mM, respectively.   
% inhibition = 100 * {[I]/([I] + IC50)}, assuming IC50 ~ Ki (where substrate concentration < Km).  
bNot reported.   
Chu X, Shih SJ, Shaw R, Hentze H, Chan GH, Owens K, Wang S, Cai X, Newton D, Castro-
Perez J, Salituro G, Palamanda J, Fernandis A, Ng CK, Liaw A, Savage MJ, and Evers R 
(2015) Evaluation of cynomolgus monkeys for the identification of endogenous 
biomarkers for hepatic transporter inhibition and as a translatable model to predict 
pharmacokinetic interactions with statins in humans. Drug Metab Dispos 43:851-863. 
Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, 
Kallipatti S, Selvam S, Sukrutharaj S, Krishnamurthy P, Marathe P, and Rodrigues AD 
(2013) Cynomolgus monkey as a potential model to assess drug interactions involving 
hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo 
extrapolation. J Pharmacol Exp Ther 344:673-685. 
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Table S6 Estimation of cynomolgus monkey OATP and NTCP inhibition at increasing doses of rifampicin (RIF) 
RIF Dose (mg/kg) RIF Free Cmax (µM) Predicted % Inhibition
a OATP1B1 OATP1B3 OATP2B1 NTCP 1 0.057 16 4 0.1 0.1 3 0.659 69 33 1 1 10 2.57 90 66 4 4 30 7.79 96 85 11 10 
RIF Dose (mg/kg) RIF Total Cmax (µM) Predicted % Inhibition
a OATP1B1 OATP1B3 OATP2B1 NTCP 1 0.2 40 13 0.3 0.3 3 2.5 89 65 4 3 10 9.7 97 88 13 12 30 29 99 96 31 29  aBased on the mean IC50 (across substrates) determined in vitro (Supplemental Table 5); % inhibition = 100 * {[I]/([I] + IC50)}, assuming IC50 ~ Ki (where substrate concentration < Km).  [I] represents plasma Cmax of RIF (total or free).  In the absence of i.v. RIF pharmacokinetic data, it was not possible to derive an absorption rate constant for RIF and estimate its liver inlet (portal) concentration.   
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CHAPTER 3 
QUANTITATIVE ANALYSIS OF ENDOGENOUS COMPOUNDS 
3.1 Introduction 
Metabolomics is a field of science, which involves the comprehensive 
quantitative and qualitative profiling of multiple metabolites and their interaction with 
environmental variables of interest such as diet, disease, environment, or exposure to 
chemicals.  In a simplistic view, a metabolomics experiment is a comparative analysis of 
samples to identify if these samples can be distinguished on the basis of quantitative 
and/or qualitative differences in their metabolic profiles.  In general, two strategies can 
be followed in metabolite profiling.  The first strategy targets limited number of 
metabolites or a subset of known metabolites that either have similar structure or 
involved in a specific metabolic pathway.  The metabolites of interest are already 
selected and their absolute concentrations are measured usually to prove a hypothesis 
based on a priori information about the targeted metabolites.  This approach is referred 
to as “targeted” metabolomics [1, 2].  The second strategy relies on a holistic approach 
towards the profiling of as many metabolites as possible without a prior knowledge of the 
identity of these metabolites.  This “non-targeted approach” produces comprehensive 
lists of metabolites of potential interest with relative quantification.  These metabolic 
changes then can then be mapped to specific pathways and provide biomarkers and/or 
mechanistic information [3]. 
Eicosanoid, bile acids, and steroid hormones represent examples of classes of 
endogenous compounds (metabolites) that are extensively characterized via various 
metabolomics approaches.  Comprehensive analysis of the eicosanoids metabolome 
helps understand their role in cell proliferation, inflammatory diseases, tissue repair, 
coagulation, and the immune system [4, 5].  Bile acids have both pathological and 
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physiological roles in liver diseases, regulating lipid, glucose, energy, and their own 
homeostasis.  Due to the wide variation of the physicochemical, pathological, and 
physiological roles of individual BAs, quantitative metabolomics is the best approach to 
elucidate the mechanisms underlying the various BA functions [6-11].  Quantitative 
analyses of steroid hormones are used clinically for the diagnosis of cushing’s 
syndrome, congenital steroid enzyme deficiency, and other endocrine disorders [12].  In 
addition, metabolomics is also widely used in agricultural applications to study plant 
responses to environmental factors, including drought, salt, low oxygen caused by 
waterlogging or flooding of the soil, temperature, light and oxidative stress [13].   
 The quantitative component of metabolomics analyses can be classified into 
relative, semi-quantitative, or absolute quantification [14, 15].  In relative quantification, 
the effect of treatment(s) on the analytes of interest is measured by comparing the 
detector responses of these analytes in samples from treatment groups relative to 
reference or control groups.  Semi-quantitative analyses are used when reference 
standards for the analytes of interest are not readily available; therefore, available 
standards of other molecules related to these analytes are used as surrogate standards 
to translate the detector responses into concentrations.  For example, parent 
compounds are sometimes used as standards to quantify their metabolites [16].  The 
assumption is that both the analytes and the surrogate molecules have similar detector 
responses.  In absolute quantification, however, concentrations of analytes are 
measured with predetermined levels of accuracy and precision using standards of the 
same analytes. 
3.2 Quantitative Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
Analysis 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the 
technique of choice for quantitative analyses because of its sensitivity, selectivity, and 
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speed [17, 18].  In LC-MS, the effluent from the LC system enters the ionization source, 
where analytes are ionized before mass-separation by the MS analyzer.  Atmospheric 
pressure ionization (API) sources, allow direct coupling of the LC system to the MS, 
where LC effluent flows directly into the ionization source.  However, due to differences 
in ionization efficiencies in the MS source, different analytes of the same concentrations 
may produce different MS responses.  Therefore, authentic standards are always 
required for the absolute quantification of analytes using LC-MS/MS. 
 Any components of biological matrices, primarily salts and phsphospholipids that 
co-elute from the chromatographic column with the analytes of interest, do compete over 
the same charges with the analytes in the MS source, which may suppress/enhance the 
signal intensity of these analytes.  Therefore, the same analyte with the same 
concentration can produce different MS responses, when exist in different matrices.  
This phenomenon is known as matrix effect [19].   
Typically; biological samples are prepared before analyses to extract the 
analytes of interest from as much as possible of the irrelevant endogenous sample 
components.  The most popular extraction techniques used are protein precipitation 
(PP), liquid-liquid extraction (LLE), and solid-phase extraction (SPE).  PP can be 
achieved by (i) decreasing the dielectric constant with the addition of an organic reagent 
such as methanol or acetonitrile, (ii) increasing the ionic strength, i.e. salting out effect 
by the addition of high concentrations of ammonium sulfate, or (iii) changing the sample 
pH with the addition of concentrated acids such as perchloric acid or trichloroacetic acid, 
or concentrated alkaline reagents like sodium or potassium hydroxide.  In LLE, an 
organic solvent is used in which analytes have higher solubility in comparison to their 
solubility in the aqueous phase.  The pH of the sample is adjusted so that the drug to be 
extracted is unionized, thus facilitating partitioning into the organic solvent.  The upper 
organic layer is then aspirated, evaporated, and reconstituted in a solvent compatible 
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with the buffer system.  Trimethylbutylether, chloroform, diethylether, dichloromethane, 
and diethyl acetate are the commonly used organic solvents in LLE of biological 
samples.  SPE is the most popular sample preparation method.  In SPE, the analytes 
are selectively retained to a special adsorbent via different mechanisms of interaction, 
such as hydrophobic, electrostatic, or size exclusion.  The tremendous advances in SPE 
technology, which produces sorbents with a very wide diversity in selectivity, allow SPE 
to be suitable for the extraction of a wide spectrum of compounds with different 
physicochemical properties.  These sorbents are commercially available in different 
formats such as columns, cartridges, or syringes.  
Extraction recovery is then calculated to quantify the efficiency of the sample 
preparation method in the extraction of analytes from the matrix [20, 21].  Overall 
absolute extraction recovery is calculated as the ratio of the analyte peak area in 
samples spiked before extraction compared to the corresponding peak area in untreated 
samples prepared in neat solution (assuming no loss of analyte due to degradation by 
matrix components).  In LC-MS/MS, however, absolute extraction recovery does not only 
represent extraction efficiency of the sample preparation procedure, but also includes 
the matrix effect on the MS signal.  Matrix effect is calculated as the ratio of analyte peak 
area in samples spiked after extraction compared to the corresponding peak area in 
untreated samples prepared in neat solution.  On the other hand extraction efficiency 
can be quantified via the relative extraction recovery, which is the ratio of analyte peak 
areas in samples spiked before extraction compared to the corresponding peak area in 
samples spiked after extraction.  Therefore, Overall absolute extraction recovery = 
matrix effect × relative extraction recovery (extraction efficiency). For example, as shown 
in Figure 3.1-A, extraction of two different matrices spiked with one analyte at the same 
concentration (before extraction) resulted in absolute extraction recovery of 60% and 
30% in plasma and liver, respectively.  In contrast, spiking of the same analyte at the 
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same concentrations into the same matrices after extraction, showed 80% and 40% 
matrix effect in plasma and liver, respectively compared to neat solution (Figure 3.1-B), 
whereas, extraction efficiency is 75% for both plasma and liver.  Even though, the 
extraction method was equally efficient in extracting the analyte from both matrices, total 
extraction recovery was smaller in liver compared to plasma due to a stronger matrix 
effect.  The stronger matrix effect is expected given the complexity, diversity, and higher 
concentrations of endogenous components of liver compared to plasma. 
Standard curves should ideally be prepared in the same matrix as the test 
samples, to ensure that the same MS response is produced for an analyte existing in 
both the standard and study samples at equal concentrations.  However, by definition, 
analyte-free biological matrices do not exist for endogenous compounds.  Furthermore, 
blank matrices may not be available or can be difficult to obtain, even for some 
exogenous compounds, because they are rare matrices such as tears, seminal, and 
vaginal fluid [22, 23], or due to contamination with analytes such as antibiotics in 
wastewaters [24], or presence of identical matrix components with the same MS and 
chromatography properties as the analytes of interest such as erlotinib [25]. 
3.3 Approaches for Quantification of Endogenous Analytes 
 Various approaches (Figure 3.2) are followed to address the lack of blank 
matrices for the quantification of endogenous compounds by LC-MS/MS including, 
background subtraction [26-31], the standard addition method [24, 25, 32-44], neat 
solutions [45-52], artificial matrices of biological fluids [23, 53-73], stripped matrices [8, 
10, 11, 74-91], and surrogate analytes [66, 92-98]. 
3.3.1 Method of Background Subtraction 
 In background subtraction, the endogenous background concentrations of 
analytes in a pooled/representative matrix are subtracted from the concentrations of the 
added standards, subsequently the subtracted concentrations are used to construct the 
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calibration curve (Figure 3.2-C).  This approach allows the use of the same matrix for 
the calibration curve as the one to be analyzed, so that recovery and matrix effect are 
the same between samples and calibration curves.  However, for this method to be 
reproducible, the increase in background peak area after spiking with standards has to 
be significantly higher than the reproducibility limits of the method at best, i.e. 15-20% of 
the background peak areas.  Therefore, the lower limits of quantification (LLOQ) of these 
methods are limited by the endogenous background concentrations in the particular 
batches used as blanks in building the calibration curves, rather than by the analytical 
sensitivity.  LLOQ is defined as the concentration at which the signal-to-noise ratio is 10 
[27].  A statistical t test can also be used to define the LLOQ as the minimum 
concentration that results in the lowest statistically-significant increase in background 
concentration [30].  For example, if the concentration of an endogenous analyte in the 
matrix to be used as a blank is a 100 ng/ml, the LLOQ of this method is limited to 20 
ng/ml despite the fact that the limit of detection for this analyte could be in the pg/ml 
range.  Subtraction of peak areas after spiking with standards of concentrations lower 
than 20 ng/ml will likely result into negative values or irreproducible positive values, 
which does not allow the quantification of this analyte at concentrations lower than 20 
ng/ml.  In contrast, for an exogenous analyte with the same sensitivity as the 
abovementioned endogenous analyte, LLOQ is defined by the detection sensitivity of the 
MS, which is in the pg/ml range, because no background subtraction is performed. 
 Another drawback of this method is that the different batches of pooled bio-fluids 
that are used as blank matrices will have different background levels of endogenous 
analyte to subtract, which makes it an irreproducible process over time or between 
different labs [27, 29].  Furthermore, it is difficult to quantify multiple analytes if they have 
variable endogenous levels [27, 43].  
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 When lower LLOQ of endogenous compounds are required, the background 
concentrations in the blank matrices can be lowered by dilution of the blank matrices 
before spiking with standards, to facilitate subtraction from low-concentration standards.  
However, this means that the composition of the matrices in the study samples vs. 
calibration curve is different, which may lead to different recoveries of analytes from the 
study samples vs. calibration standards.  Therefore, before this approach is used, 
extraction recoveries of analytes between the matrix and diluted-matrix should be 
determined to be similar.  Table 3.1 summarizes representative examples of compounds 
quantified by the method of background subtraction.  For example, our group used 
three-fold diluted brain homogenates compared to actual study samples, to construct 
calibration curves for the quantitation of amino acids in mice.  However, it was 
demonstrated that extraction recoveries of amino acids from the diluted (calibration 
standards) and undiluted (study samples) were similar [29].  In another example 
background subtraction was applied for the quantification of amino acids in human 
plasma [43].  The endogenous levels of arginine, citrulline, and ornithine in the human 
plasma serving as the blank matrix were 154.4, 17.0, and 63.1 µM, respectively and the 
linear ranges using the background subtraction method were 25–200, 4–200, and 10–
200 µM, respectively.  As described above the high LLOQs were not because of the lack 
of sensitivity of the method but rather because of the high and variable endogenous 
levels of amino acids in plasma.  In another example, Gachet et al. developed a method 
for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-
acylethanolamines, and steroids in human plasma by background subtraction [27].  The 
authors observed high inter-day variability at low concentration (1.3 ng/ml) by the 
method of background subtraction.  However, this could be avoided by increasing the 
LLOQ level of the calibration curve.   
3.3.2 Method of Standard Addition 
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 In the standard addition method, every study sample is divided into aliquots of 
equal volumes.  All aliquots, but one, are separately spiked with known and varying 
amounts of the analyte standards to construct a calibration curve for every study sample 
(Figure 3.2-D).  The study sample concentration is then determined as the negative x-
intercept of the standard calibration curve prepared in that particular study sample [99].  
In the background subtraction method, a pooled matrix is used as a surrogate for the 
matrices of all study samples, which may not be the case due to variability of the matrix 
components from sample to sample or batch to batch.  In contrast, the standard addition 
method has the advantage of the use of the exact same matrix of every study sample for 
the construction of its own calibration curve.  Furthermore, this approach allows direct 
quantitation of endogenous analytes without manual subtraction of background peak 
areas.  However, this process generally requires a large amount of sample and can be 
markedly time-consuming and labor intensive.  Table 3.2 summarizes representative 
examples of compounds quantified by the method of standard addition.  This method is 
usually followed to eliminate matrix effects when analyte free matrices are not available 
[32-37, 43].  For example, abscisic acid, a phytohormone, from plant leaves [33] and the 
emission of polycyclinc aromatic hydrocarbons from petroleum refineries [37] were 
quantified using the method of standard addition because blank matrices are not 
available for these analytes.  The standard addition method is also used for the 
quantitation of exogenous analytes, when different matrix effects are observed for 
different samples [24, 38-42].  For example, antibiotics quantified in the effluents from 
wastewater-treatment plants had different recoveries and detection limits in at least two 
different wastewater effluents [39].  Similarly, matrix effect of diarrhetic shellfish 
poisoning toxins (DSPs) in scallop varied markedly between scallop samples [41].  
Standard addition can also be used if some matrix components produce MS signals that 
interfere with the analytes of interest.  For example, erlotinib was quantified in rat liver, 
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muscles, and spleen using the standard addition method because an unknown 
endogenous component of these matrices produced the same MS signal and had the 
same retention time as erlotinib [25].  
3.3.3 Surrogate Matrices 
It is often difficult to obtain biological matrix free of endogenous analyte to 
prepare calibration standards.  Hence, various matrices are used as surrogate matrices 
for the actual matrix of study samples.  Surrogate matrices can vary widely in 
complexity.  
3.3.3.1 Neat solutions 
In its simplest form, mobile-phase solvents (neat) [48, 49, 51] or pure water [45, 
47, 50, 52] can be used as a surrogate matrix.  To use neat solutions as surrogate 
matrices, it is required to demonstrate that extraction recovery and matrix effect are 
comparable with the original matrix.  Table 3.3 summarizes representative examples of 
compounds quantified using neat solutions as surrogate matrices.  For example, 
thromboxane B2 and 12(S)-hydroxyeicosatetraenoic acid were quantified in human 
serum using mixture of water/methanol/acetonitrile (80:10:10, v/v/v) as a surrogate 
matrix [51].  Authors demonstrated comparable matrix effect between neat solution and 
the original serum matrix.    
3.3.3.2 Artificial matrices 
 Various biological matrices including cerebrospinal fluid, tears, vaginal fluid, and 
sputum are scarce and are difficult to obtain.  However, if the composition of the study 
matrix is known, an artificial matrix can be prepared [100-105].  Artificial matrices are 
analyte-free, and are typically made to simulate the authentic matrices in terms of 
composition, salts content, analyte solubility, extraction recovery, and matrix effect.  
Phosphate-buffered saline (PBS) is frequently used for plasma and serum sample 
analyses because of its pH (7.4) and ionic strength.  Often, bovine (BSA) or human 
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serum albumin (HSA) is added to PBS at a concentration of 20–80 g/l to take the protein 
content of the biological matrix into account and to increase the solubility of hydrophobic 
analytes.  Table 3.4 shows more complex artificial solutions that are prepared as 
surrogates for urine, cerebrospinal fluid, vaginal fluid, semen, tears and saliva.  Table 
3.5 show representative examples of analytes quantitated using calibration curves 
prepared in in artificial matrices.  For example, isotonic saline solution was used as an 
artificial matrix for the quantitation of polyunsaturated fatty acids and ecosanoids in 
human plasma [55].  Similar recoveries were found for these analytes in saline solution 
and human plasma.  In addition, artificial tear fluid was used as a matrix for the 
characterization of ocular pharmacokinetics of amphotericin B and natamycin in rabbits.  
Authors demonstrated that QCs of amphotericin B and natamycin prepared in both real 
and artificial tear fluids showed similar accuracy and precision [23, 57].  
3.3.3.3 Stripped matrices 
 Biological matrices are stripped from particular endogenous components to 
generate analyte-free surrogate matrices that can be used as blanks for the construction 
of calibration curves [74, 77, 78].  Activated-charcoal is an efficient adsorbent; therefore, 
it is most commonly used for this purpose.  Other methods such as heating to 
decompose the analytes of interest can also be used. For example, plasma can be 
depleted of ascorbic acid by leaving it on the bench for 96 h [106].  During charcoal 
stripping, special care should be taken so that all charcoal particles are effectively 
removed from the matrix after stripping and before spiking with analytes, because the 
added analytes can readily bind to the remaining traces of charcoal, which can falsely 
decrease the measured analyte concentrations in study samples.  Furthermore, not all 
endogenous analytes are efficiently removed by charcoal.  Importantly, the composition 
of resulting stripped matrices may be drastically altered, which may lead to completely 
different extraction recoveries and matrix effects compared to the original matrices.  In 
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addition, batch-to-batch variations may occur in the efficiency of stripping due to the 
differences in the levels of endogenous compounds to be stripped in blank matrices.  
Examples of analytes quantitated using stripping of matrices are given in Table 3.6.  For 
example, our group quantified bile acids in mouse liver, bile, plasma and urine, as well 
as human plasma and urine using charcoal stripping after demonstrating similar 
extraction recoveries from stripped matrices and original matrices for two stable-labeled 
isotope internal standards [8, 10].  Similarly, we used charcoal-stripped human saliva for 
the quantification of four lysophosphatidic acids in saliva and gingival cervical fluids [82].    
Overall, the various surrogate matrix approaches allow direct and sensitive 
quantification of analytes due to the lack of endogenous background in the surrogate 
matrix.  However, analytes may have low solubility in the surrogate matrix, which could 
lead to precipitation of the analyte, nonspecific binding to the surfaces of tubes and vials, 
which will result in biased and irreproducible results.  For proper assay performance, it is 
important to demonstrate similar matrix effect and extraction recovery of all internal 
standards and analytes over the entire intended concentration range in both surrogate 
and original matrices.  Background subtraction, standard addition [53, 54, 56, 80], or 
labeled internal standards or analytes methods [8, 10, 11] can be used to determine 
extraction recovery of endogenous compounds in the original matrices.    
3.3.4 Surrogate Analytes 
 In the surrogate analyte method, stable-isotope labeled analytes are used as 
surrogate standards to construct the calibration curves for the quantification of 
endogenous analytes (Figure 3.2-F).  This method allows direct and sensitive 
quantification of analytes due to the lack of any endogenous background.  In this method 
it is assumed that the physico-chemical properties of the authentic and surrogate 
analytes are the same with the exception of molecular weight; therefore, extraction 
recovery, chromatographic retention, and signal intensity are identical or have minimal 
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differences.  However, these assumptions are not always met, and isotope standards 
may differ in retention time and MS sensitivity compared to the unlabeled analytes.  
Therefore, before the application of this approach, the ratio of the labeled to unlabeled 
analyte MS responses (the response factor (RF)), should be close to unity and should be 
constant over the entire calibration range.  If the RF does not equal one, it should be 
incorporated into the regression equation of the calibration curve [34].  To determine 
matrix effect and recovery of the authentic endogenous analytes, the background 
subtraction method as described above can be used.  The labeled and unlabeled 
standards may have slightly different retention times as well as ionization efficiencies in 
the MS source, especially with larger number of labeled deuterium atoms.  Furthermore, 
the mass difference between surrogate and authentic analytes should be sufficient, so 
that the naturally-occurring 13C isotopes of the unlabeled analyte do not overlap with the 
labeled analyte [34].  In addition, contamination of the labeled standards with trace 
amount of unlabeled analytes is common, which may also exacerbate over time under 
storage conditions due to the degradation of labeled standards into unlabeled analytes.  
Stabled-labeled surrogate standards can only be used with methods using MS detectors 
because separation of the labeled and unlabeled compounds is based only on mass 
difference.  Finally, this method is limited by the availability of expensive labeled 
standards. 
 Table 3.7 summarizes representative examples of compounds quantified by the 
surrogate analyte method.  For example, the deuterium-labeled 2H6-γ-hydroxybutyrate 
was used as a surrogate analyte for the quantitation of γ-hydroxybutyrate in human urine 
[92].  To examine the suitability of the surrogate analyte approach, calibration curves 
were prepared using both the surrogate analyte and standard addition methods.  The 
slopes of both calibration curves were similar and resulted in the same concentrations of 
tested samples.  In another example, 2H3-ketoisocaproate was used as a surrogate 
154  
 
analyte for the quantitation of ketoisocaproate in rat plasma, brain, and cerebrospinal 
fluid [93].  In this method authors demonstrated similar MS response for the surrogate 
and authentic analyte in neat solution, but the matrix effect and extraction recovery were 
not compared. 
3.4 Regulatory Guidelines 
Validation of bioanalytical methods is required to ensure that these methods are 
accurate, reproducible, robust, and reliable for their various applications.  United States 
Food and Drug Administration (USFDA) and European Medicines Agency (EMA, 
European authority) issued the most recent drafts of their guidelines for acceptance 
criteria and strategies on bioanalytical method validation in 2013 [107] and 2012 [108], 
respectively.  For sensitivity and selectivity, blank samples of the biological matrix to be 
analyzed should be obtained from at least six sources and the responses of any 
interfering components with analytes and IS should be less than 20% of the response at 
the LLOQ of the analytes and less than 5% of the response of the  internal standard (IS).  
Accuracy and precision should be measured at LLOQ, low quality control (LQC- within 
three times the LLOQ), middle QC (in the midrange), and high QC (approaching the high 
end) using a minimum of five determinations per concentration, and they should be 
within 15%, except for the LLOQ that can be up to 20%. A calibration curve should 
consist of a blank matrix, a zero standard, and at least six non-zero standards covering 
the expected dynamic range.  Accuracy for these standards should also follow the same 
criteria as the QCs.  Additional criteria regarding stability, recovery, matrix effect, and  
incurred sample analysis are also discussed in the guidelines. 
These guidelines are primarily designed to address validation of exogenous 
compounds and following their validation criteria for the quantification of endogenous 
compounds is a challenge, because of the lack of blank matrix needed to make all the 
standards and QCs that are used to obtain all these validation parameters.  This has 
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recently triggered the FDA to dedicate a section for the quantification of endogenous 
compounds in its most recent (2013) draft [107], which was not addressed in the 
previous 2001 version [109].  The FDA guidelines stated that “the biological matrix used 
to prepare calibration standards should be the same as the study samples and should 
be free of the endogenous analytes.  The suitability of analyte-free biological matrices 
needs to be assured, by demonstrating no measurable endogenous analytes and no 
matrix effect or interference when compared to the biological matrices of the study 
samples”.  The guidelines recommended that the quality control samples (QCs) should 
be prepared in the same biological matrix as study samples and that the concentrations 
of these QCs should account for the background endogenous concentrations in the 
biological matrix, i.e. using the method of background subtraction.  The guidelines also 
referred to the use of alternate (surrogate) matrices such as buffers and dialyzed serum, 
but did not recommend this approach unless an analyte-free biological matrix is not 
readily available or cannot be prepared.  If this approach is used, justification and 
evidence of similar matrix effect to the original matrix are required.    
3.5 Conclusions 
 In summary, various methods are available for the quantitative analyses 
of endogenous compounds.  Background subtraction and standard addition methods 
use the same biological matrix as the study samples to prepare the calibration 
standards, hence recovery and matrix effect for the study samples are identical to those 
of the calibration standards.  However, the sensitivity of the background subtraction 
method is limited by the endogenous levels of the analytes rather than by the sensitivity 
of the detector.  On the other hand, the standard addition method requires large sample 
volumes as calibration curves are built in each individual sample.  In contrast the 
surrogate matrix approach uses matrices devoid of endogenous analytes for preparing 
calibration standards and it allows direct and sensitive quantification of analytes.  
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Surrogate matrices include neat solutions, artificial matrices, and stripped matrices.  
However, for this method it is required to demonstrate similar matrix effect and extraction 
recovery in both the surrogate and original matrix.  Finally, similar to the background 
subtraction and standard addition methods, the surrogate analyte approach use the 
same biological matrix as the study samples to prepare the calibration standards.  
However, stable-isotope labeled analytes are used as surrogate standards to construct 
the calibration curves for the quantification of endogenous analytes.  Hence, utility of this 
method is limited by the use of MS detectors and by the availability of expensive and 
pure labeled standards.  Furthermore, it is required to demonstrate similarity in matrix 
effect and recovery between surrogate and authentic endogenous analytes.  Finally, all 
these methods represent indirect approaches to quantify endogenous compounds and 
regardless of what approach is followed, it has to be shown that none of the validation 
criteria have been compromised due to the indirect analyses.   Addressing endogenous 
compounds in the most recent version of FDA guidelines reflect the growing need for 
quantitative analysis of endogenous analytes.  However, the guidelines did not specify 
the different approaches of how to obtain analyte-free biological matrices for 
endogenous compounds.      
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Figure 3.1  A LC-MS/MS chromatograms showing differences in MS response of one analyte spiked pre- extraction (A) and post-extraction (B) into plasma, liver, as well as neat matrices at the same concentration. 
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Figure 3.2 LC-MS/MS chromatograms showing (A) background peak of endogenous 
analyte in blank matrix, (B) a neat standard with known concentration of the same 
analyte, (C) the same matrix after spiking with a standard of a known concentration 
(method of background subtraction), (D) one study sample is split into several aliquots, 
each spiked with a standard (Std.) of different concentration (method of standard 
addition), (E) analyte standard spiked into a surrogate matrix that contains no 
background (surrogate matrix method), (F) a standard of a surrogate analyte spiked into 
the same original matrix (surrogate analyte method). 
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Figure 3.3 A LC-MS/MS chromatogram showing the subtraction of the background (blank) peak area of endogenous compound (A) from the peak area of the same compound after spiking with a 500 ng/ml standard.  (B) is an exogenous compound and no background exists in the blank matrix. 
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Table 3.1  Applications of the background subtraction method. 
Class Application Matrix Analytical technique Reasona References 
Amino acids Biomarkers for cardiovascular diseases Human plasma LC-MS/MS Blank matrix not available [26] 
Amino acids Biomarkers for diabetic complications Human plasma and urine LC-MS/MS Blank matrix not available [28] 
Amino acids Biomarkers for neurodegenerative diseases Mouse brain LC-MS/MS 
Blank matrix not available. [29] 
Eicosanoids Biomarkers for cardiovascular diseases Human plasma LC-MS/MS Blank matrix not available. [30] 
Eicosanoids and steroids 
Biomarkers for inflammatory, neuropsychiatric and cardiovascular diseases 
Human plasma LC-MS/MS Blank matrix not available. [27] 
Cobalt mesoporphyrin (Antiobesity) Pharmacokinetics Rat plasma 
Atomic absorption spectroscopy  
Blank matrix not available. [31] 
aReason why background subtraction method was required. 
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Table 3.2 Applications of the method of standard addition. 
Class Application Matrix Analytical technique Reasona References 
Sphingosine 1-phosphate (Sphingolipids) 
Biomarker for atherosclerosis Human plasma LC- Fluorescence Blank matrix not available [32] 
Abscisic acid (Plant hormone) Biomarkers for plant growth  Plant leaves LC-MS/MS Blank matrix not available  [33] 
Androgens Biomarkers for endocrine disorders  human urine GC-MS Blank matrix not available  [34] Purines and Pyrimidines  Estimation of protein supply in animals Bovine and ovine urine HPLC-UV Blank matrix not available  [35] 
Bile acids Biomarkers for vascular and metabolic disorders Human serum LC-MS/MS Blank matrix not available  [36] Polycyclic aromatic hydrocarbons Monitoring of pollutant from petroleum refinery Flame TOF Blank matrix not available [37] 
Erlotinib (Anticancer) Pharmacokinetics Rat liver, spleen and muscles MALDI-TOF 
Interference from matrix components [25] 
Antibiotics Monitoring of antibiotics residues in feeding stuffs Animal feeds LC-MS/MS 
variable matrix effect between samples [38] 
Trimethoprim (Antibiotics) Monitoring of drug residues in wastewater  Wastewater  LC-MS/MS 
variable matrix effect between samples [39] 
Antibiotics Monitoring of antibiotics residues in wastewater Wastewater  LC-MS/MS 
variable matrix effect between samples [24] 
Flavoring additives Monitoring aroma in food products Wheat flour doughs  GC-FID 
variable matrix effect between samples [40] 
Seafood poisons Monitoring shellfish poisons in scallop Scallops LC-MS/MS 
variable matrix effect between samples [41] 
N-carboxymethyl lysine (Amino acid) Biomarker for diabetes Human plasma LC- Fluorescence 
variable matrix effect between samples [42] 
Amino acids Biomarkers for pulmonary diseases Human plasma LC-MS/MS Blank matrix not available [43] 
Steroids Forensic  Wood LC-MS/MS Blank matrix not available [44] aReason why standard addition method was required. 
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Table 3.3 Applications of the use of neat solutions as surrogate matrices. 
Class Application Matrix Analytical technique Neat composition Validationa References 
Amino Acids Biomarkers for pelvic organ prolapse 
Human pelvic connective tissues LC-MS/MS Water 
Similar recovery in surrogate and original matrices for all analytes at three QCs  
[45] 
Amino acids Biomarkers for metabolic disorders. 
Human plasma, urine and cerebrospinal fluid  
LC-MS/MS 0.1% HCL  -  [46] 
Amino Acids and neurotransmitters 
Biomarkers for central nervous system disorders 
Rat plasma and PC12 cells  LC-MS/MS Water 
Similar recovery in surrogate and original matrices for all analytes at three QCs 
[47] 
Bile acids Biomarkers for hepatobiliary  diseases 
Mouse plasma and human serum LC-MS/MS 
50 % methanol  
Similar recovery in surrogate and original matrices for all analytes at one QC 
[48] 
Bile acids Biomarkers for hepatobiliary diseases 
Human plasma, human urine and mouse liver LC-MS/MS Methanol 
Similar recovery in surrogate and original matrices for all analytes at one QC 
[49] 
LTB4 (Eicosanoids) 
Biomarkers for inflammatory diseases  
Human exhaled breath condensate  LC-MS/MS Water - [50] 
Eicosanoids Biomarkers  for platelet activity Human serum LC-MS/MS Water/methanol/acetonitrile  
Similar calibration coefficient for surrogate and original matrices 
[51] 
Small organic acids 
Biomarkers for acidosis in malaria  
Human plasma and urine LC-MS Water  
Similar recovery in surrogate and original matrices for all analytes at three QCs 
[52] 
aValidation: How similarity of recoveries/matrix effect for original and surrogate matrices were demonstrated.  
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Table 3.4 Typical composition of commonly used artificial matricesa.   
vaginal fluid 
[100] Semen [101] Urine [102] Tears [103] 
Cerebrospinal fluid 
[104] Saliva [105] 
Glucose - 5.0 Glucose - 1.02 NaCl - 14.1 Lysozyme - 1.9 NaCl - 7.592 NaCl - 8.0 
Glycerol - 
0.16 
Sodium citrate - 
8.13 KCl - 2.8 Lactoferrin - 1.8 KCl - 0.146 
KH2PO4 - 
0.19 
Lactic acid - 
2.0 KOH - 0.881 Urea - 17.3 
α-acid glycoprotein - 
0.5 MgCl2.6H2O - 0.24 
Na2HPO4 - 
2.38 
Acetic acid - 
1.0 KCl - 0.908 
25% ammonia 
water-0.19% albumin - 0.2 
CaCl2.2H2O - 
0.174  
Albumin - 
0.018 Fructose - 2.72 CaCl2 - 0.6 mucin - 0.15 KH2PO4 - 0.154  
Urea - 0.40 Lactic acid - 0.62 MgSO4 - 0.43 γ-globulins - 0.1 Sodium lactate - 1.69  
NaCl - 3.51 Urea - 0.42 HCl - 0.02 M NaCl- 6.626, KCl -1.716 glucose - 0.719  
KOH - 1.40 BSA - 50.4  NaHCO3 -1.376 NaHCO3 - 0.924  
Ca(OH)2 - 
0.222 
NaH2PO4·H2O - 
0.0927  Lactic acid - 0.27   
pH - 4.2 Na2HPO4 - 0.858  CaCl2 - 0.147   
   NaH2PO4.H2O - 0.1   
   Lipids - 0.0798   
 aValues are in grams per liter. 
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Table 3.5 Applications of the use of artificial matrices as surrogate matrices. 
Class Application Matrix Analytical technique Surrogate matrix Validationa Reference 
Eicosanoids Biomarkers for asthma and COPD Human sputum LC-MS/MS 
Human serum albumin (HAS) in phosphate buffer saline (PBS) 
No matrix effect and ~ 100% recovery in original matrix for all analytes at one QC [53] 
Eicosanoids Biomarkers for asthma and COPD Human urine LC-MS/MS Artificial  urine 
No matrix effect in original and surrogate matrix for all analytes at one QC [54] 
Eicosanoids Biomarkers for Inflammatory, respiratory, and cancer diseases 
Human plasma LC-MS/MS Saline solution 
Similar recovery in surrogate and original matrices for all analytes at one QC [55] 8-iso-PGF2α (Eicosanoid) Biomarker for hypertension Human urine LC-MS/MS Phosphate buffer saline No matrix effect in original matrix for analyte at one QC [56] 
Natamycin (Antibiotics) Pharmacokinetics 
Rabbit lachrymal fluid LC-MS/MS Artificial tear fluid 
No matrix effect in original and surrogate matrix for analyte at three QCs [57] 
Amphotericin B (Antibiotics) Pharmacokinetics 
Rabbit lachrymal fluid LC-MS/MS Artificial tear fluid 
No matrix effect in original and surrogate matrix for analyte and IS at one QC [23] 
Sphingolipids  
Biomarkers for cancer and immune system disorder 
Human plasma LC-MS/MS 
5 % bovine serum albumin (BSA) in PBS 
No matrix effect and similar recovery in original and surrogate matrix for all analytes at two QCs 
[58] 
Pyridoxal-5’-phosphate (Vitamins) 
Biomarkers for  neurological disorders Human blood LC-MS/MS 2% BSA in PBS 
No matrix effect and similar recovery in original and surrogate matrix for analyte at two QCs 
[59] 
Vitamin D  Biomarkers for cancer, cardiovascular and autoimmune diseases 
Human serum and plasma LC-MS/MS 5% BSA in PBS 
No matrix effect in original matrix for analytes at three QCs [60] 
Ceramides Biomarkers for type 2 diabetes Human plasma LC-MS/MS 5 % BSA in water 
Similar matrix effect and recovery in original and surrogate matrix for all analytes and IS at one QC 
[61] 
homocysteine (Amino acid) Biomarkers for vascular diseases Human serum LC-MS/MS 2% BSA in water 
No matrix effect and similar recovery in original and surrogate matrix for analyte and IS at two QCs 
[62] 
Amino acids Biomarkers for immune system functions Rat plasma LC-MS/MS BSA (79g/L) - [63] Androgens Biomarkers for prostate Mouse lung, LC-MS/MS 1 g/L of PBS/BSA - [64] 
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cancer brain, liver, heart, kidney, prostate, testis, bladder 
24(S)-hydroxycholesterol  
Biomarkers for Niemann-Pick type C disease 
Human plasma and cerebrospinal fluid (CSF) 
LC-MS/MS 
5% BSA in water for plasma and 2.5% HP-β-CD for CSF 
No matrix effect and ~100% recovery in original and surrogate matrix [65] 
Steroids Endogenous biomarker for drug–drug interactions 
human and mouse plasma LC-MS/MS 4.2% HSA in PBS - [73] 
Polypeptides  Biomarkers for chronic obstructive pulmonary disease Human urine LC-MS/MS PBS 
Similar calibration coefficient for surrogate and original matrices  [66] 
Amyloid peptides Biomarkers for Alzheimer’s disease Human CSF LC-MS Artificial CSF 
Similar calibration coefficient for surrogate and original matrices [67] 
N-terminal natriuretic peptide  Biomarkers for cardiac hypertrophy Rat serum LC-MS/MS Human serum 
Similar calibration coefficient for surrogate and original matrices [68] 
Insulin-like growth factor-1  Anti-doping test 
Human and chicken dried-blood spot  
LC-MS/MS HSA (1 mg/mL) - [69] 
Purine metabolites Biomarkers for hyperuricemia Human serum LC-UV Phosphate buffer 
~ 100% recovery in original matrix for analytes and IS at one QC [70] 
Acetylcholine (Neurotransmitter) 
Biomarker for Alzheimer’s disease and schizophrenia Rat CSF LC-MS/MS Artificial CSF 
No matrix effect in original matrix [71] 
Neurotransmitters Biomarkers for diabetes, heart diseases, and anxiety 
Human plasma LC-MS/MS Heated human plasma 
Similar matrix effect and recovery between original and surrogate matrix at three QCs [72] aValidation: How similarity of recoveries/matrix effect for original and surrogate matrices were demonstrated. 
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Table 3.6 Applications of the use of stripped matrices as surrogate matrices. 
Class Application Matrix Analytical technique Validationa Reference 
Amino acids  Biomarkers for hypotension and hypovolemia  Human plasma and  urine LC-MS/MS  No matrix effect in original matrix for analyte at three QCs [60] 
Amino Acids Biomarkers for acute porphyrias Human serum and Urine  LC-MS/MS No matrix effect in original matrix for analytes at one QC [75] 
Estradiol Biomarkers for endocrine disorder Human plasma LC-MS/MS No matrix effect in original matrix for analytes at four QCs [76] 
Testosterone Biomarkers for endocrine disorder Human serum LC-MS/MS - [88] 
Steroids Biomarkers for endocrine disorder Human serum LC-MS/MS No matrix effect in stripped and original matrix for analytes for calibration curve [89] 
Steroids Biomarkers for endocrine disorder Human CSF LC-MS/MS - [90] 
Cortisol Biomarkers for endocrine disorder Human plasma LC-MS/MS No matrix effect and 100% recovery in stripped matrix at 3 QCs [91] 
Bile acids Biomarkers for hepatobiliary diseases Human plasma LC-MS/MS 
No matrix effect in original matrix for analytes at two QCs  [77] 
Bile acids Biomarkers for hepatobiliary diseases Human urine LC-MS/MS - [78] 
Bile acids Biomarkers for hepatobiliary diseases Human plasma LC-MS/MS Matrix effect and recovery is similar for stripped and original matrix for all analytes one QC [79] 
Bile Acids Biomarkers for hepatobiliary diseases Mouse liver, bile, plasma, and urine LC-MS/MS Similar recovery for stripped and original matrix for stable isotope labeled internal standards at one QC [8] 
Bile Acids Biomarkers for hepatobiliary diseases Mouse liver, bile, plasma, and urine LC-MS/MS Similar recovery for stripped and original matrix for stable isotope labeled internal standards at one QC [11] 
Bile acids Biomarkers for hepatobiliary diseases Human urine and serum LC-MS/MS Similar recovery for stripped and original matrix for stable isotope labeled internal standards at one QC [10] 
Bile Acid Biomarkers for hepatobiliary diseases Rat plasma LC-MS/MS No matrix effect in stripped and original matrix for analytes for calibration curve [80] 
Bile Acid Biomarkers for hepatobiliary diseases Sea Lamprey plasma and tissues LC-MS/MS Similar matrix effect between original and stripped matrix for all analytes and IS at one QC [81] 
Phospholipids Biomarker for periodontal diseases 
Human saliva and gingival cervicular fluid  LC-MS/MS - [82] 
Fatty acids  
Bimarker for drug addiction, obesity, inflammation and cancer Human plasma LC-MS/MS 
No matrix effect in original matrix for analytes at one QC [83] 
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poly saccharides Biomarkers for Crohn’s, nonalcoholic fatty liver diseases, and diarrhea Human plasma LC-MS/MS 
Similar matrix effect and recovery for stripped and original matrix for all analytes and IS for 2 QCs [84] 
human serum albumin Biomarker for renal disorder Human urine LC-MS/MS - [85] 
Nucleotides Biomarker for cellular biochemical processes peripheral blood mononuclear cells  LC-MS/MS Similar matrix effect in stripped and original matrix for IS at three QCs [86] 
Eicosanoids Biomarkers for cardiovascular diseases Human Sputum LC-MS/MS No matrix effect in original matrix for all analytes at two QCs [87] aValidation: How similarity of recoveries/matrix effect for original and surrogate matrices were demonstrated. 
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Table 3.7 Applications of the surrogate analytes method. 
Class Application Matrix Analytical technique Isotope labels Validationa References 
Peptide biomarkers for lung disease Human urine LC-MS/MS 
2H and 18O 
Similar calibration coefficient for authentic analyte surrogate and surrogate analyte original matrices 
[66] 
γ-hydroxybutyrate (neurotransmitter) Forensic analysis Human urine LC-MS/MS 2H - [92] 
α-ketoisocaproic acid Biomarker for chronic uremia 
Plasma, Brain homogenate, and Cerebrospinal fluid 
LC-MS/MS 2H 
Compared MS response between labeled and unlabeled in neat solution 
[93] 
Mevalonic acid Biomarker for cholesterol lowering drugs 
Human plasma LC-MS/MS 2H 
Compared MS response between labeled and unlabeled in matrix 
[94] 
Monosaccharides Biomarker for uremia and diabetes 
Human red blood cells (RBCs) LC-MS/MS 
13C6 - [95] 
Monosaccharides Biomarker for uremia and diabetes 
Human nerve tissues LC-MS/MS 13C6 - [96] 
Amino Acids Biomarker for metabolic disorder. 
Human plasma LC-MS/MS 2H 
Similar calibration coefficient for authentic analyte surrogate and surrogate analyte original matrices 
[97] 
4β-hydroxycholesterol 
Endogenous biomarker for drug–drug interactions 
Human plasma LC-MS/MS 2H 
Compared MS response between labeled and unlabeled in neat solution 
[98] 
aValidation: How similarity of MS response for original and surrogate analytes were demonstrated.  
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CHAPTER 4 
SIMULTANEOUS LC-MS/MS ANALYSIS OF EICOSANOIDS AND RELATED 
METABOLITES IN HUMAN SERUM, SPUTUM, AND BALF 
4.1 Introduction 
Polyunsaturated fatty acids (PUFAs) are precursors of oxylipins, a large family of 
metabolites involved in various physiological roles such as regulation of cell proliferation, 
tissue repair, coagulation, and immune functions.  The eicosanoids are a large subclass 
of oxylipins, which includes over 100 lipid mediators such as prostaglandins (PG), 
thromboxanes (TX), leukotrienes (LT), hydroxyeicosatetraenoic acids (HETEs), 
dihydroxy-eicosatetraenoic acids (DHETs), hydroxyeicosapentaenoic acids (HEPEs), 
lipoxins (LXs), reolvins (RvEs) and epoxyeicosatrienoic acids (EET) [1, 2].  Eicosanoids 
are synthesized from dihomo gamma-linolenic acid (DGLA), arachidonic acid (AA), and 
eicosapentaenoic acid (EPA) via different enzymes such as cyclooxygenase enzymes 
(COX), lipoxygenase enzymes (LOX), cytochrome P450, as well as by non-enzymatic 
oxidation [3, 4]. 
Disruption of the homeostasis of eicosanoids is closely related to a range of 
inflammatory pathological conditions including asthma and chronic obstructive 
pulmonary disease (COPD), fever, pain, nephritis, cardiovascular diseases, Crohn’s 
disease, and cancer [5-9].  PGE2 regulates tumor angiogenesis in prostate cancer [10], 
whereas LTs and LXs regulate vasoconstriction and vascular permeability [11, 12].  20-
HETE regulates cerebral microvessel constriction [13], conversely, EET metabolites 
increase cerebral blood flow [14]. 
Given the clinical interest in eicosanoids and the complexity of their responses to 
biological stimuli, it is necessary to systematically monitor the changes in their 
concentrations in various tissues and biological fluids.  This requires sensitive, selective, 
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and reproducible methods for their quantification.  Quantification of eicosanoids in 
biological matrices is associated with numerous challenges including their low 
concentrations (pM-nM range) in biological fluids.  Some eicosanoids are unstable and 
can also be formed artificially ex vivo after sample collection and during sample 
preparation.  This could be overcome by measuring more stable metabolites as 
surrogates for their unstable parent compounds.  For example, TxB2 and 6-keto-PGF1α 
are measured as surrogates for TxA2 and PGI2, respectively [15-17].  Other challenges 
include the presence of multiple isomeric forms that share the same mass and 
fragmentation pattern, which makes it difficult to resolve them by mass spectrometry and 
by chromatography [18]. 
A broad range of techniques have been employed for the separation, detection, 
and quantification of eicosanoids, including HPLC-UV [19-23], enzyme immunoassays 
[24, 25], LC–fluorescence detection [26, 27], electrophoresis [28, 29], immuno-affinity 
chromatography (IAC) [30], gas chromatography–mass spectrometry (GC-MS) [18, 31-
33] and liquid chromatography–mass spectrometry  (LC–MS) [34-40].  HPLC-UV 
requires active chromophore to quantify eicosanoids.  The main disadvantages of HPLC-
UV are the limited sensitivity and specificity of UV detection in complex biological 
matrices, which typically require long run times [19-23].  Moreover, not all eicosanoids 
have active chromophores that absorb UV light at appropriate wavelengths [23, 41].  
Disadvantages of UV detection can be overcome by using fluorescence detection.  
However, eicosanoids does not have inherent fluorescence signal and requires 
derivatization with fluorescent agents.  This process is labor intensive, expensive, time 
consuming, and  produce interfering peaks from side reactions [27, 42].  Immunoassays 
were also used to quantify eicosanoids, but they are limited to one analyte per assay 
and they suffer from high cross reactivity between the numerous eicosanoid isomers [24, 
25].  GC-MS/MS provide high sensitivity and resolution of isomeric eicosanoids but this 
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technique is limited by complex sample preparation and derivatization [18, 42, 43].  The 
high sensitivity and selectivity of LC-MS/MS can overcome most of the above mentioned 
limitations, which makes it the method of choice for the quantification of eicosanoids in 
biological matrices.  Many LC-MS/MS methods, which have been reviewed recently [18, 
42, 44, 45],  have been reported for the quantification of a variety of eicosanoids in 
plasma [34-36], serum [37, 46], blood [40],  urine [38, 39, 47], tissues [26, 48, 49], lung 
cells [50], cell culture media [51], sputum [52, 53], and bronchial alveolar lavage fluid 
(BALF) [54].  The long-term goal of this project is to support a clinical study that aims to 
identify eicosanoids-based biomarkers for the prognosis of COPD.  Despite, the plethora 
of available eicosanoid LC-MS methods as cited above, we needed a sensitive method 
for the simultaneous quantification of specific eicosanoids in several matrices of interest 
to support our biomarker study.   Therefore, we have developed and validated a 
sensitive and simple LC–MS/MS method for the simultaneous quantification of 34 
eicosanoids in human serum, sputum, and BALF.   
4.2 Experimental 
4.2.1 Chemicals and Reagents 
Prostaglandin J2 (PGJ2), 20-hydroxy prostaglandin E2 (20-OH-PGE2), 
prostaglandin B2 (PGB2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), 
arachidonic acid (AA), 15-hydroxyeicosatetraenoic acid (15-HETE), 12-
hydroxyeicosatetraenoic acid (12-HETE), 11-hydroxyeicosatetraenoic acid (11-HETE), 
8-hydroxyeicosatetraenoic acid (8-HETE), 5-hydroxyeicosatetraenoic acid (5-HETE), 
leukotriene E4 (LTE4), leukotriene D4 (LTD4), leukotriene C4 (LTC4), leukotriene B4 
(LTB4), 13,14-dihydro-15-keto-prostaglandin E2 (13,14-dihydro-15-keto-PGE2), 11-Beta 
prostaglandin F2α (11-β-PGF2α), 8-iso prostaglandin F2α (8-iso-PGF2α), prostaglandin 
F2α (PGF2α), 15-keto-prostaglandin E2  (15-keto-PGE2), 6-keto-prostaglandin F1α  (6-
keto-PGF1α), thromboxane B2 (TXB2),  13,14-dihydro-prostaglandin F2α (13,14-DiOH-
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PGF2α), prostaglandin F1α (PGF1α), 13,14-dihydro-15-keto-prostaglandin F2α (13,14-
DiOH-15-keto-PGF2α), 13,14-dihydro-15-keto-prostaglandin E1 (13,14-DiOH-15-k-
PGE1), prostaglandin D1 (PGD1), 13,14-dihydro-prostaglandin E1 (13,14-DiOH-PGE1), 
thromboxane B3 (TXB3), 15- deoxy-delta 12,14 Prostaglandin J2  (15- deoxy-delta 
12,14 PGJ2), prostaglandin E1 (PGE1), prostaglandin E3 (PGE3), prostaglandin D3 
(PGD3), prostaglandin F3 α (PGF3α), 13,14-leukotriene C4 (13,14 LTC4), tetranor-
prostaglandin E metabolite (tetranor-PGEM), tetranor-prostaglandin F metabolite 
(tetranor- PGFM), 11-dehydro-thromboxane B3  (11-dehydro-TXB3), 2,3-dinor-8-iso 
prostaglandin F2α (2,3-dinor-8-iso PGF2α), and deuterated compounds (PGE2 -d4, 
TXB2-d4, AA-d8, 15-HETE-d8,and LTB4-d8)  were purchased from Cayman Chemicals 
(Ann Arbor, MI, USA).  HPLC-grade methanol (MeOH), acetonitrile (ACN), water, 
ammonium acetate, aqueous ammonia, formic acid, and acetic acid were obtained from 
Fisher Scientific (Fair Lawn, NJ). 
4.2.2 Instrumentation 
A Waters ACQUITY ultra performance liquid chromatography (UPLC) system 
(Waters, Milford, MA) coupled to an Applied Biosystem 6500 Q TRAP® quadrupole linear 
ion trap hybrid mass spectrometer with an electrospray ionization (ESI) source (Applied 
Biosystems, MDS Sciex, Foster City, CA) was used throughout.  The UPLC and MS 
systems were controlled by Empower 3.0 and Analyst 1.6.2 software, respectively.  All 
chromatographic separations were performed with an Acquity UPLC®BEH shield RP18 
column (1.7µm, 150 x 2.1 mm) equipped with an Acquity UPLC C18 guard column 
(Waters, Milford, MA).   
4.2.3 Liquid chromatographic and Mass spectrometric Conditions 
The mobile phase consisted of 0.1% acetic acid in water (mobile phase A) and 
0.1% acetic acid in ACN: MeOH (90:10) (mobile phase B), at total flow rate of 0.3 
ml/min. The chromatographic separation was achieved using 25 min gradient elution.  
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The initial mobile phase composition was 20 % B for the first 3.0 min, gradually 
increased to 65% B in 13 min, gradually increased to 95% B in 3.0 min, then held 
constant at 95% B for 4.0 min, and finally brought back to initial condition of 20 % B in 
0.20 min followed by 2-min re-equilibration.  The injection volume of all samples was 
10μl. 
The mass spectrometer parameters, such as temperature, voltage, gas pressure, 
etc., were optimized by infusing each analyte and the internal standard (IS) using a 5 
µg/ml solution in 50% MeOH via a Harvard ‘22’ standard infusion syringe pump (Harvard 
Apparatus, South Natick, MA, USA) at 10 µl/min.  All eicosanoids were detected in the 
negative ionization mode and deprotonated molecules were used as the precursors for 
selected reaction monitoring (SRM) with the following mass spectrometer source 
settings: ion spray voltage, -4000 V; source temperature, 500 °C, curtain gas, 15 AU; 
gas-1, 40 AU, gas-2, 40 AU, collision gas pressure, high; Q1/Q3 resolution, high; and 
interface heater, on.  SRM transitions for each analyte and IS, as well as their respective 
optimum MS parameters, such as declustering potential (DP), and collision energy (CE), 
are shown in Table 4.1.  
4.2.4. Preparation of Charcoal-stripped Serum for Calibration Curves 
Serum was stripped with activated charcoal to remove endogenous eicosanoids.  
Twelve mL charcoal suspension (0.66 g of dextran-coated charcoal in 100 ml of 
Dulbecco’s Phosphate buffered saline (DPBS)) was transferred into a glass tube, 
centrifuged at 4000 g for 15 minutes at 4°C, and the supernatant DPBS was discarded.  
Serum (6.0 ml) was then added on to the charcoal pellet under continuous stirring at 37 
± 1°C for two hours, centrifuged at 13,000 g for 15 min, and the supernatant was 
collected.  The process was repeated a second time for maximal removal of endogenous 
eicosanoids.  This stripped serum was used to construct serum calibration curves. 
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4.2.5 Preparation of Standard Solutions and Calibration Curves 
Aliquots from original stock solutions of every analyte were mixed to prepare 
spiking solution mixtures, which were stored in -80 °C.  Blank serum (pooled, n=10) was 
purchased from Equitech Enterprises, Inc, (Kerriville, Texas, USA) and stripped from 
endogenous eicosanoids as described above.  Blank sputum and BALF were collected 
from healthy control subjects.  Stripped serum was used to construct serum calibration 
curves, whereas sputum and BALF calibration curves were prepared in untreated 
matrices. 
The calibration ranges of the various eicosanoids were divided in to three 
categories: 0.2- 500 ng/mL, 1-500 ng/mL and 3-500 ng/mL.  Five hundred l of stripped 
blank serum, 10x-diluted stripped blank serum, untreated blank sputum, and BALF were 
spiked with spiking analyte (10X) and IS (10X) solutions, 10l each, and vortexed for 
30 seconds.  Samples were then extracted as described below and reconstituted in a 
100 µl of 50% ACN in deionized water.  Five stable-labeled eicosanoids were used as 
internal standards (IS) for the different analytes as described in table 4.1.  The final 
concentration of all five ISs was 100 ng/ml and the final concentration of analytes in 
standards and QC samples are listed in table 4.2.  
4.2.6 Sample preparation 
For serum, sputum, and BALF samples, Oasis® HLB 3cc (60mg) SPE cartridges 
(Waters, Milford, MA) were used for sample extraction.  A 500 μL samples were spiked 
with 10 μl IS, and diluted with 1500 μL 5% acetic acid in water, vortexed, and loaded 
onto SPE cartridges pre-conditioned with two ml MeOH, followed by two ml 0.1% acetic 
acid in H2O.  Loaded cartridges were washed with two ml 0.1% acetic acid in H2O and 
eluted with 2 ml MeOH.  Eluates were evaporated under vacuum at room temperature 
and reconstituted in 100 μL of 50% ACN in water i.e. samples were concentrated by 5 
folds after evaporation and reconstitution. 
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4.2.7 Extraction Recovery  
Recoveries of analytes and labeled ISs from charcoal-stripped serum, 10-x 
diluted charcoal-stripped serum, original serum, 10-x diluted serum, sputum and BALF 
were determined by dividing the peak area ratio of analyte to IS (after subtracting any 
endogenous background) from blank samples spiked before extraction to those from 
neat un-extracted standards for both the low and high QCs (n = 5).  
4.2.8 Method Validation 
The ratios of analyte to IS and the 1/x2 weighting scheme was used in all 
calibration curves.   The method was validated using five QC points for each calibration 
curve and the concentrations of the QC points are shown in table 4.2.  Five replicates of 
each QC point were analyzed each day to determine the intra- and inter-day accuracy 
and precision.  This process was repeated three times over three days in order to 
determine the inter-day accuracy and precision using freshly prepared calibration 
curves.  Intra-day accuracy and precision were calculated from the % bias [% (measured 
– theoretical)/measured concentrations] and relative standard deviation [%RSD = 
%standard deviation/mean], respectively, for the five replicates of each QC point.  Inter-
day accuracy and precision were calculated similarly using the 15 replicates of each QC 
point from the three validation runs. 
4.2.9 Stability Studies 
Stability experiments were carried out to examine the analyte stability in stock 
solutions, original matrices (samples spiked, stored at different conditions, then 
extracted before analysis), and extracted matrices (samples spiked, extracted, then 
stored at different conditions after extraction) under different conditions.  Stability studies 
included auto-sampler stability (at 4 °C for 48 hr), bench-top stability (at room 
temperature for 8 hr), freeze-thaw stability (three freeze-thaw cycles), and long-term 
stability (at -20 °C and at -80 °C for 6 months), for both the low and high QCs (n = 3). 
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4.2.10 Human Subjects 
This work was performed as a part of a clinical trial that aims to determine the 
role of the inhibition of prostaglandin E (PGE) production in restoring lung repair 
processes and thus improve outcomes of COPD.  This study was approved by the 
institutional review board (IRB) at the clinical sites where the samples were collected 
and written informed consent was obtained from all individuals.  In the healthy control 
arm of this study, control healthy subjects, age >45, who have no medical conditions that 
place them at untoward risk for bronchoscopy and broncho alveolar lavage were 
recruited after obtaining written consents.    Healthy non-smoking controls were recruited 
locally either from prior study participants or de novo and, other than smoking history, 
they met the same criteria as smoking controls and had no emphysema defined as less 
than 3% of lung voxels with density less than -950 Hounsfield units on quantitative CT 
scan.  In addition, control subjects had post bronchodilator forced expiratory volume in 
one second (FEV1) greater than or equal to 80% predicted and an FEV1/Forced Vital 
Capacity (FVE) ratio of at least 0.7.  Serum, BALF, and sputum samples were collected 
and stored in -80 °C until the time of LC-MS/MS analysis.   
4.3 Results  
4.3.1 LC-MS/MS Method Development 
In this study, a LC-MS/MS method for the quantification of eicosanoids from 
different classes including PGs, TBXs, HETE, AA, and LTs in human serum, sputum, 
and BALF was developed and validated. All eicosanoids have a free carboxylic acid 
functional group, which ionized efficiently in the negative ionization mode.  Table 4.1 
summarizes the MS/MS conditions used to quantify all 34 eicosanoids.  Figure 1 shows 
a representative LC-MS/MS chromatogram of all eicosanoid standards.  Mass 
spectrometer parameters were optimized during method development to maximize not 
only sensitivity but also selectivity.  For example, several HETEs shared the same 
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precursor as well as fragment masses; therefore, the most selective rather than the most 
sensitive SRM transitions were used for the quantification of these analytes (Figure 4.2). 
LC conditions were optimized to separate all eicosanoids of interest with a 
desirable peak shape and signal intensity using an Acquity UPLC®BEH shield RP18 
column (1.7µm, 150 × 2.1 mm). Different mobile phases with a pH range of 3-9, were 
screened to optimize LC conditions.  The less hydrophobic eicosanoids including PGs, 
TXs and LTs eluted earlier and largely independent of the mobile phase pH.  In contrast, 
acidic pH mobile phases resulted in better peak shape and longer retention of the more 
hydrophobic eicosanoids including HETEs and AA.  Therefore, acetic acid was used as 
an aqueous and organic mobile phase modifier.   
Many eicosanoids are isobaric compounds that share the same parent mass and 
also the same fragmentation pattern such as PGE2, PGD2 and, 13, 14-dihydro-15-k-
PGE2.  Therefore, these compounds have to be chromatographically resolved (Figure 
4.3).  Moreover, eicosanoids can undergo in-source fragmentation into other 
eicosanoids; therefore, even some analytes with different masses have to be resolved 
chromatographically to distinguish in-source fragments from other analytes (Figure 4.3).  
Therefore, both chromatographic separation and MS/MS specificity were required to 
quantify all eicosanoids of interest.  Under final chromatography conditions, more than 
34 eicosanoids in human serum, sputum, and BALF were separated in 25 min. 
Some eicosanoids (HETEs) had residual peak areas in serum after charcoal 
stripping.  Therefore, calibration curves for these eicosanoids were constructed using 
10x diluted charcoal stripped serum to decrease the residual peak areas after matrix 
stripping. Extraction recoveries were similar (90-115%) for these eicosanoids in diluted 
and undiluted serum and subsequently the method was validated with two sets of 
calibration curves, with and without 10-x diluted stripped serum.       
4.3.2 Method Validation 
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The method was validated for each analyte using three calibration curves 
prepared on three days.  Table 4.2 shows the validation results in human serum 
including dynamic ranges and inter-day accuracy and precision values.  Three dynamic 
ranges were used to cover all eicosanoids at relevant physiological concentrations in the 
various matrices, namely 0.2-500 ng/mL, 1-500 ng/mL, and 3-500 ng/mL.   
The method of background subtraction was used to account for the 
background/endogenous concentrations in blank matrices before spiking with analyte 
standards.  Therefore, the differences in the lower limit of quantification of the various 
eicosanoids are not necessarily due to differences in the sensitivity of the analytes, but 
rather due to the differences in the endogenous background levels in the blanks used for 
building the calibration curves.  R2 was higher than 0.998 for all eicosanoids in all 
matrices, confirming the linearity of the assay in the selected calibration ranges. 
Intra-day and inter-day accuracy and precision were determined to evaluate the 
reliability and reproducibility of this method.  Table 4.2 shows the inter-day accuracy and 
precision of standards prepared in human serum.  Validation data for all other matrices 
are shown in supplementary tables S1-3.  Accuracy and precision were ≤20% at LLOQ 
and ≤15% at the other four QC concentrations for all eicosanoids in serum, sputum, and 
BALF. 
4.3.3 Recovery 
Several protein precipitation and SPE methods were investigated to increase 
extraction recovery and decrease matrix effect. The large variation in the 
physicochemical properties between different classes of eicosanoids resulted in different 
extraction recoveries of these compounds.  The average extraction recovery of all 
analytes ranged from 57 to 115% in serum, 69 to 115% in 10-x dilute serum, 41 to 115% 
in BALF, 34 to 115% in sputum (data not shown). Our result confirms charcoal stripped 
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serum to mimic human serum with similar recovery rates using analyte/IS peak area 
ratios. 
4.3.4 Stability Studies 
Stability of eicosanoids in stocks and biological matrices were studied under various 
conditions as outlined in section 2.10.  Table 4.3 lists unstable analytes with >20% loss 
in peak area under the different storage conditions.  Eicosanoids not listed in Table 4.3 
were stable under all storage conditions.  All eicosanoids were stable in stock solutions 
and extracted serum in auto sampler at 4° C up to 24 h except compounds 8 and 27.  
However, by 48 hours the peak area of some eicosanoids decreased markedly (52-
97%).  Eicosanoids were also stable in stock solution, original matrix, and extracted 
matrix samples at room temperature on the bench up to 8 h except, 3, 18, 22, 27, 33, 39, 
41, 42, 43, and 44 in serum which were stable only for 2 hours on the bench.  In 
addition, compounds 15, 16, and 41 were stable in serum only for few minutes after 
spiking. 
Under long-term storage conditions, eicosanoids were stable in stock solution and 
original matrices at -20 °C for up to 6 months except compounds 18, 22, 33, 38, 43 and 
44 in serum.  In addition, compounds 15, 16, 41 and 42 in serum, were stable only for 
seven days after spiking. In contrast, in extracted matrices, all eicosanoids except 
compounds 15 and 16 were stable only for 3 days at -20 °C and many started degrading 
after 7 days.  In the -80 °C, all eicosanoid stocks were stable up to 6 months except for 
compounds 16 and 41, which were stable up to 2 months. 
4.3.5 Human eicosanoids profiles  
Eicosanoids profiles in serum, sputum and BALF of healthy human subjects were 
characterized using this LC-MS/MS method (Table 4.4). In accordance with previous 
reports, 12-HETE (22 ng/ml) and 8-HETE (0.6 ng/ml) were the HETEs with highest and 
lowest concentrations in serum, respectively [55, 56].  Among serum prostaglandins, 
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PGD2 and PGE2 have the highest concentrations (0.4 ng/ml), whereas PGJ2 (0.06 
ng/ml) showed the lowest concentration.  Among the three thromboxanes of interest, 
only TXB2 (6.4 ng/ml) was detected in serum.  Eicosanoids concentrations in sputum 
and BALF were on average more than 10-x lower than serum.  In sputum and BALF, 
highest concentrations were observed for HETEs (0.5-2 ng/ml).  The concentrations 
reported in this manuscript were comparable with recent reports from healthy human 
subjects using LC-MS/MS analyses in serum [40, 55, 56] and sputum [52].  
4.4 Discussion 
Due to matrix effects on the ionization of analytes in the ESI MS source, it is 
critical to prepare calibration curves in the same or equivalent matrices as the study 
samples.  This becomes a problem for endogenous analytes including eicosanoids, 
where analyte-free blank matrices are not available to spike with analyte standards of 
known concentrations for the construction of calibration curves.  Various approaches are 
followed to solve the problem of endogenous background in blank matrices for the 
construction of calibration curves, which were reviewed recently [57]. These approaches 
including method of background subtraction [34], method of standard addition [36, 54, 
58], surrogate analytes [59-61], and surrogate matrix [52, 62-69] were used for the 
quantification of eicosanoids in various biological matrices.   
As we discussed previously [57], every one of these approaches has advantages 
and disadvantages.  Therefore, we applied and compared the various approaches for 
the quantification of eicosanoids in serum and found that activated charcoal was the 
most accurate and convenient method for this application. Activated charcoal is an 
efficient adsorbent; consequently, blank serum free of eicosanoids was prepared by 
stripping serum from endogenous eicosanoids using activated charcoal.  This 
eicosanoid-free serum was used to construct the calibration curves for the analyses of 
serum samples.   The charcoal stripping conditions were optimized to maximize 
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eicosanoids depletion from serum.  Most eicosanoids were completely depleted, but 
some eicosanoids (HETEs and LTB4) had trace residual peaks in serum after stripping 
with charcoal.  For these eicosanoids, the background peak area of the remaining trace 
levels was subtracted from the peak area of the calibration curve standards, which 
allowed the construction of calibration curves with high accuracy and precision. Using 
analyte/IS peak area ratios, the recoveries of eicosanoids in the charcoal-stripped serum 
were similar to those in unstripped serum (data not shown), which indicates that matrix 
effect was the same for the study samples (unstripped serum) and calibration curve 
(stripped serum).  
Three dynamic ranges were used to cover all analytes in serum, BALF, and 
sputum at relevant physiological concentrations, namely 0.2-500 ng/mL, 1-500 ng/mL, 
and 3-500 ng/mL.  The different dynamic ranges were used because the various 
eicosanoids had different sensitivity, endogenous concentrations, and/or signal linearity.  
For example, the LLOQ of 5-HETE, 8-HETE, 11-HETE, 13-HETE, and 15-HETE was 3 
ng/mL in serum, not due to limitations in detection sensitivity (limit of detection 0.1 
ng/ml), but rather due to the relatively high residual background of these eicosanoids in 
the blank matrix used to construct the calibration curve after matrix stripping, which did 
not allow consistent subtraction from the peak areas of spiked-standards below 3 ng/ml.  
To quantify levels below 3 ng/ml, calibration curves were constructed using 10-fold 
diluted charcoal stripped serum to decrease the residual peak areas after matrix 
stripping.  Consequently, the method was validated with two sets of calibration curves, 
one set in 10-x diluted stripped plasma and another in stripped undiluted plasma.  
Recoveries of these eicosanoids in undiluted and 10-x diluted serum were similar. 
On the other hand, no matrix stripping was applied for BALF and sputum 
because we were able to obtain batches of blank matrices ranging from undetectable to 
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trace levels for most eicosanoids of interest, and this background was subtracted from 
the peak areas of calibration standards.   
Eicosanoids comprise a large family of endogenous compounds, and many 
members of this family are isobaric with very similar physio-chemical properties including 
isomers and stereoisomers.  Many eicosanoids, not only share the same mass, but also 
have the same fragmentation pattern, resulting into the same SRM transitions.  
Moreover, many eicosanoids undergo insource fragmentation, which results into 
fragments with similar masses to other eicosanoids.  In addition, interfering peaks could 
arise from other unknown endogenous components of the matrix.  Therefore, MS/MS 
specificity by itself is not always adequate to separate all eicosanoids, and 
chromatographic resolution is required for their separation in time.  For example, the 
isobaric compounds PGE2, PGD2, and 13, 14-dihydro-15-k-PGE2 are identified through 
the same 351→333 SRM transition, but were separated chromatographically (retention 
time (RT) = 11.39, 11.77, and, 12.5 min, respectively) (Figure 3).  Similarly, the isobaric 
compounds PGF2, 11- PGF2 and 8-iso-PGF2 are identified through the same 
353.2→309.1 SRM transition but were separated chromatographically (RT = 11.7, 12.0, 
and, 13.0 min, respectively) (Figure 4.1).   Variation in RT over the period of 12 months 
of utilization of this method for all analytes was less than 10%.   
Under our final LC-MS/MS conditions, all eicosanoids of interest were resolved 
from each other in less than 25 min and all standards produced single peaks.  One 
exception was TXB2 and TXB3 and their d4-labeled IS (TXB2-d4), each of which 
produced two peaks (completely chromatographically-resolved) that belonged to their 
anomers.  Both anomers for both compounds were detected in standards as well 
biological samples.  The peak areas for both anomers were summed together.   
Moreover, eicosanoids can undergo in-source fragmentation into other 
eicosanoids, which means that, sometimes, even analytes with different masses have to 
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be resolved chromatographically to distinguish in-source fragments from other analytes.  
For example, PGJ2 (333.1→315.2) and 15-dexoxy-delta 12, 14-PGJ2 (315.2→271.2) 
have different parent as well as fragment masses, yet PGJ2 produces a shadow peak 
with the same SRM of 15-dexoxy-delta 12, 14-PGJ2, i.e. 315.2→271.2.  Therefore, 
PGJ2 and 15-dexoxy-delta 12 14-PGJ2 had to be chromatographically resolved (Figure 
4.3). 
In addition to chromatographic resolution, isobaric compounds with similar SRMs 
can be distinguished if they produce specific SRMs, which may not be the most sensitive 
ones.   For example, isobaric HETEs such as 8-HETE, 11-HETE, 5-HETE, and 12-HETE 
were not resolved chromatographically, but every isomer produced unique fragments 
that were not produced by the other isomers, namely 319→154.8, 319→167.2, 
319→114.7, and 319→179, respectively, which was also shown previously [36, 45, 70, 
71].  However, these specific SRMs were less sensitive than common SRMs such as 
319→301.1 (Figure 4.2).  
Although the detection and quantification of eicosanoids concentrations have 
become a routine analysis in many biomedical laboratories, only few reports have 
addressed eicosanoid stability under different storage and analysis conditions [35, 39, 
64, 72-74].  Most of these studies have reported issues related to eicosanoid instability 
in original matrices or stock solutions for some eicosanoids.  In this report, stability 
studies were carried out in stock solution, original matrices (serum), and extracted 
matrices.  In autosampler, by 48 hours the peak area of some eicosanoids decreased 
markedly (52-97%).  This could be a result of degradation and/or precipitation due to 
evaporation of organic solvent over time.  Therefore, all samples were not stored in the 
auto-sampler longer than 24 hours.   In contrast, in extracted matrices, all eicosanoids 
except compounds 15 and 16 were stable only for 3 days at -20 °C and many started 
degrading after 7 days.  Therefore, extracted samples should be run or re-run within 
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three days from the time of sample preparation.   Sample preparation, analyses, and 
storage conditions were adjusted in this method to ensure eicosanoid stability under 
these conditions.   
Accordingly, we have excluded some eicosanoids from this method because they 
were not stable on the bench or in long-term (3, 15, 16, 41 and 42), in the autosampler 
(8, 27), storage for longer than 2 hours.  
For valid quantitative analysis, analytical standards of high purity are always 
required.  Some commercially available standards of eicosanoids contained impurities 
that were detected by LC-MS/MS at the time of purchase.  For example, PGJ2 (1) 
contained 15-Keto-PGE2 (22) (0.28%), 15-deoxy-delta 12, 14 PGJ2 (36) (3.87%), PGE3 
(38) (0.60%), unknown component (SRM = 222/123) (0.11%). Similarly, PGE3 (38) 
contained unknown component 1 (0.60%), component 2 (0.65%), and PGF3 (40) 
(5.67%).  Another example is LTC4 (16), which contains an unknown component at 
SRM similar to that of 15-HETE (9) (0.11%) but with a different retention time, and LTD4 
(15) (0.15%). These components could be impurities formed during the synthesis 
process, or degradants that formed after synthesis, during shipping, or during the 3 days’ 
stocks were stored in the -80°from the time standards arrived to the time they were 
analyzed.  Carry over and/or LC-MS system contamination was excluded by the lack of 
any of these impurities in injected blanks.  The analytes were still included in the method 
because none of the validation criteria were compromised. 
4.5 Conclusions 
In summary, a LC-MS/MS method was developed for the simultaneous 
quantification of eicosanoids in human serum, BALF, and sputum.  The method was 
sensitive, selective, accurate, and precise with a wide dynamic range.  This method was 
successfully applied to the study of eicosanoid in healthy human subjects.  The 
characterization of the detailed eicosanoids profile in healthy and COPD subjects will 
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facilitate a better understanding of the pathological and physiological role of eicosanoids 
in humans. 
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Figure 4.1 Representative chromatograms of all eicosanoid standards at 10 ng/ml under final chromatography and detection conditions in negative ESI mode.  Peaks are labeled with analytes IDs and retention time as given in table 4.1  
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Figure 4.2 Isobaric compounds that also share fragmentation patterns as well as retention times were distinguished via specific MRMs.  LC-MS/MS chromatograms of various HETEs after the injection of a 5-HETE standard at 500 ng/ml.  Isobaric HETEs including 5-HETE (13), 8-HETE (12), 11-HETE (11), and, 12-HETE (10), were not resolved chromatographically, and they produced both common and selective fragments in MS/MS.  The 319/301 transition was the most sensitive but was shared by all HETEs (a, c, e, g).  In contrast, the less sensitive but more selective transitions of HETEs were used including 319/114.7 for 5-HETE (b), 319/154.8 for 8-HETE (d), 319/167.2 for 11-HETE (f) and 319/179 for 12-HETE (h).    
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Figure 4.3 Isobaric and that undergo in-source fragmentation eicosanoids were separated chromatographically.  (a) The isobaric compounds PGE2 (7), PGD2 (6), and 13, 14-dihydro-15-k-PGE2 (18) share the same MRM transition of 351→333 and had to be separated chromatographically (retention time (RT) = 11.58, 11.77, and, 12.5 min, respectively).  (b) PGJ2 (333.1→315.2) and (c) 15-dexoxy-delta 12, 14-PGJ2 (315.2→271.2) have different precursor as well as fragment masses.  However, PGJ2 produces an in-source fragment (315.2) with the same mass as the parent 15-dexoxy-delta 12, 14-PGJ2.  Therefore, the two compounds had to be separated chromatographically.   
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Table 4.1 Summary of SRM, precursor and product ions (Q1, Q3), internal standard (IS), declustering potential (DP), collision energy (CE), and retention time (RT) used for eicosanoids in negative ESI mode. 
Analytes ID Analytes IS used SRM  (Q1/Q3) DP CE RT 1 PGJ2 PGE2-d4 333.1/315.2 -60 -12 13.60 3 20-OH-PGE2 PGE2-d4 367.1/349.3 -58 -16 6.68 4 PGB2 PGE2-d4 333.0/235.0 -90 -28 13.85 6 PGD2 PGE2-d4 351.1/271.0 -60 -20 11.77 7 PGE2 PGE2-d4 351.1/271.0 -60 -20 11.39 8 AA AA-d8 303.0/258.9 -75 -18 20.30 9 15-HETE 15-HETE-d8 319.0/175.1 -80 -20 18.10 10 12-HETE 15-HETE-d8 319.0/179.0 -80 -20 18.40 11 11-HETE 15-HETE-d8 319.0/167.2 -95 -22 18.30 12 8-HETE 15-HETE-d8 319.0/154.8 -80 -22 18.30 13 5-HETE 15-HETE-d8 319.0/114.7 -65 -20 18.50 14 LTE4 LTB4-d4 438.1/333.0 -70 -26 13.20 15 LTD4 LTB4-d4 495.1/176.8 -80 -28 11.50 16 LTC4 LTB4-d4 624.1/271.8 -110 -32 15.10 17 LTB4 LTB4-d4 335.0/194.8 -75 -22 14.90 18 13,14-DiOH-15-Keto-PGE2 PGE2-d4 351.0/333.0 -75 -20 12.50 19 11-B-PGF2α PGE2-d4 353.2/309.1 -95 -28 10.50 20 8-iso-PGF2α PGE2-d4 353.2/309.1 -95 -28 10.31 21 PGF2α PGE2-d4 353.2/309.1 -95 -28 10.97 22 15-Keto-PGE2 PGE2-d4 349.0/331.1 -45 -14 12.00 23 6-Keto-PGF1α PGE2-d4 369.0/163.0 -95 -38 8.89 24 TXB2 TXB2-d4 369.0/168.8 -75 -26 10.50 28 Ibuprofen PGE2-d4 205.0/161.0 -30 -10 15.50 29 13,14-DiOH-PGF2α PGE2-d4 355.0/311.3 -94 -34 11.80 30 PGF1α PGE2-d4 355.0/311.3 -94 -34 11.23 31 13,14-DiOH-15-Keto-PGF2α PGE2-d4 353.2/112.8 -102 -38 12.30 32 13,14-DiOH-15-Keto-PGE1 PGE2-d4 353.2/335.1 -47 -17 13.00 33 PGD1 PGE2-d4 353.2/317.1 -55 -18 12.00 34 13,14-DiOH-PGE1 PGE2-d4 355.2/337.1 -30 -20 12.3 35 TXB3 TXB2-d4 367.1/168.6 -90 -24 9.48 36 15-deoxy-delta 12,14 PGJ2 PGE2-d4 315.1/271.2 -40 -18 17.20 37 PGE1 PGE2-d4 353.2/317.1 -55 -18 11.77 38 PGE3 PGE2-d4 349.1/331.2 -30 -13 10.47 39 PGD3 PGE2-d4 349.1/331.2 -30 -13 10.77 40 PGF3α PGE2-d4 351.2/307.0 -120 -26 10.07 41 14,15-LTC4 LTB4-d4 624.1/272.1 -50 -30 13.58 42 Tetranor-PGEM PGE2-d4 327.1/309.1 -50 -15 2.49 43 Tetranor-PGFM PGE2-d4 329.0/311.1 -50 -18 2.25 44 11-De TXB3 TXB2-d4 365.1/303.2 -100 -22 10.60 45 2,3 Dinor 8-iso PGF2 PGE2-d4 325.1/237.2 -50 -15 8.51 25 TXB2-d4 NA 373.1/172.8 -27 -22 10.45 26 PGE2-d4 NA 355.1/192.9 -46 -27 11.40 
198  
 
27 AA-d8 NA 311.0/267.1 -75 -20 20.20 46 15 -HETE-d8 NA 327.2/226.2 -60 -18 18.05 47 LTB4-d4 NA 339.1/197.1 -85 -10 14.80 NA: Not Applicable. 
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Table 4.2 Dynamic range, linearity, accuracy, and precision of eicosanoids in human serum. 
Analytes ID Dynamic Range (ng/mL) 
LLOQ (0.2 ng/mL) LQC (1ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ (500ng/mL) 
Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD 1 0.2-500 111 9 95 15 90 1 98 4 112 4 4 0.2-500 101 10 98 4 91 3 92 4 90 3 6 0.2-500 99 14 101 10 94 3 94 4 94 4 7 0.2-500 109 12 94 6 101 2 104 3 113 2 14 0.2-500 104 10 88 9 92 6 94 5 114 3 17 0.2-500 110 8 105 11 97 5 99 6 115 5 18 0.2-500 110 8 87 3 85 1 87 9 100 2 20 0.2-500 99 6 103 9 92 3 97 4 97 1 21 0.2-500 105 9 101 13 99 4 109 4 115 1 22 0.2-500 103 13 88 7 91 6 103 5 116 1 24 0.2-500 94 11 109 3 100 1 99 1 106 1 28 0.2-500 106 12 92 13 91 4 95 2 103 4 29 0.2-500 104 12 100 10 103 5 108 3 108 3 30 0.2-500 105 8 101 11 96 2 101 2 108 2 31 0.2-500 90 11 90 10 93 5 89 6 85 1 32 0.2-500 103 7 86 5 86 3 86 5 115 3 33 0.2-500 103 11 97 11 96 3 97 8 93 3 34 0.2-500 107 14 79 6 88 3 85 5 90 3 35 0.2-500 93 12 92 9 100 3 103 11 96 10 36 0.2-500 110 9 96 14 88 3 90 2 114 3 37 0.2-500 105 15 90 5 94 4 99 3 98 1 38 0.2-500 105 13 94 8 90 3 97 1 104 3 39 0.2-500 96 14 103 5 95 4 95 6 107 2 44 0.2-500 103 5 102 7 102 4 100 2 112 2 45 0.2-500 96 13 105 10 90 1 94 3 113 2 
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Analytes ID Dynamic Range (ng/mL) 
LLOQ (1ng/mL) LQC (3ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ (500ng/mL) 
19 1-500 104 13 10.2 10 90 2 93 4 85 1 23 1-500 105 11 6.0 6 97 8 96 8 107 3 40 1-500 102 7 2.4 2 89 4 100 4 89 3 Analytes ID Dynamic Range (ng/mL) 
LLOQ (3ng/mL) LQC (10ng/mL) MQC (100 ng/mL) HQC (350 ng/mL) ULOQ (500ng/mL) 
9 3-500 115 4 4.7 5 115 4 103 3 100 5 10 3-500 110 10 6.5 6 115 3 105 7 99 6 11 3-500 112 6 5.4 5 107 3 103 7 102 5 12 3-500 97 15 6.2 6 114 7 106 9 99 5 13 3-500 110 12 7.4 7 105 5 98 5 94 4 43 3-500 95 12 11.6 12 105 9 110 11 106 12  
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Table 4.3 Unstable eicosanoids in different matrices under various storage conditions*. 
*Analytes with more than 20% loss by the reported time intervals under different storage conditions are presented.  NA: Not Applicable.   
Storage Condition Auto sampler at 4 °C  
Freeze-thaw three cycles at -20 °C 
Bench top at room temperature Long term stability at-20 ºC Long term stability at-80 ºC 
Matrix Extracted Matrix Original Matrix Original Matrix Extracted  Matrix Original Matrix Extracted Matrix Original Matrix 
Time up to 24 h up to 3 cycles up to 2 h up to 8 h up to 4 h up to 180 days up to 3 
days 
up to 7 
days 
up to 180 
days 
Stock 
solution 
8 and 27 17 and 42 All stable 16 and 41 NA 16 and 41 NA NA 16 and 41 
Serum 8 and 27 3, 15, 16, 18, 33, 
36, 41, 42, 43 
and 44 
3, 15, 16, 
41, and 
42 
3,15, 16, 
18, 22, 33, 
39, 41, 42, 
43, 27 and 
44 
All stable 15,16, 18, 22, 33, 
36, 38, 41, 42, 43 
and 44 
15, 16 1, 14, 15, 
16, 33, 34, 
and 41 
NA 
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Table 4.4 Concentrations (ng/ml) of eicosanoids in serum (n=5), sputum (n =2), bronchial and alveolar fluids (n =5) of healthy human subjects. 
Matrix  PGJ2 PGB2 PGD2 PGE2 15-HETE 12-HETE 11-HETE 8-HETE 5-HETE LTE4 LTB4 PGF2α 13,14-DiOH-
PGF2α 
TXB2 TXB3 
Serum Mean 0.06 0.1 0.39 0.43 1.35 22 1.3 0.55 9.4 0.3 0.44 - 0.10 6.4 0.05 
SD 0.03 0.03 0.19 0.32 0.63 14 0.6 0.28 5.5 0.16 0.10 - 0.02 5.2 0.08 
Sputum Mean - - - 0.09 1.05 2.13 0.29 0.27 2.71 - 0.72 0.04 - 0.23 - 
SD - - - 0.01 0.09 0.3 0.03 0.01 0.27 - 0.65 0.0 - 0.01 - 
Bronchial 
fluid 
Mean - - - - 0.43 0.32 0.24 0.18 0.48 - 0.09 0.04 - - - 
SD - - - - 0.25 0.18 0.17 0.19 0.24 - 0.13 0.06 - - - 
alveolar 
fluid 
Mean - - - - - - - - 0.18 - 0.1 0.08 - - - 
SD - - - - - - - - 0.09 - 0.09 0.03 - - - 
- not detected 
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Table S1. Dynamic range, linearity, accuracy, and precision of eicosanoids in human BALF. 
Analytes ID Dynamic Range (ng/mL) 
LLOQ (0.2 ng/mL) LQC (1ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ (500ng/mL) 
Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD 1 0.2-500 93 18 102 15 104 4 113 7 107 5 3 0.2-500 114 5 113 4 106 5 108 3 90 4 4 0.2-500 107 15 98 5 103 4 97 3 95 5 6 0.2-500 95 8 96 11 103 2 101 2 107 6 7 0.2-500 96 9 94 13 97 8 89 6 86 4 14 0.2-500 97 8 85 10 94 6 92 3 96 2 17 0.2-500 101 10 93 5 103 2 100 4 104 4 18 0.2-500 98 6 100 12 104 4 95 2 86 5 19 0.2-500 93 10 97 7 104 3 96 3 95 4 20 0.2-500 97 7 99 8 99 4 92 3 86 4 21 0.2-500 98 15 105 8 110 3 91 2 91 5 22 0.2-500 112 7 97 9 98 3 91 3 97 5 23 0.2-500 111 4 105 3 100 2 94 1 97 1 24 0.2-500 109 13 107 8 115 3 114 6 106 4 28 0.2-500 113 13 100 7 97 2 91 2 85 3 29 0.2-500 104 15 94 6 99 3 92 3 91 5 30 0.2-500 109 6 105 7 110 2 92 4 70 4 31 0.2-500 103 9 86 3 88 4 93 4 108 6 32 0.2-500 103 5 92 6 96 4 88 4 85 2 33 0.2-500 111 5 89 3 102 3 96 1 86 5 34 0.2-500 100 4 94 14 94 1 90 1 101 2 35 0.2-500 107 17 92 8 95 3 107 5 115 4 36 0.2-500 110 6 98 4 103 4 97 2 85 3 37 0.2-500 92 9 99 5 104 3 107 4 109 5 38 0.2-500 105 12 105 7 101 6 110 4 115 1 
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39 0.2-500 103 13 100 7 99 3 102 3 109 4 40 0.2-500 110 15 102 13 95 2 99 3 113 2 44 0.2-500 92 12 98 6 95 2 90 3 107 3 45 0.2-500 93 18 102 15 104 4 113 7 107 5  Dynamic Range LLOQ (1ng/mL) LQC (3ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ (500ng/mL) 
9 1-500 90 7 112 9 109 6 94 5 85 6 10 1-500 93 14 115 2 112 3 98 2 85 7 11 1-500 95 8 106 10 101 5 115 8 114 4 12 1-500 93 11 103 6 104 5 120 5 109 7 13 1-500 106 9 108 5 97 8 114 8 115 4   
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Table S2. Dynamic range, linearity, accuracy, and precision of eicosanoids in human sputum. 
Analytes ID Dynamic Range (ng/mL) 
LLOQ (0.2 ng/mL) LQC (1ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ (500ng/mL) 
Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD 1 0.2-500 95 15 108 5 100 3 103 1 94 3 3 0.2-500 112 12 111 4 96 3 95 3 87 5 4 0.2-500 103 10 101 6 93 5 95 3 95 4 6 0.2-500 113 6 103 6 92 2 96 2 107 1 7 0.2-500 95 12 97 11 93 4 92 2 107 3 17 0.2-500 112 8 100 4 89 3 93 2 109 3 18 0.2-500 92 27 103 15 104 3 102 2 88 3 19 0.2-500 109 6 110 5 99 2 97 3 99 3 20 0.2-500 111 5 106 5 96 2 98 2 102 3 21 0.2-500 115 9 94 6 85 3 105 6 112 4 22 0.2-500 112 11 100 12 97 3 98 1 111 2 23 0.2-500 93 9 112 3 96 11 92 1 96 2 24 0.2-500 112 16 98 4 100 4 94 3 106 2 28 0.2-500 106 4 102 11 97 1 97 3 99 3 29 0.2-500 102 5 98 3 94 2 97 2 107 2 30 0.2-500 95 9 105 5 101 3 96 2 85 1 31 0.2-500 100 10 87 4 87 3 92 1 110 3 32 0.2-500 114 5 102 7 93 6 94 3 94 4 33 0.2-500 112 2 100 2 99 3 100 2 93 4 34 0.2-500 92 80 90 6 102 12 99 2 112 2 35 0.2-500 115 3 103 2 96 2 97 1 91 2 37 0.2-500 111 7 101 6 93 2 96 1 106 2 38 0.2-500 111 10 100 4 100 12 98 3 104 1 39 0.2-500 95 9 98 5 99 3 104 2 106 1 40 0.2-500 99 7 98 11 96 10 98 2 110 1 
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44 0.2-500 99 10 93 4 93 1 92 2 115 4 45 0.2-500 95 15 108 5 100 3 103 1 94 3  Dynamic Range (ng/mL) 
LLOQ (1ng/mL) LQC (3ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ  (500ng/mL) 
14 1-500 102 13 114 4 115 4 92 6 93 2 36 1-500 88 12 105 11 92 4 98 7 112 3 9 1-500 92 12 114 6 112 4 99 5 88 3 10 1-500 105 7 101 5 112 2 97 4 86 1 11 1-500 103 5 100 3 107 5 102 5 93 2 12 1-500 106 5 108 5 115 4 102 5 85 4 13 1-500 109 4 104 5 110 3 103 4 94 3  
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Table S3. Dynamic range, linearity, accuracy, and precision of eicosanoids in 10x diluted charcoal stripped serum. 
Analytes ID Dynamic Range (ng/mL) 
LLOQ (0.2 ng/mL) LQC (1ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ (500ng/mL) 
Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD 1 0.2-500 89 11 90 6 93 3 103 4 107 5 4 0.2-500 105 14 100 4 103 4 98 3 87 3 6 0.2-500 93 11 101 9 98 4 100 4 101 3 7 0.2-500 106 6 99 3 101 2 104 3 111 3 14 0.2-500 105 6 95 10 85 3 107 6 110 10 17 0.2-500 109 9 100 8 93 3 94 3 108 3 18 0.2-500 93 12 96 6 96 2 100 3 115 3 20 0.2-500 98 9 94 8 100 4 97 3 98 3 21 0.2-500 95 15 91 10 98 2 99 4 103 4 22 0.2-500 103 9 89 4 92 3 100 2 109 4 24 0.2-500 96 12 101 3 100 2 100 1 106 1 28 0.2-500 104 8 85 8 99 3 100 2 106 4 29 0.2-500 93 9 94 11 102 3 99 5 103 3 30 0.2-500 110 9 99 4 96 3 97 2 105 4 31 0.2-500 102 13 115 3 103 2 96 3 78 8 32 0.2-500 106 10 89 3 94 2 103 3 113 5 33 0.2-500 104 10 104 7 96 6 102 3 89 6 34 0.2-500 99 9 94 4 100 4 101 2 96 3 35 0.2-500 105 12 89 14 95 3 95 2 107 2 36 0.2-500 106 9 94 11 87 7 101 9 95 4 37 0.2-500 107 5 96 6 98 3 100 3 97 3 38 0.2-500 113 11 97 6 93 2 96 1 107 1 39 0.2-500 113 9 104 6 94 5 102 3 111 3 44 0.2-500 100 10 93 8 94 4 97 2 107 3 45 0.2-500 102 10 98 8 99 2 101 2 115 2 
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 Dynamic Range (ng/mL) 
LLOQ (1ng/mL) LQC (3ng/mL) MQC (30ng/mL) HQC (100ng/mL) ULOQ  (500ng/mL) 
9 1-500 104 7 98 4 98 3 92 3 85 4 10 1-500 98 4 100 6 101 6 84 2 77 4 11 1-500 104 6 96 5 98 3 95 2 85 5 12 1-500 114 4 98 5 97 4 85 3 88 7 13 1-500 110 7 99 2 102 4 92 4 85 4 19 1-500 90 12 115 3 105 3 99 3 89 3 23 1-500 103 9 99 8 92 2 91 2 102 2 40 1-500 97 12 98 6 97 4 98 4 102 3 
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